documents incorporated reference portions proxy statement registrants annual meeting stockholders held may incorporated reference part iii annual report table contents part item business general bristolmyers squibb company may referred bristolmyers squibb bms company us incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis last years executed strategy transform next generation biopharmaceutical company transformation encompassed areas business operations part strategy divested nonpharmaceutical businesses implemented acquisition licensing strategy known stringofpearls executed productivity transformation initiative pti respect divestitures sold medical imaging business january sold convatec business august divested mead johnson nutrition company mead johnson december period completed numerous acquisition licensing transactions kosan biosciences inc june medarex inc medarex september zymogenetics inc zymogenetics october executed pti first announced december realized billion annual cost savings cost avoidance based previous strategic plans future years achieve reduced general administrative operations simplifying standardizing outsourcing certain processes services rationalized mature brands portfolio consolidated global manufacturing network eliminating complexity enhancing profitability simplified geographic footprint implemented efficient gotomarket model met goal billion cost savings cost avoidance annualized runrate basis billion annual cost savings avoidance based previous strategic plans future years progress measured annualized runrate basis amount cost savings avoidance correlate directly results operations approximately billion annual cost savings cost avoidance relates marketing selling administrative expenses relates costs products sold relates research development expenses addition pti continue review cost structure intent create modernized efficient robust balance building competitive advantages securing innovative products planning future report financial operating information one segmentbiopharmaceuticals additional information business segments see item financial statementsnote business segment information compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession manufacture products united states us puerto rico foreign countries us net sales accounted total net sales respectively net sales europe accounted total net sales net sales japan accounted total net sales net sales canada accounted total net sales products pharmaceutical products include chemicallysynthesized drugs small molecules increasing portion products produced biological processes typically involving recombinant dna technology called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections infusion revenues come products following therapeutic classes cardiovascular virology including human immunodeficiency virus hiv infection oncology neuroscience immunoscience metabolics pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity business focused innovative biopharmaceutical products rely patent rights forms regulatory protection maintain market exclusivity products us european union eu countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion patent rights regulatory forms exclusivity see intellectual property product exclusivity discussion impact generic competition business see generic competition table contents chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan canada also sell pharmaceutical products countries however data provided country bycountry basis individual country sales significant outside us eu japan canada many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products casebycase basis purposes business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate following schedule presents net sales key products estimated basic exclusivity loss us eu japanese canadian markets net sales products past currently estimated year basic exclusivity loss dollars millions us eu japan canada key products plavix b avaproavalide abilify h reyataz c sustiva franchise total revenue baraclude erbitux e l sprycel f ixempra g orencia j k n onglyzakombiglyze note currently estimated earliest year basic exclusivity loss includes statutory extensions exclusivity earned yet granted instances may able obtain additional six months exclusivity product based pediatric extension example certain instances may laterexpiring patents cover particular forms compositions drug well methods manufacturing methods using drug patents may sometimes result favorable market position products product exclusivity predicted assured new us healthcare law enacted qualifying biologic products receive years data exclusivity biosimilar enter market described detail intellectual property product exclusivity indicates brand names products trademarks owned bristolmyers squibb subsidiaries specific trademark ownership information found currently market product country region indicated references eu throughout include member states members european union year ended december basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states instances earliest latest dates basic exclusivity loss listed eu countries basic patent obtained may data protection available b data exclusivity eu expired july major markets within europe product national patents expiring specifically claim bisulfate form clopidogrel however generic alternate salt forms clopidogrel bisulfate marketed compete plavix throughout eu c data exclusivity eu expires exclusivity period relates sustiva brand include exclusivity related combination therapy e biologic product approved bla data exclusivity us expires patent specifically claims composition matter cetuximab active ingredient erbitux rights commercialize cetuximab terminate f pending application eu patent applications filed estonia latvia lithuania malta slovakia slovenia g although ixabepilone approved marketed eu approved marketed switzerland composition matter patent expected expire h rights commercialize aripiprazole us terminate april rights commercialize aripiprazole eu terminate patent protection romania denmark expired j biologic product approved bla data exclusivity us expires k data exclusivity eu expires patent covering abatacept majority eu countries expires l data exclusivity japan expires exclusivity period based regulatory data protection n exclusivity period based regulatory data protection data exclusivity canada expires table contents summary indication intellectual property position product partner thirdparty manufacturing arrangements products us applicable eu japan canada plavix plavix clopidogrel bisulfate platelet aggregation inhibitor approved protection fatal nonfatal heart attack stroke patients history heart attack stroke peripheral arterial disease acute coronary syndrome us plavix labeling updated new warnings use drugs strong moderate cyp c inhibitors prilosec omeprazole could interfere plavix reducing effectiveness labeling also updated include warnings variability response attributed cyp c genetic polymorphisms label revised include boxed warning concerning diminished effectiveness plavix patients genetic variation leading reduced formation active metabolite clopidogrel bisulfate codeveloped jointly marketed sanofiaventis sanofi information alliance sanofi see strategic alliances collaborations item financial statementsnote alliances collaborations composition matter patent us expires november fda granted us additional sixmonth period exclusivity market plavix exclusivity plavix us expected expire may plavix subject patent litigation us apotex generic companies courts upheld validity composition matter patent entering judgment favor imposing damages apotex infringing patent apotex appealing amount damages information litigation matters see item financial statementsnote legal proceedings contingencies eu regulatory data exclusivity protection expired july major markets within europe plavix benefits national patents expiring specifically claim bisulfate form clopidogrel however generic alternative salt forms clopidogrel bisulfate marketed compete throughout eu obtain bulk requirements clopidogrel bisulfate sanofi thirdparty company sanofi finish product respective facilities avaproavalide avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy irbesartan codeveloped jointly marketed sanofi information alliance sanofi see strategic alliances collaborations item financial statementsnote alliances collaborations basic composition matter patent us expires march including pediatric extension countries eu data exclusivity eu expired august avapro october avalide irbesartan manufactured company sanofi manufacture bulk requirements irbesartan finish avaproavalide facilities avalide purchase bulk requirements hydrochlorothiazide thirdparty see item risk factorswe may experience difficulties delays manufacturing distribution sale products information recent recall supply shortage abilify abilify aripiprazole atypical antipsychotic agent adult patients schizophrenia bipolar mania disorder major depressive disorder abilify also pediatric uses schizophrenia bipolar disorder among others global commercialization agreement otsuka pharmaceutical co ltd otsuka except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt information arrangement otsuka see strategic alliances collaborations item financial statementsnote alliances collaborations basic us composition matter patent abilify expires april including granted patent term extension six month pediatric extension basic composition matter patent protecting aripiprazole subject patent litigation us otsuka sole rights enforce patent information litigation matter see item financial statements note legal proceedings contingencies table contents composition matter patent force germany united kingdom uk france italy netherlands romania sweden switzerland spain denmark original expiration date extended grant supplementary protection certificate countries except romania denmark data exclusivity eu expires obtain bulk requirements aripiprazole otsuka company otsuka finish product respective facilities reyataz reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launched us july developed atazanavir worldwide license novartis pharmaceutical corporation novartis royalty paid based percentage net sales entitled promote reyataz use combination norvir ritonavir nonexclusive license agreement abbott laboratories amended royalty paid based percentage net sales market exclusivity reyataz expected expire us major eu member countries japan data exclusivity eu expires two us patents subject patent litigation us information litigation matter see item financial statementsnote legal proceedings contingencies manufacture bulk requirements atazanavir finish product facilities sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet three drug regimen combining sustiva gilead sciences incs gilead truvada emtricitabine tenofovir disoproxil fumarate atripla first complete highly active antiretroviral therapy treatment product hiv available us fixeddose combination taken daily fixeddose combinations contain multiple medicines formulated together help simplify hiv therapy patients providers information arrangement gilead see strategic alliances collaborations item financial statementsnote alliances collaborations rights market efavirenz us canada united kingdom uk france germany ireland italy spain licensed merck co inc royalty based percentage net sales composition matter patent efavirenz us expires method use patent treatment hiv infection expires possible six month pediatric extension market exclusivity sustiva expected expire countries eu another company market efavirenz japan certain atripla patents subject patent litigation us time patents covering efavirenz composition matter method use challenged information litigation matter see item financial statementsnote legal proceedings contingencies obtain bulk requirements efavirenz third parties produce finished goods facilities provide bulk efavirenz gilead responsible producing finished atripla product baraclude baraclude entecavir potent selective inhibitor hepatitis b virus approved fda march treatment chronic hepatitis b infection baraclude discovered developed internally also approved marketed countries outside us including china japan eu composition matter patent expires us patent subject patent litigation us information litigation matter see item financial statementsnote legal proceedings contingencies composition matter patent expires eu japan uncertainty chinas exclusivity laws resulted generic competition china market manufacture bulk requirements entecavir finish product facilities table contents erbitux erbitux cetuximab igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux biological product approved treatment combination irinotecan treatment patients egfrexpressing metastatic colorectal cancer mcrc failed irinotecanbased regimen monotherapy patients intolerant irinotecan fda also approved erbitux use treatment squamous cell carcinoma head neck specifically erbitux approved use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patients recurrent metastatic squamous cell carcinoma head neck prior platinumbased therapy failed october fda accepted filing supplemental biologics license application sbla firstline squamous cell carcinoma head neck granted priority review status fda since requested interim data additional study complete review application continue work fda expect provide requested information see research development additional information erbitux marketed north america us agreement imclone systems incorporated imclone predecessor company imclone llc whollyowned subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement signed october imclone merck kgaa merck japan erbitux received marketing approval japan july use treating patients advanced recurrent colorectal cancer description alliance imclone see strategic alliances collaborations item financial statementsnote alliances collaborations data exclusivity us expires patent specifically claims composition matter cetuximab active molecule erbitux erbitux approved fda health authorities monotherapy use patent use erbitux combination antineoplastic agent approved fda combination use claimed granted us patent expires including granted patent term extension inventorship use patent challenged three researchers yeda research development company ltd yeda pursuant settlement agreement executed announced december imclone sanofi yeda end worldwide litigation related use patent sanofi yeda granted imclone worldwide license use patent yeda right license use patent others yedas license patent third parties could result product competition erbitux might otherwise occur unable assess whether extent competitive impact occur quantify impact however yeda granted amgen inc amgen license use patent amgen received fda approval market egfrproduct competes erbitux obtain finished goods requirements cetuximab use north america lilly lilly manufactures bulk requirements cetuximab facilities finishing performed thirdparty lilly description supply agreement lilly see manufacturing quality assurance sprycel sprycel dasatinib multitargeted tyrosine kinase inhibitor approved treatment adults phases chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib mesylate treatment adults philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy fda approved sprycel treatment adult patients newly diagnosed philadelphia chromosomepositive ph chronic myeloid leukemia cml chronic phase sprycel internally discovered part strategic alliance otsuka information alliance otsuka see strategic alliances collaborations item financial statementsnote alliances collaborations patent term extension granted us extending term basic composition matter patent covering dasatinib june dasatinib subject patent litigation us information litigation matter see item financial statementsnote legal proceedings contingencies table contents several eu countries patent pending upon grant would expire april excluding term extensions us new chemical entity regulatory exclusivity protection expires orphan drug exclusivity expires protects product generic applications currently approved orphan indications manufacture bulk requirements dasatinib finish product facilities ixempra ixempra ixabepilone microtubule inhibitor belonging class antineoplastic agents epothilones analogs fda approved ixabepilone combination capecitabine treatment patients metastatic locally advanced breast cancer resistant treatment anthracycline taxane whose cancer taxane resistant anthracycline therapy contraindicated monotherapy treatment metastatic locallyadvanced breast cancer patients whose tumors resistant refractory anthracyclines taxanes capecitabine withdrew marketing authorization application eu march ixempra internally developed part alliance otsuka information alliance otsuka see strategic alliances collaborations item financial statementsnote alliances collaborations basic composition matter patent protecting ixabepilone us due expire may patent term extension requested upon grant would extend patent term september us new chemical entity regulatory exclusivity protection expires ixabepilone subject license agreement helmholtz zentrum fur infektionsforschung gmbh hzi relating epothilone technologies pay royalty based percentage net sales manufacture bulk requirements ixabepilone facilities including manufacturing active ingredient drug product comprises pharmaceutical kit finished baxter oncology gmbh orencia orencia abatacept biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderate severe rheumatoid arthritis inadequate response certain currently available treatments abatacept approved fda december made commercially available us february orencia discovered developed internally series patents covering abatacept method use us patent term extension granted one composition matter patents extending term us patent majority eu countries patent covering abatacept expires majority eu countries applied supplementary protection certificates would extend term patent granted data exclusivity eu expires obtain bulk abatacept thirdparty finish product facilities onglyza kombiglyze onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicated treatment type diabetes adjunct diet exercise kombiglyze saxagliptin metformin combination product indicated adjunct diet exercise improve glycemic control adults type diabetes mellitus treatment saxagliptin metformin appropriate onglyza kombiglyze codeveloped company astrazeneca plc astrazeneca worldwide except japan codevelopment cocommercialization agreement astrazeneca saxagliptin information arrangement astrazeneca otsuka japan see strategic alliances collaborations item financial statementsnote alliances collaborations patent covering saxagliptin composition matter expires us manufacture bulk requirements saxagliptin facilities including manufacturing active ingredient obtain bulk metformin hcl kombiglyze third party company thirdparty finish product facilities table contents emerging markets refined focus emerging markets represent significant opportunities growth markets characterized strong economic development rising gross domestic product growing middle class increasing wealth amongst middle class well demand quality healthcare emerging markets may provide growth opportunity pharmaceuticals industry middle next decade strategy capitalize growth opportunity innovationfocused approach approach develop commercialize select innovative products key highgrowth markets tailoring approach market individually identified five emerging markets focus brazil russia india china turkey emerging public health interests countries best align strategy well current portfolio pipeline countries also identified improving intellectual property protection order capitalize growth opportunities emerging markets must balance related risks well develop innovative pricing access strategies make products accessible patients provide reasonable return investment risks markets include intellectual property protection currency volatility reimbursement issues government stability scale issues monitor mitigate risks extent possible research development invest heavily research development rd believe critical longterm competitiveness major rd facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development also carried various facilities throughout world including belgium uk india sites us supplement internal drug discovery development programs alliances collaborative agreements agreements bring new products pipeline help us remain cutting edge technology search novel medicines drug development engage services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products management continues emphasize leadership innovation productivity quality strategies success research development activities concentrate biopharmaceutical research development efforts following disease areas significant unmet medical need affective psychiatric disorders alzheimersdementia cardiovascular primarily atherosclerosisthrombosis diabetes hepatitis hivaids obesity oncology rheumatoid arthritis related diseases solid organ transplant also continue analyze may selectively pursue promising leads areas addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug includes phase phase ii phase iii clinical trials designed specifically support new drug application particular indication assuming trials successful rd process typically takes twelve years longer three years often spent phase iii latestage development consider rd programs phase iii latestage development significant rd programs programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations drug development time consuming expensive risky average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates compounds enter phase development fail achieve regulatory approval failure rate compounds enter phase ii development approximately compounds enter phase iii development approximately total research development expenses include costs discovery research preclinical development early lateclinical development drug formulation well clinical trials medical support marketed products proportionate allocations enterprisewide costs appropriate costs spent billion billion research development activities research development spending includes payments third party collaborations contracts end employed approximately people rd activities including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel manage rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development table contents programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years listed several latestage investigational compounds phase iii clinical trials least one potential indication whether investigational compounds ultimately becomes one marketed products depends results clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors however noted assurance seek regulatory approval compounds approval sought obtained also assurance compound approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds patent coverage highlighted includes patent term extensions granted include potential patent term extensions eliquis eliquis apixaban oral factor xa inhibitor targeted prevention treatment venous thromboembolic vte disorders stroke prevention atrial fibrillation currently registrational process eu use vte prevention expect submit regulatory filings us eu indication atrial fibrillation either third fourth quarter apixaban discovered internally part alliance pfizer inc pfizer patent covering apixaban composition matter expires us nulojix nulojix belatacept biological product fusion protein novel immunosuppressive activity targeted prevention solid organ transplant rejection currently registrational process us eu prophylaxis organ rejection kidney transplant patients patent covering belatacept composition matter expires us brivanib brivanib oral small molecule dual kinase inhibitor blocks vegf receptor fgf receptor currently phase iii trials anticancer treatment potential use hepatocellular carcinoma colorectal cancer patent covering brivanib composition matter expires us dapagliflozin dapagliflozin oral sglt inhibitor potential treatment diabetes currently registrational process eu us discovered internally part alliance astrazeneca patent covering dapagliflozin composition matter currently expires october us yervoy yervoy ipilimumab biologic product monoclonal antibody currently registrational process treatment metastatic melanoma us eu also studied lung cancer well adjuvant melanoma hormone refractory prostate cancer novel class agents intended potentiate elements immunologic response compound discovered medarex subsidiary patent covering ipilimumab composition matter currently expires us necitumumab imcf necitumumab fully human monoclonal antibody investigated anticancer treatment discovered imclone part alliance company lilly studied outside us lung cancer colorectal cancer phase iii trials non small cell lung cancer lilly owns patent covering imcf composition matter expires us terminated global codevelopment cocommercialization arrangement xl metvegret inhibitor oral anticancer compound phase iii clinical trials rights returning exelixis inc exelixis table contents following table lists potential additional indications key marketed products phase iii development erbitux potential additional indications firstline nonsmall cell lung cancer firstline head neck cancer firstline colorectal cancer gastric cancer orencia potential subcutaneous formulation potential additional indication lupus nephritis plavix potential additional indication vascular event prevention atrial fibrillation sprycel potential additional indication prostate cancer ixempra potential additional indication endometrial cancer reyataz potential pediatric indication sustiva potential pediatric indication baraclude potential pediatric extension onglyza potential pediatric extension table presents key developments currently expect occur respect significant pipeline programs outcome timing expected developments dependent upon number factors including among things availability data outcome certain clinical trials acceptance presentations certain medical meetings andor actions health authorities undertake obligation publicly update information whether result new information future events otherwise eliquis potential eu approval us submission vte prevention aristotle trial results studying apixaban versus warfarin expected mid potential us eu submission stroke prevention atrial fibrillation dapagliflozin data remaining phase iii studies potential us approval treatment type diabetes nulojix potential us eu approvals prevention organ rejection kidney transplant patients threeyear phase iii data potential presentation american transplant congress may orencia potential us approval eu submission subcutaneous formulation phase iiiii lupus nephritis data available yervoy data available study combination dacarbazine dtic firstline metastatic melanoma potential us eu approval second line metastatic melanoma planned phase iii start lung cancer brivanib first phase iii study expected complete advanced unresectable hepatocellular carcinoma erbitux potential us resubmission firstline nonsmall cell lung cancer firstline head neck cancer potential us submission firstline colorectal cancer strategic alliances collaborations enter strategic alliances collaborations third parties give us rights develop manufacture market andor sell pharmaceutical products owned third parties give third parties rights develop manufacture market andor sell pharmaceutical products owned us alliances collaborations take many forms including licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances arrangements reduce risk incurring research development expenses compounds lead revenuegenerating products however profitability alliance products generally lower sometimes substantially profitability products partnered profits alliance products shared alliance partners assurance new alliances formed actively pursue arrangements view alliances important complement discovery development activities table contents strategic alliances arrangements third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally based partys material breach bankruptcy voluntary involuntary product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination upon days notice generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured number alliance agreements also permit collaborator us terminate without cause typically exercisable substantial advance written notice often exercisable specified period time elapsed collaboration agreement signed strategic alliances arrangements typically otherwise contain provisions provide party right terminate alliance short notice general retain rights product brought alliance another party partys intellectual property alliance terminates loss rights one products marketed sold us pursuant strategic alliance arrangement could material results operations cash flows case plavix abilify could material financial condition liquidity customary pharmaceutical industry terms strategic alliances arrangements generally coextensive exclusivity period may vary countrybycountry basis significant current alliances arrangements currently marketed products investigational compounds described current marketed productsinlicensed sanofi agreements sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromoted certain countries outside us tradename aprovelcoaprovel comarketed certain countries outside us us tradename karveakarvezide plavix copromoted certain countries outside us tradename plavix comarketed certain countries outside us us tradename iscover worldwide alliance operates framework two geographic territories one covering certain european asian countries referred territory one covering us puerto rico canada australia certain latin american countries referred territory b territory b managed two separate sets agreements one plavix us puerto rico products australia mexico brazil colombia argentina separate set agreements avaproavalide us puerto rico within territory territory partnership exists supply finished product country within territory manage contract certain central expenses marketing research development royalties countries within territories b structured local affiliate sanofis local affiliate either comarket separate brands ie affiliate operates independently competes selling product different trademarks copromote single brand ie product trademark within territory comarketing countries include germany spain italy irbesartan greece china clopidogrel bisulfate sell iscover karveakarvezide sanofi sells plavix aprovelcoaprovel countries except china retain right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france uk belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden taiwan south korea hong kong aprovelcoaprovel certain french export countries prior company sanofi also copromoted plavix singapore sanofi acts operating partner territory owns financial controlling interest territory ownership interest territory account investment partnership entities territory equity method recognize share results equity net income affiliates share net income partnership entities taxes million million million within territory b company sanofi copromote plavix avaproavalide us canada puerto rico territory b countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing countries act operating partner territory b majority controlling interest territory consolidate partnership results territory b recognize sanofis share results net earnings attributable noncontrolling interest net taxes million million million table contents recognized net sales territory b territory comarketing countries billion billion billion territory partnerships governed series committees enumerated functions powers responsibilities territory two senior committees final decisionmaking authority respect territory enumerated functions powers responsibilities within jurisdictions agreements sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights relating products applicable territory alliance arrangements may terminated sanofi us either whole affected country territory depending circumstances event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continues days order decree approving continues unstayed effect days ii material breach obligation major alliance agreement remains uncured days following notice breach except commencement diligent prosecution cure occurred within days notice iii deadlocks one senior committees render continued commercialization product impossible given country territory iv increase combined cost goods royalty exceeds specified percentage net selling price product v good faith determination terminating party commercialization product terminated reasons patient safety case termination rights agreements include provisions termination relevant alliance respect applicable product applicable country territory case termination due bankruptcy insolvency material breach products applicable territory termination procedures slightly different however events could lose rights either products applicable relevant country territory even case bankruptcy insolvency material breach defaulting party discussion strategic alliance sanofi see item financial statementsnote alliances collaborations otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt also collaboration agreement otsuka relating certain oncology products oncology agreement fully described current marketed productsinternally discovered terms abilify agreement amended purchase product otsuka perform finish manufacturing sale us otsuka third party customers abilify agreement expires april us june eu countries country exclusive right sell abilify agreement expires later april loss exclusivity country us germany france spain product invoiced thirdparty customers us behalf otsuka recognize alliance revenue contractual share thirdparty net sales us contractual share net sales terms agreement otsuka extend us portion abilify agreement described fully recognized expenses related product otsuka responsible commercialization expenses related product us germany france spain contractual share net sales recognize expenses related product uk italy canada presently exclusive distributor product recognize net sales related cost products sold expenses beginning january invoice thirdparty customers uk behalf otsuka company receive net sales expense reimbursement continue recognize net sales related cost products sold expenses italy canada also exclusive right sell abilify countries europe americas number countries asia countries recognize net sales related cost products sold april company otsuka extended us portion abilify agreement expected loss product exclusivity april terms extension paid otsuka million beginning january share us net sales recognize abilify changed reduced january otsuka remain responsible us expenses related commercialization abilify us time table contents beginning january expected loss us exclusivity april receive following percentages us annual net sales share us net sales billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible us expenses related commercialization abilify us us portion abilify agreement oncology agreement described include changeofcontrol provision acquired acquiring company competing product abilify new company assume abilify agreement amended oncology agreement currently exists acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire rights abilify agreement amended price according predetermined schedule agreements also provide event generic competitor abilify january option terminating abilify april amendment agreement previously amended remaining force exercise option either would receive payment otsuka according predetermined schedule oncology agreement would terminate time ii oncology agreement would continue truncated period according predetermined schedule early termination abilify agreement immediate upon notice case voluntary bankruptcy ii minimum payments made otsuka iii first commercial sale occurred within three months receipt necessary approvals days material breach occurred cured commencement cure occurred within days notice material breach days case involuntary bankruptcy petition filed dismissed addition termination available otsuka upon days notice event challenge otsukas patent rights marketbymarket basis event market product direct competition abilify upon termination expiration abilify agreement retain rights abilify recognized net sales abilify billion billion addition million extension payment total upfront licensing milestone payments made otsuka abilify agreement million discussion oncology agreement otsuka see current marketed productsinternally discovered discussion strategic alliance otsuka see item financial statementsnote alliances collaborations lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux necitumumab imcf us well codevelopment copromotion rights products canada japan information agreement respect necitumumab see investigational compounds developmentinlicensed egfr agreement respect erbitux sales north america lilly receives distribution fee based flat rate net sales north america plus reimbursement certain royalties paid lilly company lilly share one half profits losses evenly japan merck kgaa receiving half profits losses japan parties share royalties payable third parties pursuant formula set forth commercialization agreement purchase north american commercial requirements bulk erbitux lilly agreement expires erbitux north america september early termination available based material breach effective days notice material breach material breach cured commencement cure occurred upon six months notice us exists significant concern regarding regulatory patient safety issue would seriously impact longterm viability product upon termination expiration alliance retain rights erbitux share codevelopment copromotion rights erbitux merck kgaa japan agreement signed october expiring lilly merck kgaa merck japan lilly ability terminate agreement determines commercially unreasonable continue erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer recognized net sales erbitux million million million table contents discussion strategic alliance lilly see item financial statementsnote alliances collaborations gilead joint venture gilead develop commercialize atripla us canada europe company gilead share responsibility commercializing atripla us canada throughout eu certain european countries provide funding fieldbased sales representatives support promotional efforts atripla gilead recognizes atripla revenues us canada countries europe revenue efavirenz component determined applying percentage atripla revenue approximate revenue sustiva brand recognized efavirenz revenues million million million related atripla net sales joint venture company gilead continue terminated mutual agreement parties otherwise described event material breach one party nonbreaching party may terminate joint venture parties agree desirable practicable withdraw combination product markets commercialized time one generic versions partys component products appear market us party right terminate joint venture thereby acquire rights combination product us canada however three years terminated party continue receive percentage net sales based contribution bulk components atripla otherwise retains rights products discussion strategic alliance gilead see item financial statementsnote alliances collaborations current marketed productsinternally discovered astrazeneca january entered worldwide except japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement kombiglyze codeveloped astrazeneca saxagliptin agreement exclusive rights develop sell onglyza japan licensed otsuka december described investigational compounds developmentinternally discovered company astrazeneca also parties worldwide codevelopment cocommercialization agreement dapagliflozin described investigational compounds developmentinternally discovered manufacture onglyza kombiglyze certain limited exceptions recognize net sales key markets received million upfront licensing milestone payments astrazeneca meeting certain development regulatory milestones onglyza kombiglyze could receive additional million remaining development regulatory milestone saxagliptin agreement met additional million salesbased milestones met majority costs initial development plans paid astrazeneca additional development costs generally shared equally expense onglyza kombiglyze development costs net astrazenecas share research development two companies jointly develop clinical marketing strategy share commercialization expenses profits losses equally global basis excluding japan discussion strategic alliance astrazeneca see item financial statementsnote alliances collaborations otsuka simultaneously extension abilify agreement april company otsuka entered oncology agreement sprycel ixempra includes us japan eu markets oncology territory beginning collaboration fees pay otsuka annually following percentages aggregate net sales sprycel ixempra oncology territory net sales million million million million million million billion excess billion periods otsuka contribute first million certain commercial operational expenses relating oncology products oncology territory ii commercial operational expenses relating products oncology territory excess million starting otsuka right copromote sprycel us japan top five eu markets table contents oncology agreement expires respect sprycel ixempra includes changeofcontrol provision acquired abilify agreement described discussion abilfy agreement otsuka see current marketed productsinlicensed discussion strategic alliance otsuka see item financial statementsnote alliances collaborations investigational compounds developmentinlicensed exelixis october entered two collaboration agreements exelixis one license exelixis smallmolecule tgr agonist program including backups tgr agreement second collaborate discover optimize characterize smallmolecule ror antagonists ror agreement paid exelixis initial payment million could pay additional development approval milestones million tgr agreement million ror agreement exelixis also eligible receive sales performance milestones royalties net sales products tgr ror programs received exclusive worldwide license develop commercialize small molecule tgr agonists ror antagonists tgr agreement sole responsibility research development manufacturing commercialization ror agreement collaborating exelixis ror antagonist programs preclinical transition point sole responsibility research development manufacture commercialization resulting products december company exelixis entered global codevelopment cocommercialization arrangement xl license xl utility ras raf mutant tumors development exelixis terms arrangement paid exelixis million upon execution agreement additional million june company terminated development collaboration exelixis xl rights returning exelixis resulting million termination fee expensed research development company could pay exelixis development regulatory milestones million additional million salesbased milestones related xl addition company exelixis history collaborations identify develop promote oncology targets january company exelixis entered oncology collaboration license agreement exelixis pursuing development three small molecule inds codevelopment copromotion terms agreement paid exelixis million upfront licensing milestone payments date pursuant amendment agreement executed october exelixis optedout codevelopment xl company made payment exelixis amount million result company received exclusive worldwide license develop commercialize xl sole responsibility development manufacture commercialization compound successful pay exelixis development regulatory milestones million additional million salesbased milestones well royalties royalty percentage rates tiered based net sales hold equity interest exelixis december represented less outstanding shares lilly january company lilly restructured egfr commercialization agreement provide codevelopment cocommercialization necitumumab imcf fully human antibody currently phase iii development nonsmall cell lung cancer see item managements discussion analysis financial condition results operationsproduct pipeline developments update one phase iii trial restructured companies share cost developing share profits losses upon commercializing necitumumab us canada japan lilly maintains exclusive rights necitumumab markets fund development costs studies used us fund global studies pay million lilly milestone payment first approval granted us us canada recognize sales receive profits bear losses necitumumab lilly provide selling effort parties general equally participate commercialization efforts japan company lilly share commercial costs profits evenly agreement relates necitumumab continues beyond patent expiration parties agree terminate lilly manufacture bulk requirements assume responsibility fillfinish necitumumab beginning alder november company alder biopharmaceuticals inc alder entered global agreement development commercialization ald novel biologic completed phase iia development treatment rheumatoid arthritis terms collaboration agreement alder granted us worldwide exclusive rights develop commercialize ald potential indications except cancer alder retains rights granted us option codevelop ald cancer exclusive rights commercialize ald cancer outside united states paid alder million upfront licensing payment expensed research development addition could pay million developmentbased regulatorybased milestone payments potential salesbased milestones certain circumstances may exceed million royalties net sales royalty percentage rates tiered based net sales choose option pursue cancer indications could pay additional million developmentbased regulatorybased milestone payments aforementioned salesbased milestones royalties net sales royalty percentage rates tiered based net sales table contents investigational compounds developmentinternally discovered astrazeneca mentioned worldwide codevelopment cocommercialization agreement astrazeneca dapagliflozin sglt agreement dapagliflozin studied potential treatment diabetes discovered us sglt agreement received million upfront licensing payments astrazeneca could receive million development regulatory milestones met dapagliflozin additional million salesbased milestones met majority costs initial plans paid astrazeneca additional development costs generally shared equally except japan astrazeneca bears substantially development costs prior approval first indication expense dapagliflozin development costs net alliance partners share research development sglt agreement like saxagliptin agreement two companies jointly develop clinical marketing strategy share commercialization expenses profits losses dapagliflozin equally global basis manufacture dapagliflozin certain limited exceptions recognize net sales key markets respect japan astrazeneca operational cost responsibility development regulatory activities behalf collaboration though two companies jointly market product japan sharing commercialization expenses activities splitting profits losses equally like rest world also manufacture dapagliflozin recognize net sales japan like rest world dapagliflozin currently studied phase ii clinical trials japan discussion strategic alliance astrazeneca see item financial statementsnote alliances collaborations pfizer company pfizer parties worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered us studied prevention treatment broad range venous arterial thrombotic conditions pfizer funds development costs since january fund received million upfront licensing milestone payments pfizer date including million milestone filing marketing authorization application eu could receive additional million pfizer development regulatory milestones met companies jointly develop clinical marketing strategy eliquis share commercialization expenses profits losses equally global basis discussion strategic alliance pfizer see item financial statementsnote alliances collaborations otsuka january granted otsuka exclusive rights japan develop commercialize onglyza entitled receive milestone payments based certain regulatory events well salesbased payments following regulatory approval onglyza japan retained rights copromote onglyza otsuka japan otsuka responsible development costs japan royalty licensing arrangements addition strategic alliances described inlicensing outlicensing arrangements respect inlicenses agreements novartis reyataz hzi ixempra among others based current expectations respect expiration market exclusivity significant markets licensing arrangements novartis reyataz expected expire us eu japan arrangements hzi ixempra expected expire us th anniversary first commercial sale eu japan discussion market exclusivity protection including chart showing net sales key products together year basic exclusivity loss occurred expected occur us eu japan canada see products result acquisitions medarex august zymogenetics october certain compounds outlicensed third parties development commercialization expect receive milestone payments compounds move regulatory process royalties based product sales products commercialized intellectual property product exclusivity license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement table contents pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan canada certain markets regulatory intellectual property rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives extend market exclusivity period product beyond patent term us eu japan canada also provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy data protection certain markets patent protection forms market exclusivity may expired data protection particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator specific aspects law governing market exclusivity data protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term innovator may depending number factors extend expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical company files new drug application nda medicine biological product biologics license application bla filed type application filed affects regulatory exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file abbreviated nda anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition benefiting patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity table contents medicines approved nda also receive several types regulatory data protection innovative chemical pharmaceutical entitled five years regulatory data protection us competitors file fda approval generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation drug new indication basis new clinical trials receives three years data protection formulation indication biologic products new us healthcare legislation enacted abbreviated path regulatory approval biosimilar versions biological products new path approval biosimilar products us healthcare legislation significantly affects regulatory data exclusivity biological products new legislation provides regulatory mechanism allows fda approval biologic drugs similar generic copies innovative drugs basis less extensive data required full bla legislation created approval pathway biosimilar versions biological products previously exist innovative biological products longer receive essentially unlimited regulatory data exclusivity existed prior creation regulatory path biosimilar versions new law innovator marketed biological product four years biosimilar manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda new law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological product first approved fda us increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions us limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation european commission ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities marketing authorization application approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state table contents contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity canada canada medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations currently unlike us canada patent term restoration compensate patent term lost regulatory review process canada biologics generally treated chemicallysynthesized products respect patent rights regulatory exclusivity health canada issued draft guidance outlines additional information provided subsequent entry biologics also known biosimilar products generic biologics order review application marketing approval rest world countries outside us eu japan canada wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu eg switzerland among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well marketing distribution customers promote appropriate use products directly healthcare professionals providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos also provide information appropriate use products consumers us directtoconsumer print radio television advertising addition sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceuticals see government regulation price constraints sales marketing organizations explain approved uses risks benefits products medical professionals work gain access health authorities pbm mco formularies lists recommended approved medicines products including medicare part plans reimbursement lists providing information clinical profile products marketing prescription pharmaceuticals limited approved uses particular product continue develop scientific data information products provide information response unsolicited inquiries doctors medical professionals managed care organizations table contents operations include several marketing sales organizations organization markets distinct group products supported sales force typically based particular therapeutic areas physician groups sales forces often focus selling new products introduced promotion physicians increasingly targeted specialists key primary care physicians products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross sales three largest pharmaceutical wholesalers us percentage total gross sales follows mckesson corporation cardinal health inc amerisourcebergen corporation us business inventory management agreements imas substantially direct wholesaler distributor customers allow us monitor us wholesaler inventory levels requires wholesalers maintain inventory levels one month demand imas two year terms december subject certain termination provisions number smaller markets outside us eu moved distributorbased model promotion distribution entered contracts one distributors markets purchase products us promote sell within countries sales distributorbased markets represented less companys net sales competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service research development new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products sales also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales generic competition one biggest competitive challenges face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less research development researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion sales product short period time rate sales decline product expiration exclusivity varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate sales decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity see intellectual property product exclusivity table contents believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs together ability manufacture products efficiently market effectively highly competitive environment managed care organizations growth mcos us also major factor healthcare marketplace half us population participates version managed care mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations organizations consolidating fewer larger entities thus enhancing purchasing strength importance us successfully compete business mcos must often demonstrate products offer medical benefits also cost advantages compared forms care new products introduce compete products already market products later developed competitors noted generic drugs exempt costly timeconsuming clinical trials demonstrate safety efficacy often lower costs brandname drugs mcos focus primarily immediate cost drugs often favor generics reason many governments also encourage use generics alternatives brandname drugs healthcare programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures essentially equivalent brandname drug substitution must made unless prescribing physician expressly forbids exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco formularies government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments particular importance fda us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows discussion warning letter received relating manufacturing site manati puerto rico see item risk factorswe may experience difficulties delays manufacturing distribution sale products item managements discussion analysis financial condition results operations highlights table contents marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions discussion recent settlement certain investigations drug pricing sales marketing activities see item financial statementsnote legal proceedings contingencies fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs impose certain drug labeling changes relating safety mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical trials prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth oig guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement agency procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda approval approval ema obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us operate environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing markets uk germany government set pricing restrictions launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany companies also face significant delays market access new products mainly france spain italy belgium two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals recent years italy example imposed mandatory price decreases existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows table contents us internationally healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact net sales march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill new legislation makes extensive changes current system healthcare insurance benefits intended broaden coverage reduce costs bills significantly change americans receive healthcare coverage pay also significant impact companies particular companies pharmaceutical industry healthcare related industries including bms experienced continue experience additional financial costs certain changes business new healthcare law implemented example minimum rebates medicaid drug sales increased percent percent medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act also provide percent discount brandname drugs patients fall within medicare part coverage gap also referred donut hole pay annual nontaxdeductible fee federal government based allocation market share branded prior year sales certain government programs including medicare medicaid department veterans affairs department defense tricare fee classified financial reporting purposes operating expense estimates new discounts new pharmaceutical company fee us healthcare reform law including related regulations medicare coverage gap managed medicaid expansion public health service b program require additional assumptions due lack historical claims experience many markets outside us operate environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited uk instance operation profit control plan germany operation reference price system companies also face significant delays market access new products two years elapse drug approval new medicines become available countries federal state governments also pursued direct methods reduce cost drugs pay participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate government programs specify discounts certain government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases programs participate provide discounts outpatient medicines purchased certain specified entities section b public health service act discussion rebates programs see item managements discussion analysis financial condition results operationsnet sales critical accounting policies sources availability raw materials general purchase raw materials supplies required production products open market products purchase raw materials supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate raw material supply risks inventory management alternative sourcing strategies discussion sourcing see manufacturing quality assurance discussions particular products manufacturing quality assurance meet expected product demand operate manage manufacturing network including thirdparty contract manufacturers inventory related thereto manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital outofpocket expenditures well regulatory approvals maintain operate flexible manufacturing network consisting internal external resources minimize unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing see government regulation price constraints table contents pharmaceutical manufacturing facilities require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition product line changes next several years expect modify existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations february purchased acre site locate large scale multiproduct bulk biologics manufacturing facility devens massachusetts construction devens massachusetts facility began early substantially completed expect submit site regulatory approval late rely third parties manufacture supply us active ingredients necessary us manufacture certain products including plavix baraclude avalide reyataz abilify erbitux sustiva franchise orencia onglyza kombiglyze maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted additional protection cases take steps maintain approved backup source available example rely combined capacity devens massachusetts syracuse new york manati puerto rico facilities capacity available thirdparty contract manufacturers manufacture orencia commercial quantities investigational biologics compounds latestage development compounds receive regulatory approval thirdparty manufacturer rely existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet heightened processing requirements biologics business performance prospects could negatively impacted additionally thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties addition liabilities could arise failure supply products agreements arrangements could require us invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities planning manufacturing distribution maintain qualityassurance procedures relating quality integrity technical information production processes control production processes involves detailed specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling perform tests various stages production processes final product ensure product meets regulatory requirements standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used us subsidiaries thirdparty suppliers environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis expended approximately million million million capital projects undertaken specifically meet environmental requirements although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws table contents many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters see item financial statementsnote legal proceedings contingencies employees december employed approximately people continued implement comprehensive cost reduction program included work force reductions rationalization facilities discussion pti restructuring activities see item financial statementsnote restructuring foreign operations significant operations outside us conducted subsidiaries distributors geographic breakdown net sales see table captioned geographic areas item financial statementsnote business segment information discussion net sales geographic area see item managements discussion analysis financial condition results operations geographic areas international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase decrease reported dollar value net assets results operations change foreign exchange rates net favorable impact growth rate revenues predict certainty future changes foreign exchange rates effect attempt mitigate impact operational means using various financial instruments see discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnishes material us securities exchange commission sec information relating corporate governance bristolmyers squibb including standards business conduct ethics code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsstockholder services caption incorporate reference certain information parts proxy statement annual meeting stockholders sec allows us disclose important information referring manner please refer information proxy statement annual meeting stockholders annual report available website investorssec filings caption march table contents item risk factors factors described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known us risks currently consider immaterial may also impair operations face intense competition pharmaceutical manufacturers including innovative medicines lowerpriced generic products competition manufacturers competing products including lowerpriced generic versions products major challenge within us internationally facing patent expirations increasingly aggressive generic competition competition may include new products developed competitors lower prices superior performance features otherwise competitive current products ii technological advances patents attained competitors iii results clinical studies related products competitors products iv earlierthanexpected competition generic companies v business combinations among competitors major customers also could experience limited market access due real perceived differences value propositions products compared competing products depend key products net sales cash flows earnings derive majority revenue earnings key products net sales plavix contributed approximately billion representing approximately total net sales net sales abilify contributed approximately billion representing approximately total net sales three products avaproavalide reyataz sustiva franchise contributed billion net sales reduction sales one key products could significantly negatively impact net sales cash flows earnings january partner sanofi voluntarily recalled certain lots avalide us puerto rican canadian mexican argentinean markets supply avalide markets may affected indefinitely total avalide sales countries million working partner sanofi identify possible solutions issue including process adjustments alternate supply sources unable resupply markets timely manner may negative impact net sales cash flows earnings market exclusivity plavix avaproavalide us expected expire may march respectively plavix topselling product worldwide net sales approximately billion us net sales approximately billion expect plavix loses exclusivity may may rapid precipitous material decline plavix net sales reduction net income operating cash flow avaproavalide loses patent protection march may experience precipitous decline avaproavalide net sales unable support grow currently marketed products advance latestage pipeline manage costs effectively loss exclusivity plavix avaproavalide could significant material negative impact results operations cash flows financial condition data protection plavix expired eu plavix faces competition european markets data protection plavix expired july eu plavix faces competition generic alternate salt forms clopidogrel bisulfate throughout eu last two years plavix experienced substantial market share erosion price discounts plavix sales eu decreased international net sales plavix equity net income affiliates decreased respectively compared expected continue decline possible may lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value usually realized period market exclusivity us countries market exclusivity expires generic versions product approved marketed usually substantial rapid declines products sales rate decline varies country therapeutic category market exclusivity products based upon patent rights andor certain regulatory forms exclusivity scope patent rights may vary country country may also dependent availability meaningful legal remedies country failure obtain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protection products may exist certain countries historically offer right obtain certain types patents andor licensors file markets absent relevant patent protection product data exclusivity period expires generic versions product approved marketed generic clopidogrel bisulfate certain eu markets addition prior expiration data exclusivity competitor could seek regulatory approval submitting clinical trial data obtain marketing approval table contents manufacturers generic products also increasingly seeking challenge patents expire key patents covering five key products abilify atripla baraclude reyataz sprycel currently subject patent litigation cases generic manufacturers may choose launch generic product risk expiration applicable patents andor final resolution related patent litigation length market exclusivity products impossible predict certainty assurance particular product enjoy market exclusivity full period time appears estimates disclosed face increased pricing pressure restrictions us abroad managed care organizations institutional purchasers government agencies programs could negatively affect net sales profit margins pharmaceutical products subject increasing price pressures restrictions us worldwide including rules practices managed care organizations institutional governmental purchasers ii judicial decisions governmental laws regulations related medicare medicaid us healthcare reform including medicare prescription drug improvement modernization act patient protection affordable care act iii potential impact importation restrictions legislative andor regulatory changes pharmaceutical reimbursement medicare part formularies product pricing general iv delays gaining reimbursement andor reductions reimbursement amounts countries government mandated costcontainment programs eg major european markets japan canada v developments technology andor industry practices could directly indirectly impact reimbursement policies practices thirdparty payers vi limited market access due real perceived differences value propositions products compared competing products business results operations affected continue affected recent us healthcare reform legislation us described item managements discussion analysis financial condition results operationsexecutive summarybusiness environment patient protection affordable care act hr reconciliation bill containing package changes healthcare bill signed law march bills included provisions increased medicaid rebate expanded medicaid program provided additional prescription drug discounts certain patients medicare part assesses new nontaxdeductible annual fee pharmaceutical companies among things experienced continue experience significant financial costs certain changes business new healthcare law implemented higher rebates medicaid medicaid managed care plans reduced net sales million pretax income million incremental yearoveryear basis expect us healthcare reform negative impact earnings per share approximately estimate includes expected reduction net sales approximately million due new discounts associated medicare part donut hole coverage gap increase marketing sales administrative expenses approximately million due new annual nontaxdeductible pharmaceutical company fee laws also created regulatory mechanism allows approval biologic drugs similar generic copies innovative drugs basis less extensive data basis full bla us foreign laws regulations may negatively affect net sales profit margins could become subject new government laws regulations additional healthcare reform initiatives us federal state level countries including additional mandatory discounts ii changes us fda foreign regulatory approval processes may cause delays approving preventing approval new products iii tax changes phasing tax benefits heretofore available us certain foreign countries changes tax law recent amendment puerto rico internal revenue code imposing excise tax certain transactions could potentially negative impact results operations iv new laws regulations judicial governmental decisions affecting pricing reimbursement marketing within across jurisdictions v changes intellectual property law vi matters compulsory licenses could alter protections afforded one products legal regulatory changes could negatively affect business andor operating results financial condition company changes product labeling marketed products results certain studies released product approved could potentially negative impact sales product labeling pharmaceutical product changed regulatory authorities time including product market years changes often result additional data postmarketing studies headtohead trials spontaneous reporting adverse events patients healthcare professionals studies identify biomarkers objective characteristics indicate particular response product therapy studies produce important additional information product new information added products labeling affect safety risk andor efficacy benefit profile product sometimes additional information studies identifies portion patient population may nonresponsive medicine changes labeling based studies may limit patient population recent changes labeling plavix erbitux studies providing additional information may sponsored us also sponsored competitors insurance companies government institutions managed care organizations influential scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population products also negative impact sales product extent patient population product labeling becomes limited additionally certain study results especially headtohead trials could affect products formulary listing could also adverse effect sales table contents may experience difficulties delays manufacturing distribution sale products may experience difficulties delays inherent manufacturing distribution sale products seizure recalls products forced closings manufacturing plants ii supply chain continuity including result natural man made disaster one facilities critical supplier vendor well failure failure vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays due consolidation rationalization manufacturing facilities sale closure certain sites iv failure sole source single source supplier provide us necessary raw materials supplies finished goods extended period time could impact continuous supply v failure thirdparty manufacturer supply us finished product timely bases vi construction regulatory approval delays related new facilities expansion existing facilities including intended support future demand biologics products vii manufacturing distribution problems including limits manufacturing capacity due regulatory requirements changes types products produced biologics physical limitations business interruptions could impact continuous supply received warning letter fda regarding manufacturing facility manati puerto rico warning letter focused certain gmp processes practices fda identified inspection improved remediated provided response warning letter informed fda manati facility inspectionready unable timely adequately improve remediate gmp issues identified fdas satisfaction could subject additional inspectional observations fda requiring remediation observations serious could face additional negative consequences including temporary delay production facility corrective action delay approval filings january partner sanofi voluntarily recalled certain lots avalide us puerto rican canadian mexican argentinean markets working partner sanofi identify possible solutions issue including process adjustments alternate supply sources unable resupply markets timely manner may negative impact net sales cash flows earnings resolution manufacturing supply issues discussed well potential impact issues revenues earnings subject substantial risks uncertainties risks uncertainties include timing scope duration resolving manufacturing supply issues may experience difficulties delays development commercialization new products may experience difficulties delays development commercialization new products including inherent risks uncertainties associated product development compounds products may appear promising development fail reach market within expected optimal timeframe fail ever reach market approved product extensions additional indications number reasons including efficacy safety concerns delay denial necessary regulatory approvals delays difficulties producing products commercial scale level excessive costs manufacture products ii failure enter successfully implement optimal alliances appropriate discovery andor commercialization products iii failure maintain consistent scope variety promising latestage products iv failure one products achieve maintain commercial viability addition us observed recent trend fda delay approval decision new product beyond announced action date sometimes much six months longer regulatory approval delays especially common product expected risk evaluation mitigation strategy address significant riskbenefit issues inability bring product market significant delay expected approval related launch date new product could potentially negative impact net sales earnings could result significant impairment inprocess research development intangible assets finally natural man made disaster sabotage research development labs loss key molecules intermediaries could negatively impact product development cycle legal matters adverse outcomes could negatively affect business currently involved could future become involved various lawsuits claims proceedings government investigations preclude delay commercialization products adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii sales marketing practices us internationally iii adverse decisions litigation including product liability commercial cases iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers may result liability vi product pricing promotional matters vii lawsuits claims asserting violations securities antitrust federal state pricing antibribery foreign corrupt practice act laws viii environmental health safety matters ix tax liabilities assurance increase scope matters additional lawsuits claims proceedings investigations future assurance matters material adverse impact us table contents rely third parties meet contractual regulatory obligations rely suppliers vendors partners including alliances pharmaceutical companies manufacturing development commercialization products third parties meet contractual regulatory obligations relation arrangements us failure parties meet obligations andor development significant disagreements factors materially disrupt ongoing commercial relationship prevent optimal alignment partners activities could material adverse impact us addition parties violate alleged violated laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences increasingly dependent outsourcing arrangements increasing dependence thirdparty providers certain outsourced services including certain research development capabilities certain financial outsourcing arrangements certain human resource functions information technology activities systems many thirdparty providers located markets subject political risk corruption infrastructure problems natural disasters addition country specific privacy data security risks given current legal regulatory environments failure service providers meet obligations adequately deploy business continuity plans event crisis andor development significant disagreements natural man made disasters factors materially disrupt ongoing relationship providers could negatively affect operations failure execute business strategy could adversely impact growth profitability last years transformed diversified pharmaceutical related healthcare products company biopharmaceutical company focus innovative products areas high unmet medical need expected loss exclusivity us largest product plavix may time expect rapid precipitous material decline plavix net sales reduction net income operating cash flow focused building foundation future plan achieve foundation continuing support grow currently marketed products advancing latestage pipeline managing costs maintaining improving financial strength strong balance sheet risks associated strategy may able consistently replenish innovative pipeline internal research development transactions third parties competition among major pharmaceutical companies acquisition product licensing opportunities become intense eliminating opportunities making others expensive may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions additionally changes structure operations revenues costs efficiency resulting major transactions acquisitions divestitures mergers alliances restructurings strategic initiatives may result greater expected costs may take longer expected complete encounter difficulties including need regulatory approval appropriate inability expand product portfolio new products maintain competitive cost basis could materially adversely affect future results operations unable support grow currently marketed products advance latestage pipeline manage costs effectively could experience significant material negative impact results operations financial condition addition failure hire retain personnel right expertise experience operations critical business functions could adversely impact execution business strategy increasingly dependent information technology expanding social media vehicles present new risks increasingly dependent information technology systems significant breakdown invasion destruction interruption systems could negatively impact operations addition risk business interruption reputational damage infiltration data center data leakage confidential information internally thirdparty providers inappropriate use certain media vehicles could cause brand damage information leakage could lead legal implications improper collection personal information negative posts comments us social networking web site could seriously damage reputation addition disclosure nonpublic company sensitive information external media channels could lead information loss might structured processes place secure achieve information identifying new points entry social media continues expand presents new challenges adverse changes us global regional economic conditions could continuing adverse effect profitability businesses high government debt burdens continued high unemployment rates rising prices including related commodities energy lower economic growth adversely affected commercial activity us europe regions world business government austerity measures declines economic activity markets business could adversely affect demand pricing products thus reducing revenues earnings cash flow well passthrough effects us resulting significant financial instability customers distributors alliance partners suppliers critical vendors service providers counterparties certain financial instruments marketable securities derivatives future pension plan funding requirements continue sensitive global economic conditions related impact equity markets table contents changes foreign currency exchange rates interest rates could material adverse effect results operations significant operations outside us revenues operations outside us accounted revenues exposed fluctuations foreign currency exchange rates also significant borrowings exposed changes interest rates also exposed economic factors control illegal distribution sale third parties counterfeit versions products stolen products could negative impact reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards products undergo patient receives counterfeit drug may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold name one products addition thefts inventory warehouses plants intransit properly stored sold unauthorized channels could adversely impact patient safety reputation business table contents item b unresolved staff comments none item properties world headquarters located park avenue new york ny lease approximately square feet floor space lease approximately properties countries manufacture products worldwide locations owned us manufacturing locations aggregate square feet floor space geographic area follows december number locations square feet united states europe latin america middle east africa japan asia pacific canada emerging markets total portions manufacturing locations properties owned leased us us elsewhere used research development administration storage distribution information properties see item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item submission matters vote security holders matters submitted vote security holders fourth quarter year ended december table contents part ia executive officers registrant listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years lamberto andreotti executive vice president president worldwide chief executive officer director pharmaceuticals division company executive vice member senior management team president chief operating officer worldwide pharmaceuticals division company executive vice president chief operating officer president chief operating officer director company present chief executive officer director company charles bancroft vice president finance worldwide pharmaceuticals chief financial officer division company member senior management team present chief financial officer company joseph c caldarella vice president corporate controller present senior vice president corporate controller senior vice president corporate controller beatrice cazala president emea worldwide medicines international senior vice president commercial operations president emea asia pacific worldwide medicines president global commercialization europe international emerging markets president global commercialization president europe member senior management team present senior vice president commercial operations president global commercialization europe emerging markets john e celentano president health care group division company senior vice president human resources public senior vice president strategy productivity affairs philanthropy transformation member senior management team president emerging markets asia pacific present senior vice president human resources public affairs philanthropy francis cuss mb bchir frcp senior vice president discovery exploratory clinical senior vice president research development member senior management team present senior vice president research research development brian daniels md senior vice president global clinical development research senior vice president global development development division company medical affairs present senior vice president global development medical member senior management team affairs table contents carlo de notaristefani president technical operations worldwide president technical operations global support pharmaceuticals division company functions present president technical operations global support member senior management team functions anthony c hooper president us pharmaceuticals worldwide pharmaceuticals senior vice president commercial operations group division company president us japan intercontinental president americas member senior management team present senior vice president commercial operations president us japan intercontinental sandra leung vice president corporate secretary acting general general counsel corporate secretary counsel member senior management team present general counsel corporate secretary jeremy levin dphil mb bchir global head business development strategic alliances senior vice president strategy alliances member executive committee novartis institutes biomedical transactions research member senior management team senior vice president external science technology licensing senior vice president strategic transactions present senior vice president strategy alliances transactions elliott sigal md phd present executive vice president chief scientific officer executive vice president chief scientific officer president research development president research development member senior management team table contents part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common preferred stocks traded new york stock exchange nyse symbol bmy quarterly summary high low market prices presented high low high low common first quarter second quarter third quarter fourth quarter preferred first quarter second quarter third quarter fourth quarter third quarter observable trades companys preferred stock holders common stock number record holders common stock december number record holders based upon actual number holders registered books date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies dividends board directors declared following dividends per share paid quarters indicated common preferred first quarter second quarter third quarter fourth quarter december board directors declared quarterly dividend per share common stock paid february shareholders record january board directors also declared quarterly dividend per share preferred stock payable march shareholders record february table contents issuer purchases equity securities following table summarizes surrenders repurchases equity securities month period ended december total number shares approximate dollar value average price purchased part shares may yet total number paid publicly announced purchased period shares purchaseda per sharea plans programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations b may announced board directors authorized purchase billion common stock repurchase program expiration date expected take place years may board directors also terminated program previously announced june pursuant billion common stock authorized purchased approximately billion remained yet repurchased table contents item selected financial data five year financial summary amounts millions except per share data income statement dataa net sales earnings continuing operations income taxes net earnings continuing operations attributable bristolmyers squibb company net earnings continuing operations per common share attributable bristolmyers squibb company basic diluted average common shares outstanding basic diluted dividends paid bms common preferred stock dividends declared per common share financial position data december total assets cash cash equivalents marketable securitiesb longterm debt equity recognized items affected comparability results discussion items years see item managements discussion analysis financial condition results operationsexpenses b marketable securities include current noncurrent assets table contents item managements discussion analysis financial condition results operations executive summary bristolmyers squibb company may referred bristolmyers squibb bms company us global biopharmaceutical company consisting global pharmaceuticalbiotechnology international consumer medicines businesses whose mission discover develop deliver innovative medicines help patients prevail serious diseases license manufacture market distribute sell pharmaceutical products continued execute stringofpearls strategy acquisition zymogenetics inc zymogenetics october various collaboration agreements entered year met productivity transformation initiative pti objectives implemented strategic process designed achieve culture continuous improvement launched kombiglyze saxagliptin metformin united states us treatment type diabetes adults made key product pipeline advancements yervoy ipilimumab dapagliflozin eliquis apixaban baraclude entecavir sprycel dasatinib orencia abatacept received warning letter manati puerto rico facility voluntarily recalled certain lots avalide irbesartan hydrochlorothiazide us puerto rican canadian mexican argentinean markets repurchased million principal value higher interest rate debt tender offer announced billion share repurchase program million shares repurchased highlights following table summary financial highlights year ended december dollars millions except per share data net sales segment income net earnings continuing operations attributable bms net earnings discontinued operations attributable bms net earnings attributable bms diluted earnings per share continuing operations attributable bms nongaap diluted earnings per share continuing operations attributable bms cash cash equivalents marketable securities net sales worldwide net sales increased primarily due growth various key products including plavix clopidogrel bisulfate virology portfolio includes baraclude sustiva efavirenz franchise reyataz atazanavir sulfate orencia sprycel sales recently launched onglyza saxagliptin kombiglyze net sales increased prior year despite unfavorable impact increased medicaid rebates us healthcare reform reduction contractual share abilify aripiprazole net sales extension commercialization manufacturing agreement otsuka pharmaceutical co ltd otsuka declining sales mature brands strategic divestitures generic competition avalide recall government austerity measures europe reduce health care costs segment income increase segment income attributed net sales growth various key products efficient reduced spending within marketing selling administrative reduced promotional spending certain key brands coincide product life cycle table contents increase partially offset reduced equity income impact generic competition international plavix sales international partnership sanofi increased research development spending support maturing pipeline possible launch new products net earnings continuing operations attributable bristolmyers squibb company decrease primarily attributed unfavorable impact specified items affect comparability results including million charge related impairment loss sale manufacturing operations million tax charge attributed us taxable income earnings foreign subsidiaries previously considered permanently reinvested offshore gains million prior year sale certain mature brands decrease partially offset reduced upfront licensing milestone payments million litigation settlement charge increased segment income net earnings discontinued operations attributable bristolmyers squibb company completed splitoff mead johnson resulting aftertax gain approximately billion results mead johnson business related gain included discontinued operations diluted earnings per share continuing operations diluted earnings per share eps continuing operations increased due lower average outstanding common shares attributed full year impact million share reduction resulting december mead johnson splitoff common stock repurchases million shares made stock repurchase program announced may nongaap financial measures including nongaap earnings continuing operations related eps information adjusted exclude certain costs expenses gains losses specified items nongaap diluted eps continuing operations increased adjusting specified items million million detailed listing specified items information reconciliations nongaap financial measures see specified items nongaap financial measures cash cash equivalents marketable securities sources cash cash equivalents marketable securities included billion generated operating activities primary nonoperating uses cash cash equivalents marketable securities included dividend payments billion debt repurchase means tender offer million acquisition zymogenetics million common stock repurchases million capital expenditures million business environment conduct business primarily within pharmaceuticalbiotechnology industry highly competitive subject numerous government regulations many competitive factors may significantly affect sales products including product efficacy safety price costeffectiveness marketing effectiveness market access product labeling quality control quality assurance manufacturing operations research development new products successfully compete business healthcare industry must demonstrate products offer medical benefits well cost advantages new product introductions compete products already market therapeutic category addition potential competition new products competitors may introduce future manufacture branded products priced higher generic products generic competition one leading challenges globally pharmaceuticalbiotechnology industry majority innovative products commercial value usually realized period product market exclusivity product loses exclusivity longer protected patent subject new competing products form generic brands upon exclusivity loss lose major portion products sales table contents short period time competitors seeking approval biological products full biologics license application bla must file safety efficacy data address challenges biologics manufacturing involve complex processes costly traditional pharmaceutical operations new us healthcare legislation enacted described fully abbreviated path regulatory approval generic versions biological products new path approval biosimilar products us healthcare legislation significantly affects regulatory data exclusivity biological products new legislation provides regulatory mechanism allows regulatory approval biologic drugs similar generic copies innovative drugs basis less extensive data required full bla possible time reasonably assess impact new us biosimilar legislation company globally healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact net sales march us government enacted healthcare reform legislation signing law patient protection affordable care act hr reconciliation bill containing package changes healthcare bill new legislation makes extensive changes current system healthcare insurance benefits intended broaden coverage reduce costs bills significantly change americans receive healthcare coverage pay also significant impact companies particular companies pharmaceutical industry healthcare related industries including bms experienced continue experience additional financial costs certain changes business new healthcare law provisions become effective example minimum rebates medicaid drug sales increased percent percent medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act also provide percent discount brandname drugs patients within medicare part coverage gap also referred donut hole pay annual nontaxdeductible fee federal government based allocation market share branded prior year sales certain us government programs including medicare medicaid department veterans affairs department defense tricare fee classified financial reporting purposes operating expense new discounts new pharmaceutical company fee us healthcare reform law including related regulations medicare coverage gap managed medicaid expansion public health service b program historical claims experience subject additional changes estimates higher rebates medicaid medicaid managed care plans reduced net sales million pretax income million year ended december also recognized onetime tax charge million first quarter due elimination tax deductibility portion retiree healthcare costs eps impact us healthcare reform incremental yearoveryear basis expect us healthcare reform additional negative impact earnings per share approximately estimate includes expected reduction net sales approximately million due new discounts associated medicare part donut hole coverage gap increase marketing sales administrative expenses approximately million due new annual nontaxdeductible pharmaceutical company fee aggregate financial impact us healthcare reform next years depends number factors including limited pending implementation guidance potential changes sales volume eligible new rebates discounts fees impact cost sharing arrangements certain alliance partners positive impact net sales expected increase number people healthcare coverage could potentially occur future expected earliest many markets outside us operate environments governmentmandated costcontainment programs regulatory bodies groups exert downward pressure pricing pricing freedom limited uk instance operation profit control plan germany operation reference price system companies also face significant delays market access new products two years elapse drug approval new medicines become available countries growth managed care organizations mcos us played large role competition surrounds healthcare industry mcos seek reduce healthcare expenditures participants making volume purchases entering longterm contracts negotiate discounts various pharmaceutical providers market potential created large pool participants marketing prescription drugs mcos become important part strategy companies compete inclusion mco formularies generally successful major products included believe developments managed care industry including continued consolidation continue downward pressure prices pharmaceutical biotechnology production processes complex highly regulated vary widely product product shifting adding manufacturing capacity lengthy process requiring significant capital expenditures regulatory approvals biologics manufacturing involves complex processes traditional pharmaceutical operations biologics become larger percentage product portfolio continue make arrangements thirdparty manufacturers make substantial investments increase internal capacity produce biologics commercial scale one investment new stateoftheart manufacturing facility production biologics devens massachusetts expect submit site regulatory approval late table contents maintained competitive position market strive uphold position dependent success discovering developing delivering innovative costeffective products help patients prevail serious diseases subject number significant pending lawsuits claims proceedings investigations possible time reasonably assess final outcomes investigations litigations additional discussion legal matters see item financial statementsnote legal proceedings contingencies strategy past years transformed company focused biopharmaceutical company transformation encompasses areas business operations focused portfolio products yielded continue yield substantial cost savings cost avoidance turn increases financial flexibility take advantage attractive market opportunities may arise may expect loss exclusivity us largest product plavix time expect rapid precipitous material decline plavix net sales reduction net income operating cash flow events norm industry companies experience loss exclusivity product recognizing fact focused sustaining business building robust foundation future plan achieve foundation continuing support grow currently marketed products advancing pipeline managing costs maintaining improving financial strength strong balance sheet however part overall strategy build company strategy includes focus emerging markets stringofpearls optimizing mature brands portfolio managing costs strategy emerging markets develop commercialize innovative products key highgrowth markets tailoring approach market also remain focused acquisition licensing strategy known stringofpearls transactions could range collaboration license agreements acquisition companies october completed acquisition zymogenetics also entered restructured collaboration agreements various companies including eli lilly company lilly allergan inc exelixis inc exelixis oncolys biopharma inc continued core biopharmaceutical focus maximization value mature brands portfolio completed sale various mature brands related manufacturing facilities various countries managing costs another part overall strategy executed pti realized billion annual cost savings cost avoidance based previous strategic plans future years met goal billion cost savings cost avoidance annualized runrate basis achieve reduced general administrative operations simplifying standardizing outsourcing certain processes services rationalized mature brands portfolio consolidated global manufacturing network eliminating complexity enhancing profitability simplified geographic footprint implemented efficient gotomarket model billion annual cost savings avoidance based previous strategic plans future years progress measured annualized runrate basis amount cost savings avoidance correlate directly results operations approximately billion annual cost savings cost avoidance relates marketing selling administrative expenses relates costs products sold relates research development expenses addition pti continue review cost structure intent create modernized efficient robust balance building competitive advantages securing innovative products planning future table contents product pipeline developments manage research development rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth consider rd programs entered phase iii development significant programs constitute latestage development pipeline phase iii development programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations spending programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years expect latestage development programs make market latestage development programs rd programs could potentially impact revenue earnings within next years following recent significant developments marketed products latestage pipeline yervoy ipilimumab monoclonal antibody currently registrational process treatment metastatic melanoma also studied indications including lung cancer well adjuvant melanoma hormonerefractory prostate cancer august us food drug administration fda accepted filing review bla yervoy treatment adult patients advanced melanoma previously treated application granted priority review designation fda fdas current stated action date bla march may yervoy marketing authorization application maa metastatic melanoma pretreated patients validated european medicines agency ema june company announced positive results phase iii randomized double blind study yervoy demonstrated overall survival significantly extended patients previouslytreated metastatic melanoma received yervoy results statistically significant patients receiving yervoy alone yervoy combination gp peptide vaccine compared patients received control therapy gp alone fortyfour percent patients treated yervoy alive one year compared percent patients treated control arm two years percent patients treated yervoy alive compared percent patients treated control arm may company announced positive results randomized phase ii study evaluating yervoy combination standard chemotherapy previously untreated patients advanced nonsmall cell lung cancer study known met predefined criteria significant improvement pvalue immunerelated progressionfree survival primary endpoint chemotherapy alone additional analysis progressionfree survival assessed using traditional modified world health organization criteria also reached statistical significance one two dosing schedules combined yervoy standard chemotherapy eliquis apixaban oral factor xa inhibitor phase iii development prevention treatment venous thromboembolic disorders stroke prevention atrial fibrillation part strategic alliance pfizer inc pfizer based upon discussions fda agreement pfizer expect submit nda filing us including data averroes trial aristotle trial assuming positive outcome aristotle study indication stroke prevention atrial fibrillation cover broadest spectrum patients one single filing expect initial top line results aristotle data second quarter submit regulatory filings us europe either third fourth quarter february company pfizer published full results averroes study eliquis new england journal medicine study demonstrated patients atrial fibrillation af expected demonstrated unsuitable vitamin k antagonist therapy warfarin eliquis statistically superior aspirin reducing composite stroke systematic embolism without significant increase major bleeding fatal bleeding intracranial bleeding significant differences risk hemorrhagic stroke eliquis aspirin study results also showed eliquis demonstrated superiority secondary efficacy endpoint reducing composite stroke systematic embolism mycordial infarction vascular death patients af compared aspirin december company pfizer published results phase iii advance study eliquis new england journal medicine results showed eliquis statistically superior mg oncedaily enoxaparin comparable rates bleeding prevention venous thromboembolism following total hip replacement surgery november company pfizer reported phase iii appraise clinical trial patients recent acute coronary syndrome treated eliquis placebo addition mono dual antiplatelet therapy discontinued study stopped early recommendation independent data monitoring committee due clear evidence clinically important increase bleeding among patients randomized eliquis offset clinically meaningful reductions ischemic events table contents august positive preliminary data averroes trial presented european society cardiology congress stockholm sweden preliminary data demonstrated eliquis significantly reduced relative risk composite stroke systematic embolism percent without significant increase major bleeding fatal bleeding intracranial bleeding compared aspirin patients expected demonstrated unsuitable warfarin treatment minor bleeding significantly increased june company pfizer announced phase iii averroes trial ending early due clear evidence efficacy interim analysis independent data monitoring committee showed clinically important reduction stroke systematic embolism patients atrial fibrillation considered intolerant unsuitable warfarin therapy received eliquis compared aspirin interim analysis also demonstrated acceptable safety profile eliquis compared aspirin march results advance study published lancet results presented july showed eliquis statistically superior mg daily enoxaparin reducing incidence venous thromboembolism patients undergoing elective total knee replacement surgery according advance study results study results also showed numerically lower rates major clinically relevant nonmajor bleeding patients treated eliquis compared treated enoxaparin latter results meet statistical significance march eliquis marketing authorization application prevention venous thromboembolic events adult patients undergone elective hip knee replacement validated european medicines agency nulojix belatacept fusion protein novel immunosuppressive activity targeted prevention solid organ transplant rejection may fda issued complete response letter regarding bla nulojix indication prophylaxis organ rejection preservation functioning allograft adult patients receiving renal transplants use combination interleukin il receptor antagonist mycophenolic acid mpa corticosteroids december fda informed us information submitted regarding nulojix complete response request additional information outlined fda complete response letter prescription drug user fee act pdufa date fda action bla june fda advised us must resolve gmp issues raised fdas recent warning letter regarding manufacturing facility manati puerto rico prior granting approval pending bla nulojix december notified fda manati facility inspectionready upon reinspection fda satisfied could result delay approval nulojix filing see part item risk factorswe may experience difficulties delays manufacturing distribution sale products information may nulojix subject eight clinical presentations related kidney transplantation american transplant congress march fdas cardiovascular renal drugs advisory committee voted recommend approval nulojix selective co simulation blocker prophylaxis acute rejection de novo kidney transplant patients fda bound recommendations advisory committee takes advice consideration reviewing new drug applications february nulojix maa treatment prophylaxis organ rejection kidney transplant patients validated ema dapagliflozin oral sglt inhibitor phase iii development treatment diabetes part strategic alliance astrazeneca december company astrazeneca completed submission new drug application fda marketing authorization application european medicines agency dapagliflozin oncedaily oral therapy treatment adult patients type diabetes maa validated european medicines agency january september company astrazeneca announced results randomized double blind phase iii clinical study dapagliflozin th european association study diabetes easd annual meeting demonstrated addition dapagliflozin glimepiride sulphonylurea therapy produced significant reductions glycosylated hemoglobin levels hbac adult patients type diabetes compared glimepiride alone study also demonstrated dapagliflozin plus glimepiride achieved reductions secondary efficacy endpoints change total body weight oral glucose tolerance test ogtt fasting plasma glucose fpg levels baseline week compared placebo plus glimepiride people taking dapagliflozin glimepiride able achieve target hbac less compared patients taking glimepiride alone also drugrelated adverse affects reported similar rate treatment groups signs symptoms reports suggestive genital tract infections urinary tract infections frequently reported dapagliflozin treated subjects table contents september company astrazeneca also announced easd results randomized doubleblind phase iii clinical study adults type diabetes inadequately controlled metformin therapy alone study demonstrated dapagliflozin noninferior compared glipizide improving hbac added existing metformin therapy week treatment period study also demonstrated dapagliflozin plus metformin achieved significant reductions key efficacy secondary endpoints reduction total body weight baseline compared weight gain glipizide plus metformin therapy reduced number patients reporting one hypoglycemic events also frequencies adverse events serious adverse events study discontinuations comparable across treatment groups signs symptoms reports suggestive urinary tract genital infections common dapagliflozin treated subjects june findings week phase iii clinical study published demonstrated dapagliflozin administered monotherapy achieved statistically significant mean reductions mg mg doses daily primary endpoint glycosylated hemoglobin levels treatmentnave adult patients newly diagnosed type diabetes compared placebo june results week phase iii clinical study presented demonstrated addition dapagliflozin achieved reductions primary endpoint glycosylated hemoglobin level inadequately controlled type diabetes patients treated insulin without oral antidiabetes medications oads compared placebo plus insulin without oads study also demonstrated dapagliflozin achieved reductions secondary endpoints evaluated change total body weight baseline change baseline mean daily insulin dose change baseline fasting plasma glucose plavix platelet aggregation inhibitor part alliance sanofiaventis sanofi january company sanofi announced fda granted companies additional sixmonth period exclusivity market plavix exclusivity plavix us scheduled expire may march company sanofi announced revisions us prescribing information plavix include boxed warning boxed warning concerns diminished effectiveness plavix patients genetic variation leading reduced formation active metabolite patients designated poor metabolizers represent according prescribing information approximately whites blacks chinese percentage poor metabolizers estimated approximately population based published studies revisions addition updates plavix labeling reported november warnings use prilosec omeprazole certain drugs could interfere plavix reducing effectiveness march company sanofi announced approval european commission dual antiplatelet combination tablet duoplavinduocover clopidogrel mg acetylsalicylic acid mg mg indicated prevention atherothrombotic events adult patients already taking clopidogrel acetylsalicylic acid asa avalide angiotensin ii receptor blocker treatment hypertension diabetic nephropathy also part sanofi alliance january bms partner sanofiaventis voluntarily recalled certain lots avalide us puerto rican canadian mexican argentinean markets due identification less soluble form irbesartan found lots produced humacao puerto rico facility four batches produced evansville indiana facility attributed manufacturing process change supply avalide markets affected indefinitely total avalide sales countries million working partner sanofiaventis identify possible solutions issue including process adjustments alternate supply sources abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part strategic alliance otsuka february company otsuka announced fda approved abilify adjunct mood stabilizers lithium valproate maintenance treatment bipolar disorder reyataz protease inhibitor treatment hiv february fda approved update labeling reyataz include dose recommendations hivinfected pregnant women hiv combination therapy treatment recommended adult dose reyataz mg boosted mg ritonavir achieved minimum plasma concentrations hours postdose third trimester pregnancy comparable observed historically hivinfected adults post partum period atazanavir concentrations may increased therefore dose adjustment necessary patients monitored two months delivery table contents baraclude oral antiviral agent treatment chronic hepatitis b october fda approved supplemental new drug application baraclude treatment chronic hepatitis b adult patients decompensated liver disease sprycel oral inhibitor multiple tyrosine kinases indicated treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase sprycel part strategic alliance otsuka december company announced sprycel mg daily received marketing authorization european commission treatment adult patients newly diagnosed philadelphia chromosomepositive chronic myeloid leukemia chronic phase december company otsuka announced nd annual meeting american society hematology month followup results phase iii dasision study sprycel firstline treatment adults philadelphia chromosomepositive chronic phase chronic myeloid leukemia consistent month data sprycel demonstrated higher faster rates complete cytogenetic response major molecular response compared imatinib october company otsuka announced fda approved sprycel mg daily treatment adult patients newly diagnosed philadelphia chromosomepositive chronic myeloid leukemia chronic phase july company submitted review japan supplemental new drug application sprycel treatment adult patients newly diagnosed chronic myeloid leukemia june company otsuka announced phase iii study results sprycel mg daily demonstrated superior rate confirmed complete cytogenetic response compared gleevec study showed percent sprycel patients versus percent gleevec patients achieved confirmed complete cytogenetic response rates months june company otsuka announced four year followup results phase iii randomized openlabel doseoptimization study sprycel chronicphase chronic myeloid leukemia patients resistant intolerant gleevec four years patients administered sprycel mg daily overall survival ci progressionfree survival ci fouryear safety data study consistent previously reported safety profile sprycel mg daily orencia fusion protein indicated rheumatoid arthritis december fda accepted review supplemental biologics license application subcutaneous formulation orencia treatment adult patients moderate severe rheumatoid arthritis administered injection skin pdufa date august november company announced new phase iii clinical data showed weekly subcutaneous injection investigational formulation orencia following single intravenous iv loading dose provided improvement disease activity similar improvement seen monthly iv administration orencia patients moderate severe rheumatoid arthritis july japanese ministry health labour welfare approved japanese new drug application orencia treatment adults rheumatoid arthritis inadequate response existing treatment july european commission approved new indication orencia combination methotrexate mtx treatment moderate severe rheumatoid arthritis adult patients responded inadequately previous therapy one diseasemodifying anti rheumatic drugs including mtx tnfalpha inhibitor january european commission approved orencia combination methotrexate treatment moderate severe active polyarticular juvenile idiopathic arthritis pediatric patients six years age older insufficient response disease modifying antirheumatic drugs including least one tnf inhibitor table contents onglyzakombiglyze treatment type diabetes part strategic alliance astrazeneca plc astrazeneca november fda approved kombiglyze xr saxagliptin metformin hcl extendedrelease treatment type diabetes adults kombiglyze xr first onceaday metformin extendedrelease xr plus dipeptidyl peptidase inhibitor combination tablet offering strong glycemic control across glycosylated hemoglobin levels fasting plasma glucose postprandial glucose july marketing authorization application komgiblyze known us kombiglyze fixed dose combination onglyza metformin tablets treatment adults type diabetes validated european medicines agency june company astrazeneca announced results week phase iiib study adults type diabetes inadequate glycemic control metformin therapy plus diet exercise study found addition onglyza mg existing metformin therapy achieved primary objective demonstrating noninferiority compared addition titrated glipizide sulphonylurea existing metformin therapy reducing glycosylated hemoglobin levels study also found treatment onglyza mg plus metformin resulted statistically significant lower proportion subjects reporting hypoglycemic events statistically significant weight loss compared titrated glipizide plus metformin onglyza mg plus metformin also resulted significantly smaller rise per week hbac week week compared titrated glipizide plus metformin june company astrazeneca announced results week phase iii study onglyza initial combination therapy metformin produced longterm glycemic improvements measured hbac levels treatmentnave adults type diabetes mellitus inadequately controlled diet exercise compared treatment investigational mg dose onglyza metformin alone study also demonstrated higher number patients able achieve american diabetes association recommended glycosylated hemoglobin level target less onglyza metformin initial combination therapy compared monotherapy either treatment week march company astrazeneca announced commencement saxagliptin assessment vascular outcomes recorded patients diabetes mellitus trial savortimi multicenter randomized doubleblind placebocontrolled phase iv study evaluate treatment onglyza adult type diabetes patients cardiovascular risk factors five year study follow approximately patients type diabetes either history previous cardiovascular events multiple risk factors vascular disease includes patients renal impairment necitumumab imcf investigational anticancer agent part strategic alliance lilly january company lilly announced enrollment stopped phase iii inspire study necitumumab firstline treatment advanced nonsmall cell lung cancer trial evaluating addition necitumumab combination alimta pemetrexed injection cisplatin decision stop enrollment followed independent data monitoring committee dmc recommendation new recently enrolled patients continue treatment trial safety concerns related thromboembolism experimental arm study dmc also noted patients already received two cycles necitumumab appear lower ongoing risk safety concerns patients may choose remain trial informed additional potential risks investigators continue assess patients two cycles determine potential benefit treatment necitumumab continues studied another phase iii trial named squire study evaluating necitumumab potential treatment different type lung cancer called squamous nonsmall cell lung cancer combination gemzar gemcitibane hcl injection cisplatin independent dmc recommended trial continue safety concerns observed xl june company terminated development collaboration exelixis experimental cancer drug xl rights returning exelixis table contents results operations results continuing operations exclude results related mead johnson business prior splitoff december convatec business prior divestiture august medical imaging business prior divestiture january businesses segregated continuing operations included discontinued operations years presented see discontinued operations results continuing operations follows year ended december change change dollars millions vs vs net sales total expenses earnings continuing operations income taxes net sales provision income taxes effective tax rate net earnings continuing operations net sales attributable noncontrolling interest net sales attributable bristolmyers squibb company net sales net sales composition change net sales follows year ended december vs vs net sales analysis change analysis change total foreign total foreign dollars millions change volume price exchange change volume price exchange us nonus total us net sales us net sales growth attributed increased volume higher average net selling prices impact us price increases taken partially offset increased medicaid rebates attributed healthcare reform reduction contractual share abilify net sales effective january plavix abilify represented total us net sales respectively plavix contributed total us net sales growth driven primarily higher average net selling prices abilify us net sales decreased due changes abilify collaboration agreement plavix abilify represented total us net sales respectively plavix contributed total us net sales growth driven higher average net selling process increased demand abilify contributed total us net sales growth driven increased demand key products also contributed us net sales growth international net sales international net sales remained relatively flat lower average net selling prices mostly offset increased volume slight favorability foreign exchange lower average net selling prices primarily attributed government austerity measures europe reduce health care costs table contents international sales volume reflects increased net sales baraclude hiv portfolio sprycel abilify orencia decreased net sales mature brands attributed divestitures generic competition decreased net sales plavix avaproirbesartanavalide attributed increased generic competition international net sales decrease includes negative impact foreign exchange partially offset factors impacting sales growth reported international net sales include copromotion sales reported alliance partner sanofi plavix avaproavalide decreased due generic competition net sales mature brands businesses divested represented approximately total net sales year details domestic international key product net sales discussed general business seasonal information us pharmaceutical prescriber demand reference made table within estimated enduser demand sets forth comparison changes net sales estimated total prescription growth retail mail order customers certain key pharmaceutical new products us nonus net sales categorized based upon location customer recognize revenue net various sales adjustments arrive net sales reported consolidated statements earnings adjustments referred grosstonet sales adjustments described critical accounting policies reconciliation gross sales net sales significant category grosstonet sales adjustments follows year ended december dollars millions gross sales grosstonet sales adjustments chargebacks related government programs cash discounts managed healthcare rebates contract discounts medicaid rebates sales returns adjustments total grosstonet sales adjustments net sales activities ending balances significant category grosstonet sales reserve adjustments follows managed healthcare rebates chargebacks women related infants government cash contract medicaid sales children dollars millions programs discounts discounts rebates returns adjustments wic rebates total balance january provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation discontinued operations balance december provision related sales made current period provision related sales made prior periods returns payments impact foreign currency translation balance december table contents grosstonet sales adjustments percentage gross sales primarily function gross sales trends changes sales mix contractual legislative discounts rebates grosstonet sales adjustments increased overall primarily attributed enactment us healthcare reform expected future increases grosstonet sales adjustments related healthcare reform discussed executive summarybusiness environment specifically medicaid rebates increased due change minimum rebates drug sales extension medicaid rebate rate drugs sold riskbased medicaid managed care organizations managed healthcare rebates contract discounts increased mainly due increased sales chargebacks related government programs increased due increased sales us well additional rebates required certain european countries attributed government austerity measures sales returns decreased primarily due overall reduced provisions various mature brands partially offset million charge estimated returns associated avalide recall adjustments increased overall due additional rebates required certain products sold europe attributed government austerity measures higher discounts increased rebates coupon programs grosstonet sales adjustments increased specifically managed healthcare rebates contract discounts increased primarily due higher plavix medicare sales increase contractual discount rates sales returns decreased primarily due lower provisions pravachol zerit partially offset increased provisions sprycel mature brands driven higher anticipated sales returns medicaid rebates included refunds net overpayments medicaid rebates million three year period center medicare medicaid services policy group approved revised calculations table contents net sales key products represent total net sales following table presents us international net sales key products percentage change prior period foreign exchange impact compared prior period commentary detailing reasons significant variances key products provided change attributable year ended december change foreign exchange dollars millions vs vs vs vs key products plavix clopidogrel bisulfate us nonus total avaproavalide irbesartanirbesartanhydrochlorothiazide us nonus total abilify aripiprazole us nonus total reyataz atazanavir sulfate us nonus total sustiva efavirenz franchise total revenue us nonus total baraclude entecavir us nonus total erbitux cetuximab us nonus total sprycel dasatinib us nonus total ixempra ixabepilone us nonus na total orencia abatacept us nonus total onglyzakombiglyze saxagliptinsaxagliptin metformin us na na nonus na na total na na mature products us nonus total change excess table contents plavix platelet aggregation inhibitor part alliance sanofi us net sales increased primarily due higher average net selling prices estimated total us prescription demand decreased increased international net sales continue impacted launch generic clopidogrel products eu countries since august negative impact net sales relates eu sales comarketing countries equity net income affiliates relates share sales partnership sanofi europe asia expect continued erosion plavix net sales eu impact international net sales equity net income affiliates january company sanofi announced fda granted companies additional sixmonth period exclusivity market plavix exclusivity plavix us scheduled expire may see item financial statementsnote legal proceedings contingenciesplavix litigation discussion plavix exclusivity litigation us eu avaproavalide known eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy also part sanofi alliance us international net sales decreased primarily due decreased overall demand due generic competition eu reduced supply avalide addition million sales return adjustment recorded result avalide recall estimated total us prescription demand decreased us net sales decreased primarily due decreased overall demand estimated total us prescription demand decreased international net sales increased primarily due higher average net selling prices partially offset unfavorable foreign exchange impact abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder part strategic alliance otsuka us net sales decreased primarily due reduction contractual share net sales recognized increased medicaid rebates healthcare reform decrease partially offset higher average net selling prices increased overall demand us net sales increased primarily due increased overall demand new indications certain patients bipolar disorder major depressive disorder higher average net selling prices increase partially offset million amortization million extension payment made otsuka april estimated total us prescription demand increased international net sales increased due increased prescription demand aided new bipolar indication second quarter eu offset unfavorable foreign exchange impact reyataz protease inhibitor treatment hiv us net sales increased primarily due higher estimated total us prescription demand us net sales increased due higher estimated total us prescription demand higher average net selling prices international net sales increased primarily due higher demand across markets europe key driver due june approval firstline treatment sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg product sold joint venture gilead us net sales increased primarily due higher estimated total us prescription demand us net sales increased primarily due higher estimated total us prescription demand well higher average net selling prices international net sales increased primarily due higher demand partially offset unfavorable foreign exchange international net sales increased primarily due continued demand generated launch atripla canada eu fourth quarter partially offset unfavorable foreign exchange impact baraclude oral antiviral agent treatment chronic hepatitis b worldwide net sales increased primarily due continued strong demand international markets continue implement global campaign raise awareness chronic hepatitis b part overall market expansion effort table contents erbitux monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use colorectal cancer head neck cancer erbitux part strategic alliance lilly sold us almost exclusively us net sales continue decrease primarily due lower demand lower average net selling prices sprycel oral inhibitor multiple tyrosine kinases indicated treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase sprycel part strategic alliance otsuka worldwide net sales increased primarily due higher demand previously launched markets growth attributed recently launched markets well higher us average net selling prices fourth quarter sprycel mg daily approved firstline treatment adult patients newly diagnosed philadelphia chromosomepositive chronic myeloid leukemia chronic phase us eu ixempra microtubule inhibitor treatment patients metastatic locally advanced breast cancer part strategic alliance otsuka net sales continue remain flat orencia fusion protein indicated adult patients moderate severe rheumatoid arthritis inadequate response one currently available treatments methotrexate antitumor necrosis factor therapy worldwide net sales increased primarily due increased demand us net sales also impacted higher average selling prices worldwide net sales increased primarily due increased demand onglyzakombiglyze treatment type diabetes onglyza launched various countries third quarter kombiglyze launched fourth quarter mature products includes products lost exclusivity major markets counter brands us net sales remained relatively flat continued generic erosion certain products partially offset higher average net selling prices international net sales decreased due continued generic erosion certain brands including taxol pravachol pravastatin sodium lower average net selling prices europe year year impact rationalization divestitures nonstrategic product portfolio lower demand certain counter products net sales included million recothrom net sales product acquired zymogenetics acquisition october see item financial statementsnote acquisitions details estimated us prescription change data provided throughout report includes information retail mail order channels reflect information channels hospitals home healthcare clinics federal facilities including va hospitals longterm care among others first quarter changed service provider us prescription data wolters kluwer health inc wk supplier market research audit data pharmaceutical industry external reporting purposes internal demand products prior used prescription data based next generation prescription service version national prescription audit provided ims health ims continuously seek improve quality estimates prescription change amounts ultimate patientconsumer demand reviewing estimate calculation methodologies processes analyzing internal thirdparty data expect continue review refine methodologies processes calculation estimates continue review analyze third parties data used calculations estimated prescription data based source prescription audit provided suppliers product respective recordkeeping projection processes data subject inherent limitations estimates based sampling may include margin error table contents change sprycel demand calculated based upon tablets sold though retail mail order channels based upon data obtained ims health ims national sales perspectives audit product ims recordkeeping projection processes data subject inherent limitations estimates based sampling may include margin error calculated estimated total us prescription change weightedaverage basis reflect fact mail order prescriptions include greater volume product supplied compared retail prescriptions mail order prescriptions typically reflect day prescription whereas retail prescriptions typically reflect day prescription calculation derived multiplying mail order prescription data factor approximates three adding retail prescriptions believe calculation estimated total us prescription change based weightedaverage approach provides superior estimate total prescription demand retail mail order channels use methodology internal demand reporting estimated enduser demand following tables set forth key products sold us years ended december total us net sales year ii change reported us net sales year iii estimated total us prescription change retail mail order channels calculated us based third party data weightedaverage basis iv months inventory hand wholesale distribution channel year ended december december change us change us months total us net sales net sales total prescriptions hand dollars millions wk wk ims plavix avaproavalide abilify reyataz sustiva franchisea baraclude erbituxb na na na sprycel ixemprab na na na orenciab na na na onglyza kombiglyzec na na na na sustiva franchise total revenue includes sales sustiva revenue bulk efavirenz included combination therapy atripla months hand relates sustiva b erbitux ixempra orencia parenterally administered products prescriptionlevel data physicians write prescriptions products c onglyza launched us august kombiglyze launched us fourth quarter onglyza month inventory hand december kombiglyze months inventory hand december support initial product launch change excess pursuant us securities exchange commission sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception us products estimated levels inventory distribution channel excess one month hand december international products estimated levels inventory distribution channel excess one month hand september kombiglyze months inventory hand us support initial product launch inventory nominal expected worked less amount time demand new product increases post launch dafalgan analgesic product sold principally europe months inventory hand direct customers compared months inventory hand december level inventory hand primarily due september launch new dosage france fervex cold flu product months inventory hand internationally direct customers compared months inventory hand december level inventory hand primarily due lower expected demand table contents videx antiviral product months inventory hand internationally direct customers compared months inventory hand december level inventory hand primarily due government purchasing patterns brazil principen antibiotic product months inventory hand direct customers compared months inventory hand december increased level inventory due lower demand reenforcement antibiotic law mexico requires prescriptions antibiotics us products sold exclusively wholesalers distributors generally determined months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products provided distributors factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes businesses outside us significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely cases direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available developed variety methodologies estimate data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly rely variety methods estimate direct customer product level inventory calculate months hand factors may affect estimates include generic competition seasonality products direct customer purchases light price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing annual report disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q geographic areas general products available countries world largest markets us france canada japan italy spain germany china united kingdom net sales geographic areas based location end customer follows net sales change total net sales vs vs dollars millions united states europe japan asia pacific canada latin america middle east africa emerging markets total see net sales discussion us net sales increase net sales europe decreased primarily due unfavorable foreign exchange impact decreased net sales certain mature brands due divestitures increased generic competition plavix avaproavalide partially offset sales growth major european markets abilify hiv portfolio baraclude sprycel onglyza orencia sales growth previously mentioned products tempered continuing fiscal challenges european countries healthcare payers including government agencies reduced expected continue reduce cost healthcare actions directly indirectly impose additional price reductions support expanded use generic drugs measures include limited mandatory discounts rebates price reductions reflected net sales net sales decreased primarily due unfavorable foreign exchange impact decreased net sales certain mature brands due divestitures increased generic competition plavix partially offset sales growth major european markets hiv portfolio abilify baraclude sprycel orencia net sales japan asia pacific canada increased primarily due favorable foreign exchange impact increased net sales baraclude sprycel partially offset decreased net sales certain mature brands due divestitures generic competition net sales remained relatively flat decreased net sales certain mature brands unfavorable foreign exchange impact offset increased net sales baraclude sprycel table contents net sales latin america middle east africa increased primarily due increased net sales sprycel reyataz baraclude orencia favorable foreign exchange impact partially offset decreased net sales mature brands net sales decreased primarily due unfavorable foreign exchange impact decreased net sales certain mature brands partially offset increased net sales reyataz orencia plavix emerging markets brazil russia india china turkey net sales emerging markets increased primarily due favorable foreign exchange impact increased net sales baraclude sprycel abilify reyataz net sales increased primarily due increased net sales baraclude sprycel partially offset unfavorable foreign exchange impact consists primarily sales supply agreements active pharmaceutical ingredients including temporary supply agreements facilitate recent divestitures manufacturing facilities continuing supply agreements alliance partners net sales decreased primarily due winddown temporary supply agreements related manufacturing facility divestitures elimination bulk sales pharmaceutical ingredients previously manufactured us latina italy facility divested reduced sales irbesartan bulk pharmaceutical ingredients alliance partner due declining worldwide avaproavalide sales net sales increased primarily due temporary supply agreements entered facilitate divestiture certain manufacturing facilities pakistan egypt australia single country outside us contributed total net sales expenses expenses change net sales vs vs dollars millions cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring litigation expense net equity net income affiliates gain sale imclone shares incomeexpense total expenses change excess cost products sold cost products sold consist material costs internal labor overhead owned manufacturing sites thirdparty processing costs supply chain costs changes foreign currency forward contracts offset manufacturing related assets liabilities denominated foreign currencies essentially costs managed primarily global manufacturing organization referred technical operations addition discovery royalties attributed licensed products connection alliances well amortization milestone payments occur regulatory approval also included costs percentage net sales vary periods result product mix price inflation costs attributed rationalization manufacturing sites resulting accelerated depreciation impairment charges stranded costs addition changes foreign currency may also provide volatility given high percentage total costs denominated foreign currencies decrease costs products sold percentage net sales primarily attributed favorable product mix us price increases favorable foreign exchange partially offset reduction share abilify sales related extended commercialization manufacturing agreement abilifyand collaboration fee paid otsuka sprycel ixempra oncology collaboration beginning additional medicare rebates granted us healthcare reform international price decreases related government austerity measures european economic crisis improvement cost products sold percentage net sales driven favorable foreign exchange higher us average net selling prices favorable product mix realized manufacturing efficiencies pti offset higher manufacturing costs attributed inflation costs include manufacturing rationalization charges million primarily related implementation pti compared million rationalization charges recognized table contents marketing selling administrative marketing selling administrative expenses consist employee salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs expenses attributed product manufacturing costs research development expenses expenses managed regional commercialization functions global functions finance law information technology human resources decrease primarily attributed reduction sales related activities certain key products coincide respective life cycle prior year impact million funding payment made bms foundation reduction abilify sales force otsuka established sales force promotion abilify sprycel ixempra reduced project standardization implementation costs role new accounting human resource related systems overall efficiencies gained pti continuous improvement initiatives decrease resulted favorable foreign exchange impact efficiencies gained pti advertising product promotion advertising product promotion expenses consist related media sample direct consumer programs decrease primarily attributed reduced spending promotion certain key products coincide product life cycle otsukas reimbursement certain abilify sprycel ixempra advertising product promotion expenses partially offset increased spending onglyza launch pipeline products decrease attributed reduced spending promotion products nearing patent expirations favorable foreign exchange impact partially offset increased spending onglyza launch pipeline products research development research development expenses consist internal salary benefit costs thirdparty grants fees paid clinical research organizations supplies facility costs total research development expenses include costs discovery research preclinical development early lateclinical development drug formulation well clinical trials medical support marketed products proportionate allocations enterprisewide costs appropriate costs expenses also include thirdparty licensing fees typically paid upfront well regulatory contractual milestones met certain expenses shared alliance partners based upon contractual agreements approximately expenses managed global research development organization approximately total spend attributed development activities remainder attributed preclinical research activities expenses vary periods number reasons including timing upfront licensing milestone payments decrease primarily attributed timing upfront licensing milestone payments partially offset additional spending support maturing pipeline compounds obtained stringofpearls strategy upfront licensing milestone payments expensed research development million primarily attributed exelixis allergan pdl biopharma inc million primarily attributed zymogenetics alder nissan million primarily attributed exelixis pdl biopharma inc kai pharmaceuticals inc increase attributed additional spending support maturing pipeline compounds obtained stringofpearls strategy offset favorable foreign exchange impact acquired inprocess research development charge related acquisition kosan biosciences inc kosan provision restructuring changes provision restructuring primarily attributable timing implementation certain pti continuous improvement initiatives litigation expense net amount includes million insurance reimbursement prior litigation partially offset additional reserves established certain average wholesale prices awp litigation expense primarily due million securities litigation settlement information see item financial statementsnote legal proceedings contingencies equity net income affiliates equity net income affiliates primarily related international partnership sanofi varies based international plavix net sales included within partnership decrease attributed impact alternative salt form clopidogrel generic clopidogrel competition international plavix net sales commencing additional information see item financial statementsnote alliances collaborations table contents gain sale imclone shares gain sale imclone shares attributed receipt approximately billion cash tendering investment imclone see item financial statementsnote alliances collaborations detail incomeexpense incomeexpense include year ended december dollars millions interest expense interest income impairment loss sale manufacturing operations lossgain debt repurchase ars impairment net foreign exchange transaction gainslosses gain sale product lines businesses assets acquisition related items income alliance partners pension curtailment settlement charges incomeexpense interest expense decreased year year primarily due lower overall interest rates floating rate debt amortization resulting termination interest rate swaps less debt outstanding repurchases interest income increased primarily due higher average cash cash equivalents marketable securities balances higher returns continued diversification investment portfolio interest income decreased primarily due lower interest rates compared partially offset higher average cash cash equivalents marketable securities balances impairment loss sale manufacturing operations primarily attributed disposal manufacturing operations latina italy see item financial statementsnote restructuring auction rate securities ars impairment charge recognized due severity duration decline value future prospects issuers ability intent hold securities recover value value ars december million impact foreign exchange mainly due foreign exchange hedges discontinued qualify cash flow hedges net foreign exchange transaction loss includes million charge remeasurement venezuelan monetary assets devaluation bolivar net foreign exchange gain primarily due sudden dramatic strengthening us dollar second half generated significant gains foreign currency denominated transactions see item financial statementsnote financial instruments gain sale product lines businesses assets primarily related sale mature brands including businesses within indonesia australia business egypt acquisition related items attributed acquisition zymogenetics medarex see item financial statementsnote acquisitions income alliance partners includes income earned sanofi partnership amortization certain upfront licensing milestone receipts related alliances pension settlementscurtailments primarily attributed amendments eliminated crediting future benefits related service us pension plan participants amendments resulted curtailment charge million million respectively remainder charges resulted lump sum payments certain plans exceeded sum plan interest costs service costs resulting acceleration portion previously deferred actuarial losses although activity driven pti certain divestitures additional charges may recognized future particularly us pension plans due lower threshold resulting elimination service costs see item financial statements note pension postretirement postemployment liabilities detail table contents specified items following specified items affected comparability results periods presented herein items excluded segment results marketing year ended december cost selling research provision products litigation income dollars millions sold administrative development restructuring expense expense total restructuring activity downsizing streamlining worldwide operations impairment loss sale manufacturing operations accelerated depreciation asset impairment shutdown costs pension curtailment settlement charges process standardization implementation costs total restructuring litigation charges net upfront licensing milestone payments iprd impairment acquisition related items product liability charges total income taxes items outofperiod tax adjustment specified tax charge decrease net earnings continuing operations year ended december cost marketing research provision products selling litigation income dollars millions sold administrative development restructuring expense expense total restructuring activity downsizing streamlining worldwide operations accelerated depreciation asset impairment shutdown costs pension curtailment settlement charges process standardization implementation costs gain sale product lines businesses assets total restructuring litigation charges bms foundation funding initiative loss sale investments upfront licensing milestone payments acquisition related items debt repurchase product liability chargesinsurance recoveries total income taxes items decrease net earnings continuing operations table contents acquired marketing inprocess gain year ended december cost selling research research provision sale products litigation imclone income dollars millions sold administrative development development restructuring expense shares expense total restructuring activity downsizing streamlining worldwide operations accelerated depreciation asset impairment shutdown costs pension curtailment settlement charges process standardization implementation costs gain sale leaseback properties termination lease contracts gain sale product lines businesses total restructuring litigation settlement insurance recovery product liability upfront licensing milestone payments acquired inprocess research development ars impairment loss sale debt repurchase gain sale imclone shares total income taxes items decrease net earnings continuing operations nongaap financial measures nongaap financial measures including nongaap earnings continuing operations related eps information adjusted exclude certain costs expenses gains losses specified items information intended enhance investors overall understanding past financial performance prospects future example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap among items gaap measures excluded purposes determining adjusted earnings adjusted measures charges related implementation pti gains losses purchase sale businesses product lines investments discontinued operations restructuring exit costs accelerated depreciation charges asset impairments charges recoveries relating significant legal proceedings upfront licensing milestone payments inlicensing products achieved regulatory approval immediately expensed iprd charges prior special initiative funding bristolmyers squibb foundation significant tax events detailed listing items excluded nongaap earnings continuing operations see specified items similar charges gains items recognized prior periods reasonably possible reoccur future periods table contents reconciliation gaap nongaap follows year ended december year ended december specified specified dollars millions except per share data gaap items nongaap gaap items nongaap net earnings continuing operations attributable bms earnings attributable unvested restricted shares net earnings continuing operations attributable bms used diluted eps calculation average common shares outstandingdiluted diluted eps continuing operations attributable bms income taxes effective income tax rate earnings continuing operations income taxes effective income tax rate lower us statutory rate due decision permanently reinvest earnings certain manufacturing operations ireland puerto rico switzerland offshore us federal research development tax credit favorable tax rates ireland puerto rico grants scheduled expire prior increase effective tax rate primarily due million tax charge recognized fourth quarter resulted additional us taxable income earnings foreign subsidiaries previously considered permanently reinvested offshore additional information see item financial statementsnote income taxes discontinued operations december completed splitoff remaining interest mead johnson means exchange offer bms shareholders august completed divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partners lp avista january completed divestiture bristolmyers squibb medical imaging medical imaging avista see item financial statementsnote discontinued operations noncontrolling interest noncontrolling interest primarily related partnerships sanofi territory covering americas related plavix net sales see item financial statementsnote alliances collaborations increase noncontrolling interest corresponds increased net sales plavix us net earnings discontinued operations attributable noncontrolling interest primarily relates publicly owned portion mead johnson prior complete divestiture splitoff summary noncontrolling interest follows year ended december dollars millions sanofi partnerships noncontrolling interestpretax income taxes net earnings continuing operations attributable noncontrolling interestnet taxes net earnings discontinued operations attributable noncontrolling interestnet taxes net earnings attributable noncontrolling interestnet taxes table contents financial position liquidity capital resources net cash position december follows dollars millions cash cash equivalents marketable securitiescurrent marketable securitiesnoncurrent total cash cash equivalents marketable securities shortterm borrowings including current portion longterm debt longterm debt total debt net cash position maintain significant level working capital approximately billion december billion december paid billion dividends reacquired million aggregate principal value outstanding debt million means tender offer acquired zymogenetics million repurchased million common stock future periods expect cash generated us operations together existing cash cash equivalents marketable securities borrowings capital markets sufficient cover cash needs working capital capital expenditures strategic alliances acquisitions milestone payments dividends paid us common stock debt repurchases rely shortterm borrowing meet liquidity needs cash cash equivalents marketable securities held outside us approximately billion billion december respectively either utilized fund nonus operations repatriated back us taxes previously provided cash repatriations subject restrictions certain jurisdictions may subject withholding taxes cash cash equivalents marketable securities held us billion december represented approximately total balance cash cash equivalents marketable securities held us billion december increase resulted internal restructuring certain legal entities diversified investment portfolio acquired noncurrent marketable securities including purchases corporate debt securities investments subject changes fair value result interest rate fluctuations market factors may impact results operations investment policy places limits investments amount time maturity investments institution policy also requires investments made highly rated corporate financial institutions see item financial statementsnote cash cash equivalents marketable securities continue monitor potential impact deteriorating economic conditions certain european countries discussed geographic areas related impact prescription trends pricing discounts creditworthiness customers ability collect outstanding receivables countries currently believe conditions material impact liquidity cash flow financial flexibility billion five year revolving credit facility syndicate lenders maturing december extendable consent lenders facility contains customary terms conditions including financial covenant whereby ratio consolidated net debt consolidated capital exceed end quarter compliance covenant since inception facility borrowings outstanding facility december additional source liquidity sell trade accounts receivables principally nonus governments hospital customers primarily japan italy portugal spain third parties receivables sold nonrecourse basis approximated million million respectively sales agreements allow recourse event uncollectibility retain interest underlying asset sold credit ratings moodys investors service moodys longterm shortterm credit ratings currently prime respectively longterm credit outlook remains stable outlook standard poors sp longterm shortterm credit ratings currently respectively longterm credit rating remains stable outlook fitch ratings fitch longterm shortterm credit ratings currently f respectively longterm credit rating changed august stable negative outlook credit ratings considered investment grade longterm ratings designate low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings designate strongest capacity timely repayment table contents cash flows following discussion cash flow activities december dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flows operating activities represent cash receipts cash disbursements related activities investing activities financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items depreciation amortization impairment charges stockbased compensation charges gains losses attributed investing financing activities gains losses sale product lines businesses changes operating assets liabilities reflect timing differences receipt payment cash associated transactions recognized results operations net impact changes operating assets liabilities aggregated net cash outflow million cash inflows million million items included impact changes receivables inventories deferred income accounts payable income taxes receivablepayable operating assets liabilities discussed detail continue maximize operating cash flows working capital initiatives designed improve working capital items directly affected changes sales volume receivables inventories accounts payable improvements driven several actions including nonrecourse factoring nonus trade receivables revised contractual payment terms customers vendors enhanced collection processes various supply chain initiatives designed optimize inventory levels progress area monitored period component annual incentive plan following summarizes certain working capital components expressed percentage trailing twelve months net sales trailing trailing december twelve month december twelve month dollars millions net sales net sales net trade receivables inventories accounts payable total changes operating assets liabilities aggregated net cash outflow million including cash outflows receivables million primarily attributed increased sales cash outflows operating assets liabilities million primarily related pension funding excess current year expense million partially offset increased rebate sales returns million primarily due increase medicaid rebates effective january agencies administrative delays payments managed care organizations cash inflows accounts payables million primarily attributed timing vendor alliance payments cash inflows inventories million primarily related work inventory balances changes operating assets liabilities aggregated net cash inflow million including cash inflows accounts payable million primarily attributed timing payments vendors alliances well impact working capital initiative discussed cash inflows receivables million primarily attributed additional factoring nonus trade receivables japan spain cash inflows deferred income million mainly due milestone payments received pfizer million astrazeneca million partially offset amortization table contents cash outflows operating assets liabilities million primarily related pension funding excess current year expense million payment otsuka amortized reduction net sales extension period million changes operating assets aggregated net cash inflow million including cash inflows income tax payablereceivable million includes impact receipt million tax refund including interest related prior year foreign tax credit carryback claim cash inflows accounts payables million primarily attributed timing vendor alliance payments cash inflows inventory million primarily attributed utilization inventories built prior year new product launches strategic builds existing products launches including new indications abilify cash inflows deferred income million primarily due receipt upfront licensing milestone payments alliance partners cash outflows accounts receivables million attributed increased sales cash outflows operating assets liabilities million primarily due net litigation related payments million attributed settlement certain pricing sales litigation accrued prior periods pension funding excess current year expense million increase noncurrent inventory million investing activities net cash used investing activities billion including net purchases marketable securities billion purchase zymogenetics inc million capital expenditures million net cash used investing activities billion including acquisition medarex billion net cash acquired million net purchases marketable securities billion capital expenditures million mead johnson cash included splitoff million proceeds sale businesses investments including businesses within asiapacific region million australia million proceeds sale genmab celldex securities million net cash provided investing activities billion including proceeds divestiture convatec billion medical imaging million proceeds tendering shares imclone billion proceeds sale leaseback paris france facility million proceeds sale businesses including mature brands business egypt million capital expenditures million included expenditures associated construction biologic facility devens massachusetts acquisition kosan million financing activities net cash used financing activities billion including dividend payments billion debt repurchase means tender offer million common stock repurchase million net proceeds exercise stock options million net proceeds termination interest rate swap agreements million table contents net cash used financing activities million including dividend payments billion repayment mead johnson revolving credit facility million early extinguishment certain debt securities million net proceeds issuance mead johnson notes billion revolving credit facility million net proceeds mead johnson ipo million net proceeds termination interest rate swap agreements million net proceeds exercise stock options million net cash used financing activities billion including dividend payments billion redemption floating rate convertible senior debentures due billion repayment notes due august million yen notes due million repurchase notes million net proceeds issuance notes due million notes due billion net proceeds termination interest rate swap agreements million net proceeds stock option exercises million reflects exercise fewer stock options due decrease average stock price compared prior periods dividends declared per common share december declared quarterly dividend per common share expect pay dividend full year per share decrease total dividends despite per share increase primarily attributed million share reduction mead johnson splitoff dividend decisions made quarterly basis board directors table contents contractual obligations payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb longterm liabilities totalc includes estimated future interest payments shortterm longterm debt securities also includes accrued interest payable recognized consolidated balance sheets consists primarily accrual interest shortterm longterm debt well accrual periodic cash settlements derivatives netted counterparty b due uncertainty related timing reversal uncertain tax positions shortterm uncertain tax benefits provided table see item financial statementsnote income taxes detail c table excludes future contributions us pensions postretirement postemployment benefit plans required contributions contingent upon numerous factors including minimum regulatory funding requirements funded status plan due uncertainty future obligations excluded table contributions us international plans expected million see item financial statementsnote pension postretirement postemployment liabilities detail addition committed approximately billion aggregate potential future research development milestone payments third parties part inlicensing development programs early stage milestones defined milestones achieved phase iii clinical trials comprised billion total committed amount late stage milestones defined milestones achieved post phase iii clinical trials comprised billion total committed amount payments agreements generally due payable upon achievement certain developmental regulatory milestones specific timing predicted addition certain royalty obligations calculated percentage net sales agreements also provide salesbased milestones aggregate approximately billion would obligated pay alliance partners upon achievement certain sales levels discussion contractual obligations see item financial statementsnote pension postretirement postemployment liabilities note short term borrowings longterm debt note financial instruments note leases sec consent order previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain inventory management agreements imas us pharmaceutical wholesalers account nearly total gross sales us biopharmaceuticals products current terms imas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three table contents largest wholesalers currently account approximately total gross sales us biopharmaceuticals products inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us biopharmaceuticals businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast biopharmaceuticals business outside us significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent recently issued accounting standards see item financial statementsnote accounting policies discussion impact related recently issued accounting standards critical accounting policies prepare financial statements conformity accounting principles generally accepted us preparation financial statements conformity us generally accepted accounting principles gaap requires use estimates assumptions affect reported amounts assets liabilities including disclosure contingent assets contingent liabilities date financial statements reported amounts revenue expenses reporting period critical accounting policies important financial condition results operations require difficult subjective complex judgments part management application often result need make estimates effect matters inherently uncertain new discounts us healthcare reform law medicare coverage gap managed medicaid expansion public health service b program require additional assumptions due lack historical claims experience addition new pharmaceutical company fee estimate subject external data well calculation based companys relative share industry results uncertainty factors surrounding estimates judgments used preparation consolidated financial statements actual results may vary estimates accounting policies discussed audit committee board directors revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates require difficult subjective complex judgments part management recognize revenue title substantially risks rewards ownership transferred customer generally occurs date shipment net grosstonet sales adjustments discussed involve significant estimates judgments discussions revenue recognition see item financial statementsnote accounting policiesrevenue recognition sales rebate return accruals grosstonet sales adjustments following significant categories grosstonet sales adjustments chargebacks managed healthcare rebates contractual discounts medicaid rebates cash discounts sales returns adjustments involve significant estimates judgments require us use information external sources see net sales reconciliation gross sales net sales significant category grosstonet sales adjustment chargebacks related government programs us businesses participate programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price account chargebacks reducing accounts receivable amount equal estimate chargeback claims attributable sale determine estimate chargebacks primarily based historical experience regarding programs chargebacks current contract prices programs consider chargeback payments levels inventory distribution channel claim processing time lag adjust reduction accounts receivable periodically throughout quarter reflect actual experience table contents cash discounts us certain countries offer cash discounts generally approximating sales price incentive prompt payment account cash discounts reducing accounts receivable full amount discounts consider payment performance adjust accrual reflect actual experience managed healthcare rebates contract discounts offer rebates discounts managed healthcare organizations us manage prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit addition commercial plans well globally contract counterparties hospitals group purchasing organizations beginning rebates medicare part program include discount companys brandname drugs patients fall within medicare part coverage gap addition accrue rebates us department defense tricare retail pharmacy refund program account managed healthcare rebates contract discounts establishing accrual amount equal estimate managed healthcare rebates contractual discounts attributable sale determine estimate managed healthcare rebates contractual discounts accrual primarily based historical experience regarding rebates discounts current contract prices consider sales performance products subject managed healthcare rebates contract discounts levels inventory distribution channel adjust accrual periodically throughout quarter reflect actual experience medicaid rebates us businesses participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities discounts rebates provided latter programs included medicaid rebate accrual considered medicaid rebates purposes discussion retroactive january minimum rebates medicaid drug sales increased medicaid rebates also extended drugs used riskbased medicaid managed care plans beginning march account medicaid rebates establishing accrual amount equal estimate medicaid rebate claims attributable sale determine estimate medicaid rebates accrual primarily based historical experience regarding medicaid rebates well expansion prospective basis participation nonmandatory aspects qualifying federal state government programs legal interpretations applicable laws related medicaid qualifying federal state government programs new information regarding changes medicaid programs regulations guidelines would impact amount rebates consider outstanding medicaid claims medicaid payments levels inventory distribution channel adjust accrual periodically throughout quarter reflect actual experience sales returns account sales returns establishing accrual amount equal estimate sales recognized related products expected returned returns established products determine estimate sales return accrual primarily based historical experience regarding sales returns also consider factors could impact sales returns factors include levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products instances expected precipitous declines demand following loss exclusivity consider factors adjust accrual periodically throughout quarter reflect actual experience event product recall product discontinuance consider reasons impact actions adjust sales return accrual appropriate taking account historical experience estimated levels inventory distribution channel product discontinuances estimates continuing demand sales returns accruals new products estimated primarily based historical sales returns experience similar products within line product within similar therapeutic category limited circumstances new product extension existing line product historical experience products similar therapeutic category reliably estimate expected returns new product defer recognition revenue right return longer exists developed sufficient historical experience estimate sales returns also consider shelf life new products determine whether adjustment sales return accrual appropriate shelf life connection new products tends shorter shelf life established products may still developing optimal manufacturing process new product would lengthen shelf life addition higher launch quantities may manufactured advance launch date ensure sufficient supply exists satisfy market demand cases assess reduced shelf life together estimated levels inventory distribution channel projected demand determine whether adjustment sales return accrual appropriate table contents pharmaceutical company fee pharma fee beginning pay annual nontaxdeductible fee federal government based allocation market share branded prior year sales certain government programs including medicare medicaid department veterans affairs department defense tricare pharma fee amount finalized preliminary funding based information oneyear lag pharma fee calculated based market data company well industry participants company full visibility fee classified financial reporting purposes operating expense adjustments addition grosstonet sales adjustments described make grosstonet sales adjustments example offer sales discounts significantly nonus businesses also offer consumer coupons rebates us business addition number countries outside us including certain major european countries provide rebates government entities generally account grosstonet sales adjustments establishing accrual amount equal estimate adjustments attributable sale generally determine estimates accruals grosstonet sales adjustments primarily based historical experience performance commitments government entities relevant factors including estimated levels inventory distribution channel adjust accruals periodically throughout quarter reflect actual experience use information external sources use information external sources estimate grosstonet sales adjustments estimate inventory wholesalers based projected prescription demandbased sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals effective january changed service provider us prescription data wk supplier market research audit data pharmaceutical industry project prescription demandbased sales many us biopharmaceutical products prior used prescription data based nextgeneration prescription service version national prescription audit provided ims also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information retirement benefits pension plans postretirement benefit plans accounted using actuarial valuations key assumptions used calculating cost pension benefits discount rate expected longterm rate return plan assets consultation actuaries evaluate select key assumptions others used calculating cost pension benefits salary growth retirement turnover healthcare trends mortality rates based expectations actual experience appropriate determine assumptions remeasurement date including december year calculate liability information date pension expense following year depending assumptions used pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors determining discount rate use yield high quality corporate bonds coincides cash flows plans estimated payouts citigroup pension discount curve used determining discount rate us plans us plans pension expense determined using weighted average discount rate present value benefit obligations december us plans determined using discount rate discount rate used determining us plans pension expense reduced expense would increased approximately million assumed discount rate used determining projected benefit obligation december reduced projected benefit obligation would increased approximately million table contents determining expected longterm rate return plan assets estimate returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increased million detailed discussion retirement benefits see item financial statementsnote pension postretirement postemployment liabilities business combinations consolidated financial statements reflect acquired business completion acquisition assets acquired liabilities assumed recognized date acquisition respective fair values excess purchase price estimated fair values net assets acquired recognized goodwill determining fair value intangible assets including iprd typically use income method method starts forecast expected future net cash flows risk adjusted based estimated probabilities technical regulatory success cash flows adjusted present value applying appropriate discount rate reflects risk factors associated cash flow streams significant estimates assumptions inherent income method methods include amount timing projected future cash flows amount timing projected costs develop iprd commercially viable products discount rate selected measure risks inherent future cash flows assessment assets life cycle competitive trends impacting asset including consideration technical legal regulatory economic barriers entry well expected changes standards practice indications addressed asset specific intangible assets following approaches utilized iprd valued market participant view values preexisting relationship acquiree consider terms respective collaboration arrangement including cost profit sharing splits projects unit account typically global view would consider potential jurisdictions indications january acquired iprd projects initially capitalized considered indefinitelived assets subject annual impairment reviews often upon occurrence certain events compounds reach commercialization assets amortized expected useful lives prior january amounts allocated acquired iprd expensed date acquisition technology related specific platforms valued based upon expected annual number antibodies achieving early candidate nomination status technology commercial products valued utilizing multiperiod excessearnings method income approach premise value intangible asset equal present value aftertax cash flows solely attributed intangible asset licenses valued utilizing discounted cash flow method utilizing estimates future riskadjusted milestone royalty payments projected earned respective products estimated economic term compounds development significant delays obtaining marketing approval inability bring respective product market could result related intangible assets partially fully impaired commercialized products inability meet sales forecasts could result related intangible assets partially fully impaired determining useful life intangible asset based upon period expected contribute future cash flows pertinent matters associated asset environment operates considered including legal regulatory contractual provisions well effects obsolescence demand competition economic factors amortization periods intangible assets typically follows iprd upon commercialization patent life respective product licenses term respective license arrangement technology estimated life technology table contents zymogenetics inc acquisition october acquired zymogenetics inc aggregate purchase price million million net cash acquired see item financial statementsnote acquisitions estimated fair value identifiable intangible assets million included million iprd projects million assigned pegylatedinterferon lambda currently phase iib development treatment hepatitis c million assigned phase ii product million licenses attributed five products various stages development ultimate realization iprd projects depend upon successful regulatory approvals received market factors relevant typical biopharmaceutical product million technology associated recothrom whollyowned commercialized product developed marketed use topical hemostat control moderate bleeding surgical procedures amortized year life projected cash flows utilized valuation assumed initial positive cash flows commence shortly receipt expected regulatory approvals subject trial results among things estimated occur number years projected cash flows discounted actual cash flows attributed project likely different assumed medarex inc acquisition september acquired remaining outstanding shares medarex already owned us approximately billion see item financial statementsnote acquisitions estimated fair value identifiable intangible assets billion included billion iprd billion assigned yervoy fully human antibody currently phase iii development treatment metastatic melanoma fda accepted filing review biologics license application yervoy pretreated advanced melanoma stated action date march also ongoing yervoy phase ii study lung cancer well phase iii studies adjuvant melanoma hormonerefractory prostate cancer ultimate realization yervoys asset value depend upon successful regulatory approvals received market factors typical biopharmaceutical product remaining iprd assigned four projects phase ii development projects various stages development generated medarex technology developed licensing partners may generate milestone payments royalties upon commercialization million technologies attributed technology platforms produce high affinity fully human antibodies use broad range therapeutic areas including immunology oncology developed technology amortized expected useful lives years million licenses attributed three separate license arrangements received regulatory approval licenses amortized expected useful lives years projected cash flows assumed initial positive cash flows commence shortly receipt expected regulatory approvals subject trial results among things approved could potentially early projected cash flows discounted actual cash flows attributed project likely different assumed impairment goodwill goodwill tested least annually impairment using twostep process first step identify potential impairment second step measures amount impairment loss goodwill considered impaired carrying amount reporting units goodwill exceeds estimated fair value biopharmaceutical segment includes several separate reporting units based geography aggregated impairment testing purposes based upon recent annual impairment test completed first quarter fair value goodwill substantially excess related carrying value discussion goodwill acquired inprocess research development intangible assets see item financial statementsnote accounting policiesgoodwill acquired inprocess research development intangible assets indefinitelived intangible assets including iprd indefinitelived intangible assets subject amortization tested impairment annually frequently events changes circumstances indicate asset might impaired consider various factors including stage development table contents current legal regulatory environment competitive landscape considering industrys success rate bringing developmental compounds market iprd impairment charges may occur future periods recognized million charge related medarex project ceased development longlived assets periodically evaluate whether current facts circumstances indicate carrying value depreciable assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows produced longlived asset appropriate grouping assets compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted value estimated future cash flows report asset disposed lower carrying value estimated net realizable value estimates future cash flows based reasonable supportable assumptions projections requiring judgment changes key assumptions businesses prospects changes market conditions could result impairment charges impairment charges longlived assets million million million discussion impairment longlived assets see item financial statementsnote accounting policiesimpairment longlived assets million asset impairment charge recognized connection writedown assets fair value less cost sell manufacturing operations latina italy met held sale criteria additional million charge recognized operations sold see item financial statementsnote restructuring additional information manufacturing operation also evaluated impairment result lower sales forecasts facility depreciated expected useful life net carrying value approximately million december anticipated undiscounted cash flows attributed facility exceeds net carrying value significant amount result impairment recognized expected cash flows estimated based current sales forecasts expectations subject change based upon near long term production volumes margins generated facility well potential alternative future use may lead future impairment marketable securities investments companies marketable securities classified available sale therefore reported fair value changes fair value reported accumulated comprehensive income declines fair value considered temporary charged earnings fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity determining security otherthantemporarily impaired typically consider severity duration decline future prospects issuer ability intent hold security recovery declines fair value determined credit related charged earnings transfers fair value levels recognized beginning reporting period average cost method used determining realized gains losses sale available sale securities realized gains losses included incomeexpense level investments including frs ars utilize valuation models including based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity valuation subject uncertainties difficult predict utilize considerable amount judgment estimation factors may impact valuation include changes credit ratings securities well underlying assets supporting securities rates default underlying assets underlying collateral value discount rates counterparty risk ongoing strength quality market credit liquidity discussions current noncurrent marketable securities frs ars see item financial statementsnote fair value measurement note cash cash equivalents marketable securities account less owned companies ability exercise significant influence using equity method accounting share net income losses equity investments included equity net income affiliates consolidated statements earnings investments whose fair market value falls carrying value assess decline temporary consider intent ability hold investments market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity impairment losses recognized incomeexpense decline market value deemed temporary table contents contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies see item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives judgments subject change adjustments deferred tax valuation allowances made earnings period assessments made net deferred tax assets billion billion december respectively net valuation allowances billion billion december respectively recognized deferred tax assets december related us federal net operating loss carryforward million us federal research development tax credit carryforward million net operating loss carryforward expires varying amounts beginning research development tax credit carryforwards expire varying amounts beginning realization carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured believe likely deferred tax assets realized provide taxes undistributed earnings foreign subsidiaries expected reinvested permanently offshore company completed internal restructuring certain legal entities contributed million tax charge recognized fourth quarter possible us tax authorities could assert additional material tax liabilities arising restructuring assertion occur company would vigorously challenge assertion believes would prevail however assurance result prior mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions relied upon certain assumptions representations covenants mead johnson regarding future conduct business matters could effect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement example mead johnson agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets agreed indemnify mead johnson certain taxes related business prior completion ipo created part restructuring facilitate ipo table contents established liabilities possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes see item financial statementsnote accounting policiesincome taxes note income taxes special note regarding forwardlooking statements annual report including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years included important factors cautionary statements included annual report particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made undertake obligation release publicly revisions forwardlooking statements result new information future events otherwise table contents item quantitative qualitative disclosures market risk exposed market risk due changes currency exchange rates interest rates result certain derivative financial instruments used available costeffective basis hedge underlying economic exposure primary net foreign currency translation exposures euro japanese yen canadian dollar british pound australian dollar mexican peso chinese renminbi foreign currency forward contracts used manage exposures instruments generally qualify cash flow hedge accounting treatment managed consolidated basis efficiently net exposures thus take advantage natural offsets derivative instruments also used part interest rate risk management strategy derivative instruments used principally comprised fixedto floating interest rate swaps generally qualify fairvalue hedge accounting treatment addition financial instruments including derivatives subject counterparty credit risk consider part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant portion revenues earnings cash flow exposed changes foreign currency rates use foreign currency forward contracts manage foreign exchange risk primarily arises certain intercompany transactions designate derivative instruments foreign currency cash flow hedges appropriate addition exposed foreign exchange transaction risk arises nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies order manage risks use foreign currency forward contracts offset exposures certain assets liabilities earnings denominated certain foreign currencies foreign currency forward contracts designated hedges therefore changes fair value derivatives recognized earnings incomeexpense occur estimate appreciation underlying currencies hedged levels us dollar december variables held constant would decrease fair value foreign exchange forward contracts held december million realized would effect earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets order manage risk use nonus dollar borrowings hedge foreign currency exposures net investment certain foreign affiliates nonus dollar borrowings designated hedges net investments effective portion foreign exchange gains losses hedges recognized part foreign currency translation component accumulated oci additional information see item financial statementsnote financial instruments interest rate risk use interest rate swaps part interest rate risk management strategy interest rate swaps used principally fixedtofloating rate swaps designated fairvalue hedges swaps intended provide us appropriate balance fixed floating rate debt estimate increase basis points shortterm longterm interest rates would decrease fair value interest rate swaps million excluding effects counterparty credit risk realized would affect earnings remaining life swaps marketable securities subject changes fair value result interest rate fluctuations market factors policy invest highly rated institutions place limits amount time maturity investments individual institution estimate increase basis points interest rates general would decrease fair value debt security portfolio approximately million credit risk periodically sell nonus trade receivables means reduce collectability risk sales agreements provide recourse event uncollectibility retain interest underlying asset sold monitor investments counterparties objective minimizing concentrations credit risk investment policy places limits amount time maturity investments individual counterparty policy also requires investments made primarily highly rated corporate financial us government government supported institutions use derivative instruments exposes us credit risk fair value derivative instrument contract positive exposed credit risk counterparty fails perform fair value derivative instrument contract negative counterparty exposed credit risk fail perform obligation required post collateral derivative table contents contract liability position require counterparties post collateral derivatives asset position us seek minimize credit risk derivative instruments entering transactions reputable financial institutions policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information see item financial statementsnote fair value measurement note cash cash equivalents marketable securities note shortterm borrowings longterm debt note financial instruments table contents bristolmyers squibb company consolidated statements earnings dollars shares millions except per share data item financial statements supplementary data year ended december earnings net sales cost products sold marketing selling administrative advertising product promotion research development acquired inprocess research development provision restructuring litigation expense net equity net income affiliates gain sale imclone shares incomeexpense total expenses earnings continuing operations income taxes provision income taxes net earnings continuing operations discontinued operations earnings net taxes gain disposal net taxes net earnings discontinued operations net earnings net earnings attributable noncontrolling interest net earnings attributable bristolmyers squibb company amounts attributable bristolmyers squibb company net earnings continuing operations net earnings discontinued operations net earnings attributable bristolmyers squibb company earnings per common share continuing operations attributable bristolmyers squibb company basic diluted earnings per common share attributable bristolmyers squibb company basic diluted dividends declared per common share accompanying notes integral part consolidated financial statements table contents bristolmyers squibb company consolidated statements comprehensive income retained earnings dollars millions year ended december comprehensive income net earnings comprehensive incomeloss foreign currency translation foreign currency translation reclassified net earnings due business divestitures foreign currency translation hedge net investment derivatives qualifying cash flow hedges net taxes derivatives qualifying cash flow hedges reclassified net earnings net taxes derivatives reclassified net earnings due business divestitures net taxes pension postretirement benefits net taxes pension postretirement benefits reclassified net earnings net taxes pension postretirement benefits reclassified net earnings due business divestitures net taxes available sale securities net taxes available sale securities reclassified net earnings net taxes total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable bristolmyers squibb company retained earnings retained earnings january net earnings attributable bristolmyers squibb company cash dividends declared retained earnings december accompanying notes integral part consolidated financial statements table contents bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories deferred income taxes prepaid expenses total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses deferred income accrued rebates returns us foreign income taxes payable dividends payable total current liabilities pension postretirement postemployment liabilities deferred income us foreign income taxes payable liabilities longterm debt total liabilities commitments contingencies note equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total bristolmyers squibb company shareholders equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements table contents bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities net earnings attributable noncontrolling interest depreciation amortization deferred income tax expense stockbased compensation expense acquired inprocess research development impairment charges gain related divestitures discontinued operations gain sale imclone shares gains changes operating assets liabilities receivables inventories accounts payable deferred income us foreign income taxes payable net cash provided operating activities cash flows investing activities proceeds sale maturities marketable securities purchases marketable securities additions property plant equipment capitalized software proceeds sale businesses property plant equipment investments proceeds divestitures discontinued operations mead johnsons cash splitoff purchase businesses net cash acquired proceeds sale imclone shares proceeds sale leaseback properties net cash used inprovided investing activities cash flows financing activities shortterm debt repayments longterm debt borrowings longterm debt repayments interest rate swap terminations issuances common stock excess tax benefits sharebased arrangements common stock repurchases dividends paid proceeds mead johnson initial public offering net cash used financing activities effect exchange rates cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements table contents note accounting policies basis consolidation consolidated financial statements prepared conformity united states us generally accepted accounting principles gaap include accounts bristolmyers squibb company may referred bristolmyers squibb bms company controlled majorityowned subsidiaries intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date codevelopment cocommercialization license arrangements entered parties various therapeutic areas terms including upfront licensing contingent payments arrangements assessed determine whether terms give economic control entity may require consolidation entity entities consolidated controlled means majority voting interest referred variable interest entities arrangements material variable interest entities including associated codevelopment cocommercialization license arrangements determined exist reclassifications certain prior year amounts reclassified conform current year presentation use estimates preparation financial statements requires use management estimates assumptions based complex judgments significant assumptions employed estimates used determining fair value intangible assets restructuring charges accruals sales rebate return accruals including related us health care reform legal contingencies tax assets tax liabilities stockbased compensation expense pension postretirement benefits including actuarial assumptions see note pension postretirement postemployment liabilities fair value financial instruments direct observable market quotes inventory obsolescence potential impairment longlived assets allowances bad debt well estimates used applying revenue recognition policy new discounts us healthcare reform law medicare coverage gap managed medicaid expansion public health service b program require additional assumptions due lack historical claims experience addition new pharmaceutical company fee estimate subject external data well calculation based companys relative share industry results actual results may differ estimated results revenue recognition revenue recognized title substantially risks rewards ownership transferred customer generally time shipment however certain sales made nonus businesses recognized date receipt purchaser see note alliances collaborations discussion revenue recognition related alliances revenues reduced time recognition reflect expected returns estimated based historical experience business trends provisions made time revenue recognition discounts rebates estimated sales allowances based historical experience updated changes facts circumstances including impact new legislation healthcare reform appropriate provisions recognized reduction revenue limited circumstances new product extension existing line product historical experience products similar therapeutic category exists revenue deferred right return longer exists sufficient historical experience estimate sales returns developed sales rebate return accruals sales rebate return accruals established related revenue recognized resulting reduction sales establishment liability accrual recognized based estimate proportion recognized revenue result rebate return chargeback accruals related government programs cash discounts established similar manner recognized reduction accounts receivable table contents income taxes provision income taxes determined using asset liability approach accounting income taxes approach deferred taxes represent future tax consequences expected occur reported amounts assets liabilities recovered paid provision income taxes represents income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax bases assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made cash cash equivalents cash cash equivalents consist us treasury securities government agency securities bank deposits time deposits money market funds cash equivalents primarily highly liquid investments original maturities three months less time purchase recognized cost approximates fair value cash cash equivalents maintained foreign currencies million december subject currency rate risk marketable securities investments companies marketable securities classified available sale date purchase reported fair value december fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity declines fair value considered temporary charged earnings considered temporary reported component accumulated comprehensive income oci shareholders equity declines fair value determined credit related charged earnings average cost method used determining realized gains losses sale available sale securities investments less owned companies ability exercise significant influence maintained accounted using equity method accounting share net income losses equity investments included equity net income affiliates consolidated statements earnings equity investments reviewed impairment assessing decline market value investment carrying value temporary making determination factors evaluated determining whether loss value recognized includes consideration intent ability hold investments market price market price fluctuations investments publicly traded shares inability investee sustain earnings capacity justifying carrying amount investment impairment losses recognized expense decline market value deemed temporary inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation generally computed straightline method based estimated useful lives related assets estimated useful lives major classes depreciable assets follows buildings years machinery equipment fixtures years impairment longlived assets current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques including discounted table contents value estimated future cash flows assets disposed reported lower carrying value estimated net realizable value capitalized software certain costs obtain internal use software significant systems projects capitalized amortized estimated useful life software costs obtain software projects significant expensed incurred business combinations acquired business included consolidated financial statements upon obtaining control acquired assets acquired liabilities assumed recognized date acquisition respective fair values excess purchase price estimated fair values net assets acquired recognized goodwill business combinations entered january legal costs audit fees business valuation costs business acquisition costs expensed incurred goodwill acquired inprocess research development intangible assets goodwill tested impairment annually using twostep process first step identifies potential impairment second step measures amount impairment loss goodwill impaired carrying amount reporting units goodwill exceeds estimated fair value biopharmaceuticals segment includes several separate reporting units based geography aggregated impairment testing purposes annual goodwill impairment assessment completed first quarter subsequently monitored potential impairment remaining quarters none indicated impairment goodwill fair value inprocess research development iprd acquired business combination determined based present value research projects projected cash flows using income approach future cash flows predominately based net income forecast project consistent historical pricing margins expense levels similar products revenues estimated based relevant market size growth factors expected industry trends individual project life cycles life research projects underlying patent determining fair value research project expected revenues first adjusted technical risk completion resulting cash flows discounted rate approximating companys weightedaverage cost capital iprd acquired january initially capitalized considered indefinitelived assets subject annual impairment reviews often upon occurrence certain events review requires determination fair value respective intangible assets fair value intangible assets less carrying value impairment loss recognized difference compounds reach commercialization assets amortized expected useful lives prior january amounts allocated acquired iprd expensed date acquisition patentstrademarks licenses technology amortized straightline basis estimated useful lives considered impaired net carrying value exceeds estimated fair value restructuring restructuring charges recognized result actions streamline operations rationalize manufacturing facilities judgment used estimating impact restructuring plans including future termination benefits exit costs incurred actions take place actual results could vary estimates product liability accruals product liability established undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically assessment efforts progress additional information becomes available receivables related insurance thirdparty recoveries product liabilities recognized undiscounted basis probable recovery realized contingencies loss contingencies legal proceedings claims may occur wide range matters including government investigations shareholder lawsuits product environmental liability tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies recognized realized table contents derivative financial instruments derivative financial instruments used principally management interest rate foreign currency exposures held issued trading purposes derivative instruments recognized fair value changes derivatives fair value recognized earnings unless specific hedge criteria met derivative designated fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings derivative designated cash flow hedge effective portions changes fair value derivative reported accumulated comprehensive income oci subsequently recognized earnings hedged item affects earnings cash flows classified consistent underlying hedged item derivatives designated assigned hedges forecasted transactions specific assets specific liabilities hedged assets liabilities sold extinguished forecasted transactions hedged longer probable occur gain loss immediately recognized designated hedge earnings nonderivative instruments also designated hedges net investments foreign affiliates nonderivative instruments mainly euro denominated longterm debt effective portion designated nonderivative instrument recognized foreign currency translation section oci ineffective portion recognized earnings shipping handling costs shipping handling costs included marketing selling administrative expenses million million million million million included discontinued operations advertising product promotion costs advertising product promotion costs expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized oci net assets subsidiaries highly inflationary economies remeasured functional currency reporting currency remeasurement recognized earnings research development research development costs expensed incurred strategic alliances third parties provide rights develop manufacture market andor sell pharmaceutical products rights owned party certain research development payments alliance partners contingent upon achievement certain predetermined criteria milestone payments achieved prior regulatory approval product expensed research development milestone payments made connection regulatory approvals capitalized amortized cost products sold remaining useful life asset capitalized milestone payments tested recoverability periodically whenever events changes circumstances indicate carrying amounts may recoverable research development recognized net reimbursements connection collaboration agreements upfront licensing milestone receipts obtained development deferred amortized estimated life product income amortization period upfront licensing milestone receipts new materially modified arrangement january assessed determined considering terms arrangements recently issued accounting standards new accounting standards adopted january none impact consolidated financial statements upon adoption among items standards provide clarifying criteria determining transferor surrendered control transferred financial assets removed concept qualifying specialpurpose entity table contents require ongoing reassessment primary beneficiary variable interest entity eliminate quantitative approach previously required determining primary beneficiary provide guidance determining primary beneficiary entity power direct activities variable interest entity significantly impacts entities economic performance obligation absorb losses right receive benefits events significant variable interest entity january new revenue recognition standard adopted applied new materially modified revenue arrangements upfront licensing fees contingent milestones relating research development deliverables guidance provides principles application guidance whether multiple deliverables exist arrangement separated consideration allocated eliminates residual method allocating revenue requires allocation consideration received bundled revenue arrangement among separate deliverables introducing estimated selling price method valuing elements vendorspecific objective evidence thirdparty evidence selling price available expands related disclosure requirements adoption standard expected material impact consolidated financial statements beginning annual nontaxdeductible fee paid federal government based allocation companys market share branded prior year sales certain government programs including medicare medicaid department veterans affairs department defense tricare fee classified operating expense note alliances collaborations sanofi company agreements sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartanirbesartan hydrochlorothiazide angiotensin ii receptor antagonist indicated treatment hypertension diabetic nephropathy plavix clopidogrel bisulfate platelet aggregation inhibitor worldwide alliance operates framework two geographic territories one americas principally us canada puerto rico latin american countries australia europe asia accordingly two territory partnerships formed manage central expenses marketing research development royalties supply finished product individual countries general country level agreements either copromote whereby partnership formed parties sell brand comarket whereby parties operate sell brands independently place agreements expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patents exclusivity rights applicable territory company acts operating partner owns majority controlling interest territory covering americas australia sanofis ownership interest territory company consolidates country partnership results territory reflects sanofis share results noncontrolling interest company recognizes net sales territory comarketing countries outside territory eg germany italy irbesartan spain greece discovery royalties owed sanofi included cost products sold cash flows operating activities partnerships territory covering americas australia included within operating activities companys consolidated statements cash flows distributions partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis also recognized within operating activities sanofi acts operating partner owns majority controlling interest territory covering europe asia companys ownership interest territory included assets company consolidate partnership entities territory accounts equity method reflects share results equity net income affiliates company routinely receives distributions profits provides funding ongoing operations partnerships territory covering europe asia reflected cash provided operating activities company sanofi separate partnership governing copromotion irbesartan us alliance company recognizes income related amortization deferred income associated sanofis million payment company acquisition interest irbesartan license us upon formation alliance deferred income continue amortized expected expiration license income attributed certain supply activities development optout royalties sanofi also reflected net income table contents following summarized financial information reflected consolidated financial statements year ended december dollars millions territory covering americas australia net sales discovery royalty expense noncontrolling interest pretax profit distributions sanofi territory covering europe asia equity net income affiliates profit distributions company net sales europe comarketing countries income irbesartan license fee income supply activities development optout royalties december dollars millions investment affiliates territory covering europe asia deferred income irbesartan license fee following summarized financial information interests partnerships sanofi territory covering europe asia consolidated accounted using equity method year ended december dollars millions net sales cost products sold gross profit marketing selling administrative advertising product promotion research development incomeexpense net income current assets current liabilities cost products sold includes discovery royalties million million million paid directly sanofi expenses shared based applicable ownership percentages current assets current liabilities include approximately million billion billion related receivablespayables attributed respective years net cash distributions company sanofi well intercompany balances partnerships within territory remaining current assets current liabilities consist thirdparty trade receivables inventories amounts due company sanofi purchase inventories royalties expense reimbursements otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia bipolar mania disorder major depressive disorder except japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt terms agreement company purchases product otsuka performs finish manufacturing sale thirdparty customers company otsuka product currently copromoted otsuka us canada united kingdom uk germany france spain us germany france spain product invoiced thirdparty customers company behalf otsuka company recognizes alliance revenue contractual share thirdparty net sales reduced us starting january company continues receive thirdparty net sales france germany spain expense reimbursement beginning january company invoice thirdparty customers uk behalf otsuka company receive net sales expense reimbursement company recognizes alliance revenue abilify shipped risks rewards ownership transferred thirdparty customers certain countries company presently exclusive distributor product exclusive right sell abilify company recognizes net sales related cost products sold expenses table contents april company otsuka agreed extend us portion commercialization manufacturing agreement expected loss product exclusivity april terms agreement company paid otsuka million amortized reduction net sales extension period unamortized balance included assets beginning january share abilify us net sales company recognizes changed reduced january period otsuka responsible us expenses related commercialization abilify reimbursements netted principally advertising product promotion selling general administrative expenses beginning january expected loss us exclusivity april including expected six month pediatric extension company receive following percentages us annual net sales share us net sales billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible us expenses related commercialization abilify addition company otsuka announced entered oncology collaboration sprycel dasatinib ixempra ixabepilone includes us japan european union eu markets oncology territory beginning collaboration fees company pay otsuka annually following percentages net sales sprycel ixempra oncology territory net sales million million million million million million billion excess billion periods otsuka contribute first million certain commercial operational expenses relating oncology products ii commercial operational expenses relating products territory excess million starting otsuka right copromote sprycel company us japan top five eu markets us extension oncology collaboration include changeofcontrol provision case acquisition company acquiring company competing product abilify new company assume abilify agreement amended oncology collaboration exists today acquiring company product competes abilify otsuka elect request acquiring company choose whether divest abilify competing product scenario abilify divested otsuka would obligated acquire companys rights abilify agreement amended agreements also provide event generic competitor abilify january company option terminating abilify april amendment agreement previously amended remaining force company exercise option either company would receive payment otsuka according predetermined schedule oncology collaboration would terminate time ii oncology collaboration would continue truncated period according predetermined schedule eu agreement remained unchanged expire june countries company exclusive right sell abilify agreement expires later th anniversary first commercial sale country expiration applicable patent country addition million extension payment total milestone payments made otsuka agreement december million million expensed iprd remaining million capitalized intangible assets amortized cost products sold remaining life agreement us table contents following summarized financial information related alliance reflected consolidated financial statements year ended december dollars millions abilify net sales including amortization extension payment oncology products collaboration fees otsukas reimbursement operating expense amortization expense extension payment amortization expense upfront licensing milestone payments december dollars millions assets extension payment intangible assets upfront licensing milestone payments january company granted otsuka exclusive rights japan develop commercialize onglyza company expects receive milestone payments based certain regulatory events well salesbased payments following regulatory approval onglyza japan retained rights copromote onglyza otsuka japan otsuka responsible development costs japan lilly company epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lillys november acquisition imclone systems incorporated imclone codevelopment promotion erbitux cetuximab necitumumab imcf us expires erbitux september company also codevelopment copromotion rights products canada japan erbitux indicated use treatment patients metastatic colorectal cancer use treatment squamous cell carcinoma head neck egfr agreement respect erbitux sales north america lilly receives distribution fee based flat rate net sales north america plus reimbursement certain royalties paid lilly included cost products sold october company imclone amended codevelopment agreement merck kgaa merck provide cocommercialization erbitux japan rights agreement expire however lilly ability terminate agreement determines commercially unreasonable lilly continue erbitux received marketing approval japan july use erbitux treating patients advanced recurrent colorectal cancer company receives pretax profit merck sales erbitux japan shared equally lilly companys share profits commercialization japan included income company amortizing million previously capitalized milestone payments accounted license acquisition remaining term agreement amortization classified costs products sold upon execution initial commercialization agreement company acquired ownership interest imclone accounted equity method company sold shares imclone approximately million recognized pretax gain million november january company lilly restructured egfr commercialization agreement described company imclone relates necitumumab novel targeted cancer therapy currently phase iii development nonsmall cell lung cancer restructured companies share cost developing potentially commercializing necitumumab us canada japan lilly maintains exclusive rights necitumumab markets company fund development costs studies used us fund global studies company pay million lilly milestone payment upon first approval us us canada company recognize sales receive profits bear losses necitumumab lilly provide selling effort parties general equally participate commercialization efforts japan company lilly share commercial costs profits evenly agreement relates necitumumab continues beyond patent expiration parties agree terminate may terminated time company months advance notice months prior launch either party uncured material breach parties agree terminate lilly manufacture bulk requirements assume responsibility fillfinish necitumumab beginning table contents following summarized financial information related alliance reflected consolidated financial statements year ended december dollars millions net sales distribution fees royalty reimbursements amortization expense milestone payments equity net income affiliates income japan commercialization fee december dollars millions intangible assets upfront licensing milestone payments gilead company gilead sciences inc gilead joint venture develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combining companys sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate us canada europe company accounts participation us joint venture equity method accounting recognizes share joint venture results equity net income affiliates consolidated statements earnings us canada european countries company records revenue bulk efavirenz component atripla upon sales product third party customers revenue efavirenz component determined applying percentage atripla revenue approximate revenue sustiva brand limited number eu countries company recognizes revenue atripla since product purchased gilead distributed third party customers following summarized financial information related alliance reflected consolidated financial statements year ended december dollars millions net sales equity net loss affiliates astrazeneca company maintains two worldwide codevelopment cocommercialization agreements astrazeneca plc astrazeneca first worldwide excluding japan codevelopment cocommercialization onglyza saxagliptin dppiv inhibitor saxagliptin agreement second worldwide including japan codevelopment cocommercialization dapagliflozin sodiumglucose cotransporter sglt inhibitor sglt agreement compounds studied treatment diabetes discovered company kombiglyze codeveloped astrazeneca saxagliptin agreement agreement two companies jointly develop clinical marketing strategy share commercialization expenses profits losses equally global basis excluding case saxagliptin japan company manufacture products companies cocommercialize dapagliflozin japan share profits losses equally agreement company option decline involvement cocommercialization given country instead receive royalty royalty percentage rates company optsout cocommercialization agreements tiered based net sales july fda approved onglyza adjunct diet exercise improve blood sugar glycemic control adults treatment type diabetes mellitus august company astrazeneca launched onglyza us october onglyza received marketing authorization use eu treat adults type diabetes combination either metformin sulfonylurea thiazolidinedione agents alone diet exercise provide adequate glycemic control december fda approved kombiglyze saxagliptin metformin combination therapy treatment type diabetes adults company received astrazeneca total million upfront licensing milestone payments related saxagliptin agreement million upfront licensing payments related sglt agreement december including million received payments deferred amortized useful life products income additional milestone payments expected received company upon successful achievement various development regulatory events well salesbased milestones saxagliptin agreement company could table contents receive additional million remaining development regulatory milestone saxagliptin met additional million sales based milestones saxagliptin met sglt agreement company could receive additional million development regulatory milestones dapagliflozin met additional million salesbased milestones dapagliflozin met agreement company astrazeneca also share development commercialization costs majority development costs initial development plans paid astrazeneca astrazeneca bearing costs initial agreed upon development plan dapagliflozin japan additional development costs shared equally net reimbursements company development costs related saxagliptin dapagliflozin netted research development following summarized financial information related alliance reflected consolidated financial statements year ended december dollars millions net sales amortization income upfront licensing milestone payments research development reimbursements tofrom astrazeneca december dollars millions deferred income upfront licensing milestone payments pfizer company pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis apixaban anticoagulant discovered company studied prevention treatment broad range venous arterial thrombotic conditions company received million upfront licensing payments addition company received million milestone payment april commencement phase iii clinical trials prevention major adverse cardiovascular events acute coronary syndrome million milestone filing marketing authorization application eu payments deferred amortized useful life products income pfizer fund development costs initial development plan effective january going forward company fund net reimbursements company eliquis development costs netted research development company may also receive additional payments pfizer additional million based achieving development regulatory milestones companies jointly develop clinical marketing strategy share commercialization expenses profits losses equally global basis manufacture product arrangement following summarized financial information related alliance reflected consolidated financial statements year ended december dollars millions amortization income upfront licensing milestone payments research development reimbursements pfizer december dollars millions deferred income upfront licensing milestone payments exelixis october company entered two metabolic collaboration agreements exelixis inc one license exelixis smallmolecule tgr agonist program including backups tgr agreement second collaborate discover optimize characterize smallmolecule ror antagonists ror agreement company paid exelixis initial payment million expensed research development could pay additional development approval milestones million tgr agreement million ror agreement exelixis also eligible receive additional million salesbased milestones tgr ror programs royalties net sales products tgr ror programs company received exclusive worldwide license develop commercialize small molecule tgr agonists ror antagonists tgr agreement company sole responsibility research development manufacturing commercialization ror agreement company collaborating exelixis ror antagonist programs preclinical transition point company sole responsibility research development manufacture commercialization resulting products table contents december company exelixis entered global codevelopment cocommercialization arrangement xl metvegret inhibitor oral anticancer compound license xl utility ras raf mutant tumors development exelixis terms arrangement company paid exelixis million upon execution agreement paid additional million expensed research development june company terminated development collaboration exelixis xl rights returning exelixis resulting million termination fee expensed research development company could pay exelixis development regulatory milestones million additional million salesbased milestones related xl addition company exelixis history collaborations identify develop promote oncology targets january company exelixis entered oncology collaboration license agreement exelixis pursing development three small molecule inds codevelopment copromotion terms agreement paid exelixis million upfront licensing milestone payments date pursuant amendment agreement executed october exelixis optedout codevelopment xl company made payment exelixis amount million expensed research development result company received exclusive worldwide license develop commercialize xl sole responsibility development manufacture commercialization compound successful pay exelixis development regulatory milestones million additional million salesbased milestones well royalties royalty percentage rates tiered based net sales december company held equity investment exelixis represented less outstanding shares alder november company alder biopharmaceuticals inc alder entered global agreement development commercialization ald novel biologic completed phase iia development treatment rheumatoid arthritis terms arrangement alder granted company worldwide exclusive rights develop commercialize ald potential indications except cancer alder retains rights granted company option codevelop exclusive rights cocommercialize outside united states company paid alder million upfront licensing payment expensed research development addition company could pay million developmentbased regulatory based milestone payments potential salesbased milestones certain circumstances may exceed million royalties net sales company chooses option pursue cancer indications company could pay additional million developmentbased regulatorybased milestone payments aforementioned salesbased milestones royalties net sales royalty percentage rates tiered based net sales note business segment information company operates one biopharmaceuticals segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization global supply chain organization utilized responsible development delivery products market products distributed sold five regional organizations serve united states europe latin america middle east africa japan asia pacific canada emerging markets business also supported global corporate staff functions segment information presented consistent financial information regularly reviewed chief operating decision maker purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross sales three largest pharmaceutical wholesalers us percentage total gross sales follows mckesson corporation cardinal health inc amerisourcebergen corporation table contents selected geographic area information follows property plant net sales equipment dollars millions united states europe japan asia pacific canada latin america middle east africa emerging markets total net sales key products follows year ended december dollars millions plavix avaproavalide abilify reyataz sustiva franchise total revenue baraclude erbitux sprycel ixempra orencia onglyzakombiglyze mature products total capital expenditures depreciation property plant equipment within biopharmaceuticals segment follows year ended december dollars millions capital expenditures depreciation segment income excludes impact significant items indicative current operating performance ongoing results earnings attributed sanofi noncontrolling interest reconciliation earnings continuing operations income taxes follows year ended december dollars millions biopharmaceuticals segment income reconciling items downsizing streamlining worldwide operations impairment loss sale manufacturing operations accelerated depreciation asset impairment shutdown costs process standardization implementation costs gain sale product lines businesses assets litigation recoverycharges upfront licensing milestone payments acquired inprocess research development ars impairment loss sale gain sale imclone shares bms foundation funding initiative noncontrolling interest earnings continuing operations income taxes table contents note restructuring productivity transformation initiative pti designed fundamentally change way business run meet challenges changing business environment take advantage diverse opportunities marketplace transformation nextgeneration biopharmaceutical company continues addition pti strategic process designed achieve culture continuous improvement enhance efficiency effectiveness competitiveness continue improve cost base implemented following pti restructuring charges recognized year ended december dollars millions employee termination benefits exit costs provision restructuring net impairment loss sale manufacturing operations accelerated depreciation asset impairment shutdown costs pension curtailment settlement charges process standardization implementation costs total cost gain sale product lines businesses assets net charges accelerated depreciation asset impairment charges shutdown costs included cost products sold primarily relate rationalization manufacturing network biopharmaceuticals segment assets continue depreciated cease use date facility remaining charges primarily attributed process standardization activities attributed pension plan curtailment charges recognized incurred restructuring charges included termination benefits workforce reductions manufacturing selling administrative research development personnel across geographic regions approximately following table represents activity employee termination exit cost liabilities year ended december dollars millions liability beginning year charges change estimates provision restructuring net foreign currency translation charges discontinued operations spending mead johnson splitoff convatec divestiture liability end year connection continued optimization manufacturing network operations latina italy sold international chemical investors se ici may resulting million loss loss consisted million impairment charge recorded attributed writedown assets fair value less cost sale assets met held sale criteria million working capital adjustments transaction related fees million million subordinated promissory note payable installments may received consideration additional charges may required pertaining companys obligation fund portion icis future restructuring costs million million part transaction one year supply agreement entered ici company nonexclusive supplier certain products ici also three year tolling manufacturing agreement extended additional two years entered ici company supply certain raw material products processed finished latina facility distributed company various markets table contents note acquisitions zymogenetics inc acquisition october bms acquired outstanding shares common stock zymogenetics inc zymogenetics october aggregate purchase price approximately million acquisition related costs million classified incomeexpense zymogenetics focused developing commercializing therapeutic proteinbased products treatment human diseases companies collaborated development pegylatedinterferon lambda novel interferon currently phase iib development treatment hepatitis c infection acquisition provides company full rights develop commercialize pegylatedinterferon lambda also brings proven capabilities therapeutic proteins revenue recothrom fda approved specialty surgical biologic goodwill generated acquisition primarily attributed full ownership rights pegylated interferon lambda goodwill iprd intangible assets valued acquisition nondeductible tax purposes purchase price allocation follows dollars millions purchase price cash identifiable net assets cash marketable securities inventory current longterm assets inprocess research development intangible assets technology deferred income taxes current longterm liabilities total identifiable net assets goodwill includes million recorded long term assets inventory expected utilized excess one year includes million related pegylatedinterferon lambda attributed recothrom amortized years results zymogenetics operations included accompanying consolidated financial statements october pro forma supplemental financial information provided impact acquisition material operating results medarex inc acquisition september company acquired means tender offer secondstep merger remaining outstanding shares stock equivalents medarex already owned total purchase price million acquisition costs million classified incomeexpense medarex focused discovery development commercialization fully human antibodybased therapeutic products address major unmet healthcare needs areas oncology inflammation autoimmune disorders infectious diseases result acquisition full rights yervoy ipilimumab currently phase iii development received increases biologics development pipeline creating balanced portfolio small molecules biologics goodwill generated acquisition primarily attributed balanced portfolio associated biopharma model potential optimize existing yervoy programs goodwill iprd intangible assets valued acquisition nondeductible tax purposes table contents purchase price allocation follows dollars millions purchase price cash fair value companys equity medarex held prior acquisition total identifiable net assets cash marketable securities current longterm assets inprocess research development intangible assets technology intangible assets licenses shortterm borrowings current longterm liabilities deferred income taxes total identifiable net assets goodwill income approximately million recognized remeasurement fair value equity interest medarex held acquisition date includes ownership interest genmab million ownership celldex therapeutics inc million subsequently sold december loss million includes approximately billion related yervoy amortized years amortized years results medarex operations included accompanying consolidated financial statements august pro forma supplemental financial information provided impact acquisition material operating results kosan biosciences inc acquisition june company completed acquisition kosan biosciences inc kosan cancer therapeutics company library novel compounds including hsp inhibitors cancer microtubule stabilizers may additional potential neurodegenerative diseases net purchase price approximately million transaction accounted purchase method accounting purchase price allocated acquiredinprocess research development million net assets million goodwill million note mead johnson nutrition company initial public offering february mead johnson completed initial public offering ipo sold million shares class common stock per share net proceeds million deducting million underwriting discounts commissions offering expenses allocated noncontrolling interest capital excess par value stock upon completion ipo million shares mead johnson class common stock million shares mead johnson class b common stock held company representing interest mead johnson combined voting power outstanding common stock rights holders shares class common stock class b common stock identical except regard voting conversion share class common stock entitled one vote per share share class b common stock entitled ten votes per share convertible time election holder one share class common stock class b common stock automatically converted shares class common stock various agreements related separation mead johnson entered including separation agreement transitional services agreement tax matters agreement registration rights agreement employee matters agreement table contents note discontinued operations mead johnson nutrition company splitoff splitoff remaining interest mead johnson completed december splitoff effected exchange offer previously held million shares mead johnson converting class b common stock class common stock million outstanding shares companys stock resulting pretax gain million million net taxes shares received connection exchange valued using closing price december reflected treasury stock gain exchange determined using sum fair value shares received plus net deficit mead johnson attributable company less taxes direct expenses related transaction including tax reserve million established convatec disposition august divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partners lp avista completed gross purchase price million resulting pretax gain million million net taxes medical imaging disposition january divestiture bristolmyers squibb medical imaging medical imaging avista completed gross purchase price approximately million resulting pretax gain million aftertax loss million transitional relationships discontinued operations subsequent respective dispositions cash flows income associated mead johnson convatec medical imaging businesses continued generated relating activities transitional nature result agreements intended facilitate orderly transfer business operations include among others services accounting customer service distribution manufacturing activities related convatec medical imaging businesses completed december amended mead johnson agreement expires september income generated transitional activities included incomeexpense expected material future results operations cash flows table contents following summarized financial information related mead johnson convatec medical imaging businesses segregated continuing operations reported discontinued operations date disposition year ended december dollars millions net sales mead johnson convatec medical imaging net sales earnings income taxes mead johnson convatec medical imaging earnings income taxes provision income taxes earnings net taxes gain disposal mead johnson convatec medical imaging gain disposal provision income taxes gain disposal net taxes net earnings discontinued operations less net earnings discontinued operations attributable noncontrolling interest net earnings discontinued operations attributable bristolmyers squibb company table contents note earnings per share year ended december amounts millions except per share data basic eps calculation income continuing operations attributable bms earnings attributable unvested restricted shares income continuing operations attributable bms common shareholders net earnings discontinued operations attributable bms eps numerator basic eps denominator basic average common shares outstanding eps basic continuing operations discontinued operations net earnings eps numerator diluted income continuing operations attributable bms earnings attributable unvested restricted shares income continuing operations attributable bms common shareholders net earnings discontinued operations attributable bms eps numerator diluted eps denominator diluted average common shares outstanding contingently convertible debt common stock equivalents incremental shares attributable sharebased compensation plans average common shares outstanding common share equivalents eps diluted continuing operations discontinued operations net earnings net earnings discontinued operations used eps calculation net earnings discontinued operations attributable bms earnings attributable unvested restricted shares net earnings discontinued operations attributable bms used eps calculation antidilutive weightedaverage equivalent shares stock incentive plans total antidilutive shares table contents note incomeexpense incomeexpense includes year ended december dollars millions interest expense interest income impairment loss sale manufacturing operations lossgain debt repurchase auction rate securities ars impairment net foreign exchange transaction gainslosses gain sale product lines businesses assets acquisition related items income alliance partners pension curtailment settlement charges incomeexpense note income taxes components earnings continuing operations income taxes categorized based location taxing authorities follows year ended december dollars millions us nonus total provisionbenefit income taxes attributable continuing operations consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision effective tax rate reconciliation effective tax rate us statutory federal income tax rate earnings income taxes dollars millions earnings continuing operations income taxes us statutory rate tax effect foreign subsidiaries earnings previously considered permanently reinvested offshore foreign tax effect certain operations ireland puerto rico switzerland state local taxes net valuation allowance us federal state foreign contingent tax matters acquired inprocess research development expense us federal research development tax credit impairment financial instruments foreign table contents increase effective tax rate due million charge recognized fourth quarter resulted primarily additional us taxable income earnings foreign subsidiaries previously considered permanently reinvested offshore million charge completion us tax return million benefit completion us tax return unfavorable earnings mix high low tax jurisdictions partially offset certain favorable discrete tax adjustments million compared million benefit primarily resulting effective settlements us international uncertain tax positions outofperiod tax adjustment million related previously unrecognized net deferred tax assets primarily attributed deferred profits financial reporting purposes related certain alliances december material current prior periods decrease effective tax rate primarily due higher pretax income us including gain sale imclone shares unfavorable earnings mix high tax jurisdictions unfavorable tax impact related iprd ars impairment charges additional million benefit completion us tax return partially offset million benefit related final settlement audit internal revenue service irs deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions foreign net operating loss carryforwards milestone payments license fees deferred income us federal net operating loss carryforwards pension postretirement benefits state net operating loss credit carryforwards intercompany profit inventory items us federal research development tax credit carryforwards foreign deferred tax assets sharebased compensation legal settlements depreciation repatriation foreign earnings acquired intangible assets tax deductible goodwill us federal foreign tax credit carryforwards valuation allowance deferred tax assets recognized deferred income taxes current deferred income taxes noncurrent us foreign income taxes payable current liabilities noncurrent total valuation allowance deferred tax assets established likely deferred tax assets realized december valuation allowance million established following items million foreign net operating loss table contents tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal net operating loss carryforwards changes valuation allowance follows year ended december dollars millions balance beginning year provision valuation allowance release valuation allowanceother comprehensive income goodwill balance end year us federal net operating loss carryforwards acquired result acquisitions zymogenetics medarex kosan biosciences inc kosan adnexus subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning research development tax credit carryforwards expire varying amounts beginning realization research development tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration although realization assured management believes likely deferred tax assets realized income tax payments million million million income tax payments net million cash refund related foreign tax credit carryback claim current tax benefit realized upon exercise stock options credited capital excess par value stock million million december us taxes provided approximately billion undistributed earnings foreign subsidiaries undistributed earnings invested expected permanently invested offshore future earnings repatriated us earnings determined remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes would provided company favorable tax rates ireland puerto rico grants scheduled expire prior company completed internal restructuring certain legal entities contributed million charge recognized fourth quarter possible us tax authorities could assert additional material tax liabilities arising restructuring assertion occur company would vigorously challenge assertion believes would prevail however assurance result business conducted various countries throughout world subject tax numerous jurisdictions result significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported may require several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross reductions tax positions related current year gross additions tax positions related prior years gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year uncertain tax benefits reduce deferred tax assets extent uncertainty directly related asset otherwise recognized either current non current us foreign income taxes payable unrecognized tax benefits recognized table contents would impact effective tax rate million million million december respectively gross additions tax positions related current year year ended december include million tax reserves related transfer various international units mead johnson prior ipo splitoff transaction recognized discontinued operations gross reductions tax positions related prior years year ended december include million liabilities related mead johnson accrued interest penalties unrecognized tax benefits classified either current noncurrent us foreign income taxes payable accrued interest related unrecognized tax benefits million million million december respectively accrued penalties related unrecognized tax benefits million million million december respectively interest penalties related unrecognized tax benefits classified income tax expense expensebenefit related interest unrecognized tax benefits expense million benefits million million expensebenefit related penalties unrecognized tax benefits expense million benefits million million company currently examination number tax authorities including major tax jurisdictions listed table proposed adjustments tax issues transfer pricing certain tax credits deductibility certain expenses company estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits primarily settlement related involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits company also anticipates reasonably possible new issues raised tax authorities may require increases balance unrecognized tax benefits however estimate increases reasonably made time company believes adequately provided open tax years tax jurisdiction income tax returns filed us federal jurisdiction various state foreign jurisdictions exceptions company subject us federal state local nonus income tax examinations tax authorities following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico table contents note fair value measurement fair value financial assets liabilities classified one following categories level quoted prices unadjusted active markets accessible measurement date identical assets liabilities fair value hierarchy gives highest priority level inputs level observable prices based inputs quoted active markets corroborated market data level unobservable inputs used little market data available fair value hierarchy gives lowest priority level inputs december december quoted quoted prices prices active significant significant active significant significant markets unobservable markets unobservable identical observable identical observable assets inputs inputs assets inputs inputs dollars millions level level level total level level level total available sale us treasury bills us government agency securities equity securities prime money market funds corporate debt securities commercial paper fdic insured debt securities us treasury money market funds us government agency money market funds auction rate securities floating rate securities frs total available sale assets derivatives interest rate swap derivatives foreign currency forward derivatives total derivative assets total assets fair value derivatives foreign currency forward derivatives interest rate swap derivatives natural gas contracts total derivative liabilities total liabilities fair value majority ars private placement securities longterm nominal maturities rated standard poors primarily represent interests insurance securitizations valuation models utilized rely exclusively level inputs due lack observable market quotes ars portfolio inputs based expected cash flow streams collateral values including assessments counterparty credit quality default risk underlying security discount rates overall capital market liquidity fair value ars determined using internally developed valuations based part indicative bids received underlying assets securities evidence fair value table contents frs longterm debt securities coupons reset periodically benchmark interest rate million principal par frs received known reported defaults frs due current lack active market frs general lack transparency underlying assets qualitative analysis relied upon value frs including discussion brokers fund managers default risk underlying security overall capital market liquidity level inputs declines fair value reported temporary loss comprehensive income intentions sell investments likely investments required sold recovery amortized cost basis financial assets liabilities utilize level level inputs direct indirect observable price quotes utilized including libor euribor yield curves foreign exchange forward prices nymex futures pricing common stock price quotes summary valuation techniques level level financial assets liabilities us treasury bills us government agency securities us government agency money market funds valued quoted market price observable pricing sources reporting date equity securities valued using quoted stock prices new york stock exchange national association securities dealers automated quotation system reporting date prime money market funds net asset value per share corporate debt securities commercial paper valued quoted market price observable pricing sources reporting date fdic insured debt securities valued quoted market price observable pricing sources reporting date us treasury money market funds valued quoted market price observable pricing sources reporting date interest rate swap derivative assets liabilities valued using libor euribor yield curves less credit valuation adjustments reporting date counterparties contracts highlyrated financial institutions none experienced significant downgrades valuations may fluctuate considerably periodtoperiod due volatility underlying interest rates driven market conditions duration swap addition credit valuation adjustment volatility may significant impact valuation interest rate swaps due changes counterparty credit ratings credit default swap spreads foreign currency forward derivative assets liabilities valued using quoted forward foreign exchange prices reporting date counterparties contracts highlyrated financial institutions none experienced significant downgrades valuations may fluctuate considerably periodtoperiod due volatility underlying foreign currencies majority foreign currency forward derivatives mature within two years counterparty credit risk considered significant table contents note cash cash equivalents marketable securities cash cash equivalents million december million december consisted prime money market funds government agency securities treasury securities cash equivalents primarily consist highly liquid investments original maturities three months less time purchase recorded cost approximates fair value following table summarizes current noncurrent marketable securities accounted available sale debt securities equity securities december december unrealized unrealized unrealized unrealized gain loss gain loss amortized accumulated accumulated amortized accumulated accumulated dollars millions cost basis oci oci fair value cost basis oci oci fair value current marketable securities certificates deposit corporate debt securities commercial paper fdic insured debt securities us government agency securities total current noncurrent marketable securities corporate debt securities us treasury bills us government agency securities fdic insured debt securities auction rate securities floating rate securities total noncurrent assets equity securities frs unrealized loss position months december following table summarizes activity financial assets utilizing level fair value measurements noncurrent current noncurrent dollars millions frs ars total frs frs ars total fair value january sales settlements unrealized gainslosses fair value december december million noncurrent available sale corporate debt securities us government agency securities us treasury bills fdic insured debt securities floating rate securities mature within five years million corporate debt securities mature within six years auction rate securities mature beyond years table contents note receivables receivables include december dollars millions trade receivables less allowances net trade receivables alliance partners receivables prepaid refundable income taxes miscellaneous receivables receivables receivables netted deferred income related alliance partners recognition income result alliance partner receivables deferred income reduced million million december respectively additional information regarding alliance partners see note alliances collaborations nonus receivables sold nonrecourse basis million million respectively aggregate receivables due three pharmaceutical wholesalers us represented total trade receivables december respectively second quarter government greece announced intends convert certain past due receivables government run hospitals non interest bearing notes paid one three year periods december notes process issued receivables million million included longterm assets million charge attributed imputed discount expected noninterest bearing notes expected collection period recognized incomeexpense changes allowances follows year ended december dollars millions balance beginning year provision bad debt chargebacks discounts bad debts writtenoffpayment chargebacks discounts discontinued operations balance end year note inventories inventories include december dollars millions finished goods work process raw packaging materials inventories inventories expected remain onhand beyond one year million million december respectively included non current assets addition million inventories currently sold us us food drug administration fda approves manufacturing process change inventories noncurrent assets include capitalized costs related production products programs phase iii development subject final fda approval million million december respectively status regulatory approval process probability future sales considered assessing recoverability costs table contents note property plant equipment property plant equipment includes december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment depreciation expense million million million million million included discontinued operations capitalized interest million million million note goodwill intangible assets changes carrying amount goodwill segment follows dollars millions biopharmaceuticals total balance january medarex acquisition mead johnson splitoff distributions balance december zymogenetics acquisition balance december intangible assets include december december gross net gross net estimated carrying accumulated carrying carrying accumulated carrying dollars millions useful lives amount amortization amount amount amortization amount licenses years technology years capitalized software years total finitelived intangible assets inprocess research development note total intangible assets changes intangible assets follows dollars millions intangible assets carrying amount january capitalized software additions zymogenetics acquisition medarex acquisition mead johnson splitoff sale convatec amortization licenses technology amortization capitalized software impairment charges intangible assets carrying amount december amortization expense included discontinued operations million million table contents expected future amortization expense december finitelived intangible assets million million million million million million thereafter note accrued expenses accrued expenses include december dollars millions employee compensation benefits royalties accrued research development restructuringcurrent pension postretirement benefits accrued litigation total accrued expenses note sales rebates return accruals reductions trade receivables listing accrued rebates returns liabilities follows december dollars millions chargebacks related government programs cash discounts reductions trade receivables managed healthcare rebates contract discounts medicaid rebates sales returns adjustments accrued rebates returns note deferred income deferred income includes december dollars millions upfront licensing milestone receipts atripla deferred revenue gain saleleaseback transactions total deferred income current portion noncurrent portion upfront licensing milestone receipts amortized expected life product see note alliances collaborations information pertaining revenue recognition transactions alliances collaborations deferred gain saleleaseback transactions relates several sale leaseback transactions amortized remaining lease terms related facilities million million million see note leases information pertaining gain saleleasebacks transactions table contents note equity changes common shares treasury stock capital excess par value stock follows cost capital excess common shares treasury treasury par value dollars shares millions issued stock stock stock balance january employee stock compensation plans balance december mead johnson ipo adjustments mead johnson net asset transfer mead johnson splitoff employee stock compensation plans balance december stock repurchase program employee stock compensation plans balance december accumulated balances related component comprehensive incomeloss oci net taxes follows derivatives pension accumulated foreign qualifying currency effective postretirement available comprehensive dollars millions translation hedges benefits sale securities incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss balance december reconciliation noncontrolling interest follows dollars millions balance january mead johnson ipo adjustments mead johnson net asset transfer mead johnson splitoff net earnings attributable noncontrolling interest comprehensive income attributable noncontrolling interest distributions balance december noncontrolling interest primarily related partnerships sanofi territory covering americas net sales plavix net earnings attributable noncontrolling interest presented net taxes million million million consolidated statements earnings corresponding increase provision income taxes distribution partnership profits sanofi sanofis funding ongoing partnership operations occur routine basis included within operating activities consolidated statements cash flows activity includes pretax income distributions related partnerships net earnings noncontrolling interest included discontinued operations million million treasury stock recognized cost reacquire shares treasury shares acquired mead johnson splitoff recognized fair value stock splitoff date shares issued treasury recognized utilizing firstin firstout method may board directors authorized repurchase billion common stock repurchases may made either open market private transactions including repurchase plans established accordance rule b securities exchange act amended stock repurchase program expiration date expected take place next years may suspended discontinued time company repurchased million shares average price approximately per share aggregate cost million includes million transaction fees table contents note pension postretirement postemployment liabilities company certain subsidiaries sponsor defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan covers us employees represents approximately consolidated pension plan assets obligations funding policy contribute amounts fund past service liability plan benefits based primarily participants years credited service final average compensation plan assets consist principally equity fixedincome securities comprehensive medical group life benefits provided substantially us retirees elect participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities similar plans exist employees certain countries outside us net periodic benefit cost defined benefit pension postretirement benefit plans includes pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service costbenefit amortization net actuarial loss net periodic benefit cost curtailments settlements special termination benefits total net periodic benefit cost continuing operations discontinued operations total net periodic benefit cost us retirement income plan several plans amended june amendments eliminate crediting future benefits relating service effective december salary increases continue considered additional fiveyear period determining benefit obligation related prior service plan amendments accounted curtailment result applicable plan assets obligations remeasured remeasurement resulted million reduction accumulated oci million net taxes corresponding decrease unfunded status plan due curtailment updated plan asset valuations change discount rate curtailment charge million also recognized incomeexpense second quarter remaining amount unrecognized prior service cost addition participants reclassified inactive benefit plan purposes actuarial gains losses amortized expected weightedaverage remaining lives plan participants years connection plan amendment contributions principal defined contribution plans us puerto rico increased effective january net impact actions expected reduce future retiree benefit costs although future costs continue subject market conditions factors including actual expected plan asset performance interest rate fluctuations lumpsum benefit payments certain plan assets related obligations transferred us retirement income plan several plans new plans sponsored mead johnson active mead johnson participants resulting million reduction accumulated oci million net taxes first quarter corresponding decrease unfunded status plan due updated plan asset valuations change discount rate net actuarial loss prior service cost expected amortized accumulated oci net periodic benefit cost dollars millions pension benefits benefits amortization net actuarial loss amortization prior service costbenefit table contents changes defined benefit postretirement benefit plan obligations assets funded status amounts recognized consolidated balance sheets follows pension benefits benefits dollars millions benefit obligations beginning year service costbenefits earned year interest cost plan participants contributions curtailments settlements actuarial lossesgains transfer mead johnson retiree drug subsidy benefits paid special termination benefits exchange rate gainslosses benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions plan participants contributions settlements transfer mead johnson retiree drug subsidy benefits paid exchange rate lossesgains fair value plan assets end year funded status assetsliabilities recognized assets accrued expenses pension postretirement liabilities accrued benefit cost funded status recognized accumulated comprehensive loss net actuarial loss net obligation adoption prior service costbenefit total table includes activity related mead johnson pension postretirement plans part separation activities certain defined benefit pension postretirement plan assets liabilities transferred separate mead johnson sponsored defined benefit pension postretirement plans final transfers occurring december related plan assets liabilities transferring participants allocated based assumptions set forth plan transfer agreement accumulated benefit obligation defined benefit pension plans million million december respectively additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets table contents actuarial assumptions weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit cost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matches duration benefit obligations used determining discount rate citigroup pension discount curve used developing discount rate us plans several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years expected return plan assets determined using expected rate return calculated value assets referred marketrelated value fair value plan assets exceeds marketrelated value million december marketrelated value exceeds fair value plan assets million december change primarily driven asset gains offset full recognition significant losses incurred plan assets differences assumed actual returns amortized marketrelated value straightline basis threeyear period gains losses resulted changes actuarial assumptions changes discount rate differences assumed actual experience differences actual assumed returns plan assets gains losses except differences amortized market related value amortized extent exceed higher marketrelated value projected benefit obligation respective plan result approximately million related pension benefits expected amortized majority remaining actuarial losses amortized life expectancy plans participants us plans expected remaining service periods plans assumed healthcare cost trend rates december follows healthcare cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate assumed healthcare cost trend rates effect amounts reported healthcare plans onepercentagepoint change assumed healthcare cost trend rates would following effects percentage percentage dollars millions point increase point decrease effect total service interest cost effect postretirement benefit obligation table contents plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total equity funds equity securities fixed income funds venture capital limited partnerships government mortgage backed securities corporate debt securities shortterm investment funds us treasury agency securities insurance contracts collateralized mortgage obligation bonds event driven hedge funds asset backed securities state municipal bonds real estate cash cash equivalents total plan assets fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity transfers fair value levels recognized beginning reporting period investment valuation policies per investment class follows equity funds securities classified level include publicly traded equities traded national securities exchange valued last reported sales price reporting date securities classified level valued net asset value shares held year end based fair value underlying investments level equity funds valued estimated fair value estimated fair value based fair value underlying investment values cost plus minus accumulated earnings losses approximates fair value equity securities securities classified level include publicly traded equities traded national securities exchange valued last reported sales price reporting date publicly traded equities traded overthecounter market valued last reported bid price reporting date fixed income funds securities classified level include publicly traded equities traded national securities exchange valued last reported sales price reporting date securities classified level valued net asset value shares held year end based fair value underlying investments venture capital limited partnerships interests classified level carried estimated fair value estimated fair value based fair value underlying investment values cost plus minus accumulated earnings losses approximates fair value government mortgage backed securities securities classified level valued quoted market price broker dealer quotations transparent pricing sources reporting date corporate debt securities securities classified level either valued quoted market prices observable pricing sources reporting date valued based upon comparable securities similar yields credit ratings securities classified level valued estimated bids brokers third party vendor sources utilize expected cash flow streams data including counterparty credit quality default risk discount rates overall capital market liquidity shortterm investment funds securities classified level valued net asset value shares held year end based fair value underlying investments short term investments primarily invested short term money market instruments table contents us treasury agency securities securities classified level valued quoted market prices observable pricing sources reporting date securities classified level valued quoted market price broker dealer quotations transparent pricing sources reporting date insurance contracts interests classified level carried contract value approximates estimated fair value estimated fair value based fair value underlying investment insurance company insurance contracts held certain nonus pension plans collateralized mortgage obligation bonds securities classified level either valued quoted market prices observable pricing sources reporting date valued based upon comparable securities similar yields credit ratings purpose underlying loan securities classified level valued estimated bids brokers thirdparty vendor sources utilize expected cash flow streams data including counterparty credit quality default risk discount rates overall capital market liquidity event driven hedge funds securities classified level valued net asset value shares held year end based fair value underlying investments event driven hedge funds primarily invest long short relative country positions various strategies including global fixed income global currencies global equities commodities emerging market debt inflationindexed bonds asset backed securities securities classified level either valued quoted market prices observable pricing sources reporting date valued based upon comparable securities similar yields credit ratings purpose underlying loan securities classified level valued estimated bids brokers thirdparty vendor sources utilize expected cash flow streams data including counterparty credit quality default risk discount rates overall capital market liquidity state municipal bonds securities classified level valued quoted market price broker dealer quotations transparent pricing sources reporting date real estate interests classified level either valued quoted market prices observable pricing sources reporting date valued based upon comparable investments interests classified level valued net asset value shares held year end based fair value underlying investments cash cash equivalents securities classified level highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement following summarizes activity financial assets utilizing level fair value measurements collateralized corporate mortgage asset venture capital equity debt obligation backed real limited insurance dollars millions funds securities bonds securities estate partnerships contracts total fair value january purchases sales issuances settlements net realized lossesgains unrealized gainslosses fair value december purchases sales issuances settlements net realized lossesgains unrealized gains fair value december investment strategy emphasizes equities order achieve higher expected returns lower expenses required cash contributions longterm target asset allocation public equity us international private equity fixed income maintained us pension plans cash contributions benefit payments used rebalance back targets necessary investments well diversified within three major asset categories approximately table contents us pension plans equity investments actively managed venture capital limited partnerships typically valued three month lag bristolmyers squibb company common stock represents less plan assets december contributions contributions us pension plans million million including million mead johnson million contributions us pension plans expected approximate million million contributed january contributions international pension plans million million million contributions international plans expected range million million estimated future benefit payments benefits pension medicare dollars millions benefits gross subsidy net years savings plan principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match qualified defined contribution plans amended allow increased matching additional company contributions effective expense related plan million million million post employment benefit plan postemployment liabilities longterm disability benefits million million december respectively expense related benefits million million million termination indemnity plans statutory termination obligations europe recognized undiscounted basis assuming employee termination measurement date liability recognized obligations million december million december note employee stock benefit plans employee stock plans may shareholders approved stock award incentive plan plan plan replaced stock incentive plan plan expired may plan provides million new shares common stock reserved delivery participants plus shares remaining available new grants plan shares recaptured outstanding awards plan shares actually delivered participants connection award restrictions lapsed reduce number shares reserved shares tendered prior year pay purchase price options shares previously utilized satisfy withholding tax obligations upon exercise continue available reserved shares common stock reserved issuance pursuant stock plans options conversions preferred stock million million december respectively shares available granted active plans million million december respectively adjusted combination plans shares stock option exercise share unit vesting issued treasury stock table contents plan plan executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable installments per year first fourth anniversaries grant date maximum term years additionally plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price plan plan provide granting common stock key employees subject restrictions continuous employment restrictions expire four year period date grant compensation expense recognized restricted period restricted stock units granted instead restricted stock since stock unit right receive stock end specified vesting period voting rights beginning market share units granted certain executives plan vesting market share units conditioned upon continuous employment vesting date payout factor equals least payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs per year four years plan plan also incorporated longterm performance awards awards three year cycle delivered form target number performance share units number shares ultimately issued calculated based actual performance compared earnings targets performance criteria established beginning performance period awards annual goals maximum payout threshold targets met performance period payment made plan annual period stockbased compensation expense follows years ended december dollars millions stock options restricted stock market share units longterm performance awards total stockbased compensation expense continuing operations discontinued operations total stockbased compensation expense deferred tax benefit related stockbased compensation expense alternative method determine pool excess tax benefits elected stock options stock option activities follows shares common stock issued weightedaverage shares millions plan exercise price shares balance january exercised expired forfeited balance december december unrecognized compensation cost related stock options million expected recognized weightedaverage period years beginning company stopped granting stock options form compensation grants additional restricted stock units market share units additional information related stock option grants exercises plan plan summarized follows year ended december amounts millions except per share data stock options granted weightedaverage grant date fair value per share total intrinsic value stock options exercised cash proceeds exercise stock options table contents following table summarizes information concerning stock compensation plans currently outstanding exercisable options number securities issued upon weightedaverage exercise exercise outstanding options price outstanding shares millions rights options rights plan category equity compensation plans approved shareholders equity compensation plans approved shareholders plan terminated shares longer granted following table summarizes significant ranges outstanding exercisable options december amounts millions except per share data options outstanding options exercisable weighted weighted average weighted average weighted remaining average aggregate remaining average aggregate contractual exercise intrinsic contractual exercise intrinsic number life price per value number life price per value range exercise prices outstanding years share millions exercisable years share millions vested expected vest aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december million inthemoney options exercisable december million outstanding options exercisable weightedaverage exercise price december fair value stock options estimated grant date using blackscholes option pricing model stock options service condition model applying multiple input variables determine probability satisfying market conditions options service market conditions following weightedaverage assumptions used valuation expected volatility riskfree interest rate dividend yield expected life yrs yrs expected volatility assumption required blackscholes model derived calculating year historical volatility weighting equally derived implied volatility blended historical implied volatility approach expected volatility believed representative future stock price trends using historical volatility riskfree interest rate assumption based upon us treasury yield curve effect grant date dividend yield assumption based historical expected dividend payouts expected life stock options represents weightedaverage period stock options remain outstanding derived output latticebinomial model expected life impacted underlying assumptions calibration model model assumes employees exercise behavior function options remaining vested life extent option inthemoney model estimates probability exercise function two variables based historical exercises cancellations prior option grants made expense based awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates table contents restricted stock awards restricted stock units weightedaverage shares thousands number shares grantdate fair value nonvested shares january granted vested forfeited nonvested shares december expected vest restricted stock awards restricted stock units vest ratably four year period december unrecognized compensation cost related nonvested restricted stock million expected recognized weightedaverage period years fair value nonvested shares restricted stock awards units determined based closing trading price companys common stock grant date total fair value vested shares million million million respectively million shares granted weighted average grant date fair value million shares granted weighted average grant date fair value market share units weightedaverage shares thousands number shares grantdate fair value nonvested shares january granted vested forfeited nonvested shares december expected vest market share units vest ratably four year period based share price performance december unrecognized compensation cost related nonvested market share units million expected recognized weightedaverage period years fair value market share units estimated date grant using model applying multiple input variables determine probability satisfying market conditions model uses following input variables expected volatility riskfree interest rate dividend yield expected volatility based four year historical volatility levels companys common stock current implied volatility fouryear riskfree interest rate derived federal reserve based market share units contractual term expected dividend yield based historical dividend payments fair value market share unit amortized vesting period award longterm performance awards longterm performance share units determined based achievement annual performance goals vested end three year period fair value performance awards based closing trading price common stock grant date fair value performance share units granted discounted participated dividends fair value performance share units granted discounted using risk free interest rate date grant participate dividends performance share units granted million million million weighted average grant date fair value respectively assuming payout share units outstanding million december million december million shares issued december unrecognized compensation cost related performance share unit plan million expected recognized weightedaverage period years total fair value vested shares million million million respectively table contents note shortterm borrowings longterm debt shortterm borrowings include december dollars millions bank drafts principal value yen notes due convertible senior debentures due demand note payable mead johnson total part medarex acquisition medarexs outstanding convertible senior notes due may assumed notes adjusted right receive cash time principal amount outstanding equivalent per share time prior maturity substantially redeemed longterm debt includes december dollars millions principal value notes due euro notes due euro notes due notes due notes due notes due debentures due debentures due debentures due othermaturing subtotal adjustments principal value fair value interest rate swaps unamortized basis adjustment swap terminations unamortized bond discounts total included debt floating rate convertible senior debentures due redeemed holders par september fundamental change ownership occurs debentures callable par time company debentures conversion price equal conversion rate shares principal amount subject certain antidilutive adjustments maximum conversion rate shares principal amount debentures pay interest quarterly annual rate equal three month libor reset quarterly minus yield never less zero february mead johnson company borrower mead johnson guarantor indirect majorityowned subsidiaries entered three year syndicated revolving credit facility agreement fourth quarter mead johnson borrowed million revolving credit facility issued various notes totaling billion proceeds used repay certain intercompany debt prior splitoff table contents million aggregate principal value debt repurchased tender offer million notional amount interest rate swaps related debt repurchases terminated following table summarizes activity swap including principal repurchase loss termination basis adjustment gain dollars millions value price repurchase proceeds terminated swaps loss debentures due notes due total million aggregate principal value debt repurchased million notional amount interest rate swaps related debt repurchases terminated following table summarizes activity swap including principal repurchase loss termination basis adjustment gain dollars millions value price repurchase proceeds terminated swaps loss debentures due debentures due notes due total million aggregate principal value debt repurchased million notional amount interest rate swaps related debt repurchases terminated following table summarizes activity swap including principal repurchase gain termination basis adjustment gain dollars millions value price repurchase proceeds terminated swaps loss notes due debentures due debentures due notes due total discussion interest rate swaps see note financial instruments interest payments net amounts related interest rate swaps million million million principal value longterm debt obligations million december million due remaining million due later fair value longterm debt million million december respectively estimated based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments billion five year revolving credit facility syndicate lenders maturing december maintained facility extendable consent lenders contains customary terms conditions including financial covenant whereby ratio consolidated net debt consolidated capital exceed end quarter company compliance covenant since inception facility borrowings outstanding facility december december million financial guarantees provided form standby letters credit performance bonds standby letters credit insurance companies support thirdparty liability programs performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority outstanding financial guarantees expire within year expected funded table contents note financial instruments financial instruments include cash cash equivalents marketable securities receivables accounts payable debt instruments derivatives due short term maturity carrying amount receivables accounts payable approximate fair value exposure market risk due changes currency exchange rates interest rates result certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign currency forward contracts used manage cash flow exposures primary net foreign currency exposures hedged euro japanese yen canadian dollar british pound australian dollar mexican peso fixedtofloating interest rate swaps used part interest rate risk management strategy swaps qualify fairvalue hedge accounting treatment certain net asset changes due foreign exchange volatility hedged nonus dollar borrowings qualify net investment hedge derivative financial instruments present certain market counterparty risks however concentration counterparty risk mitigated limiting amounts individual counterparty using banks worldwide standard poors moodys longterm debt ratings higher addition conventional derivative financial instruments utilized consolidated financial statements would materially impacted counterparties failed perform according terms agreement currently collateral form securitization required furnished counterparties derivative financial instruments following summarizes fair value outstanding derivatives december december december december balance sheet fair fair balance sheet fair fair dollars millions location notional value notional value location notional value notional value derivatives designated hedging instruments interest rate contracts assets accrued expenses foreign currency forward contracts assets accrued expenses hedge net investments longterm debt natural gas contracts accrued expenses total derivatives notional value natural gas contracts million decatherms december qualifying hedges cash flow hedges foreign currency forward contracts foreign currency forward contracts utilized hedge forecasted intercompany transactions certain foreign currencies contracts designated foreign currency cash flow hedges appropriate notional fair value amounts contracts million million net liability million million net liability december respectively majority contracts qualify hedges probable forecasted cash flows effective portion changes fair value temporarily reported accumulated oci recognized earnings hedged item affects earnings following table summarizes significant outstanding foreign currency forward contracts december fair value contracts based yearend currency rates viewed relation fair value underlying hedged transactions overall reduction exposure adverse fluctuations foreign currency exchange rates weightedaverage notional fair value dollars millions except currency rates strike price amount assetliability maturity foreign currency forwards euro euro japanese yen japanese yen table contents deferred losses foreign currency forward contracts qualifying cash flow hedge accounting million million net taxes december expected reclassified earnings within next months effectiveness assessed inception hedge quarterly basis assessments determine whether derivatives designated qualifying hedges continue highly effective offsetting changes cash flows hedged items ineffective portion change fair value included current period earnings impact hedge ineffectiveness earnings significant cash flow hedge accounting discontinued forecasted transaction longer probable occurring originally forecasted date days thereafter hedge longer effective discontinued foreign exchange hedges reported incomeexpense significant interest rate contracts terminated swaps qualify cash flow hedges recognized accumulated oci amortized earnings remaining life debt hedged debt remains outstanding impact oci earnings foreign currency forward contracts natural gas contracts forward starting swaps qualified cash flow hedges follows foreign currency forward natural gas forward starting contracts contracts swaps total impact dollars millions net carrying amount january cash flow hedges deferred oci cash flow hedges reclassified cost products soldinterest expense effective portion change deferred taxes cash flow hedges reclassified net earnings due business divestitures net carrying amount december hedge net investment nonus dollar borrowings primarily million notes due million notes due billion total used hedge foreign currency exposures net investment certain foreign affiliates borrowings designated hedge net investment effective portion foreign exchange gains losses recognized foreign currency translation cta component accumulated oci december million million notes due dedesignated impact oci earnings nonderivative debt designated hedge net investment follows net investment hedges dollars millions net carrying amount january change spot value nonderivative debt designated hedge gainloss recognized incomeexpense net overhedged portion net carrying amount december fair value hedges interest rate contracts derivative instruments used part interest rate risk management strategy principally fixedtofloating interest rate swaps designated fairvalue hedges total notional amounts fair value outstanding interest rate swaps million million net assets million million net assets december respectively swaps underlying debt benchmark risk hedged recognized fair value swaps intended create appropriate balance fixed floating rate debt basis adjustment debt qualifying fair value hedging relationships amortized earnings adjustment interest expense remaining life debt underlying swap terminated prior maturity table contents fixedtofloating interest rate swaps executed convert million debentures due million debentures due million notes due fixed rate debt variable rate debt fixedtofloating interest rate swaps executed convert million notes due notes due fixed rate debt variable rate debt swaps qualified fair value hedge debt instrument fixedtofloating interest rate swap agreements million notional amount million notional amount terminated generating proceeds million million notional amount fixedtofloating interest rate swap agreements terminated proceeds million million notional amount fixedtofloating interest rate swap agreements terminated proceeds million proceeds swap terminations less accrued interest deferred amortized interest expense remaining life underlying debt additionally company terminated certain interest rate swap agreements connection repurchase certain debt obligations resulted net proceeds million million million gain loss attributable transactions immediately recognized incomeexpense discussion companys debt repurchase see note shortterm borrowings longterm debt following summarizes interest rate swaps outstanding december notional amount underlying variable rate year fair dollars millions debt received transaction maturity value swaps associated notes due month us libor notes due month us libor notes due month us libor million notes due month eur euribor million notes due month eur euribor debentures due month us libor notes due month us libor notes due month us libor debentures due month us libor total interest rate swaps impact interest expense interest rate swaps qualified fair value hedges follows dollars millions recognized reduction interest expense amortization basis adjustment swap terminations recognized reduction interest expense total nonqualifying foreign currency forward contracts foreign currency forward contracts also utilized hedge foreign currencydenominated monetary assets liabilities primary objective contracts protect us dollar value foreign currencydenominated monetary assets liabilities effects volatility foreign exchange rates might occur prior receipt settlement us dollars contracts designated hedges adjusted fair value incomeexpense occur substantially offset change fair value underlying foreign currency denominated monetary asset liability notional fair value amounts contracts significant december furthermore foreign currency forward contracts also used offset exposure certain assets liabilities earnings denominated certain foreign currencies contracts designated hedges adjusted fair value incomeexpense occur december company hold foreign exchange contracts contracts mature within next months impact earnings nonqualifying foreign currency forward contracts significant years ended december table contents note leases minimum rental commitments noncancelable operating leases primarily real estate motor vehicles effect december follows years ending december dollars millions later years total minimum rental commitments operating lease expense million million million million million included discontinued operations sublease income material years ended december saleleaseback administrative facility paris france completed million million resulting pretax gain million gain deferred reduce future lease costs lease period note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business relating product liability patent commercial consumer environmental securities matters company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated litigation expense net included million insurance reimbursement prior litigation offset additional reserves certain average wholesale prices awp litigation million securities litigation settlement million related awp litigation net revised estimates previously accrued amounts cash payments related significant litigation million million million significant matters described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product sales generic competition intellectual property plavix litigation plavix currently companys largest product ranked net sales plavix patents subject number challenges us including litigation apotex inc apotex corp apotex described less significant markets product company product partner sanofi companies intend vigorously pursue enforcement patent rights plavix plavix litigation us patent infringement litigation apotex related matters previously disclosed companys us territory partnership alliance sanofi plaintiff pending patent infringement lawsuit instituted united states district court southern district new york district court entitled sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceuticals holding partnership v apotex suit based us patent patent composition matter patent discloses claims among things hydrogen sulfate salt clopidogrel medicine made available us companies plavix also previously reported district court upheld validity enforceability patent maintaining main patent protection plavix us november district court also ruled apotexs generic clopidogrel bisulfate product infringed patent permanently enjoined apotex engaging activity infringes patent including marketing generic product us patent expires table contents apotex appealed district courts decision december united states court appeals federal circuit circuit court affirmed district courts ruling sustaining validity patent apotex filed petition circuit court rehearing en banc march circuit court denied apotexs petition case remanded district court proceedings relating damages july apotex filed petition writ certiorari us supreme court requesting supreme court review circuit courts decision november us supreme court denied petition declining review circuit courts decision december company filed motion district court summary judgment damages january apotex filed motion seeking stay ongoing damages proceedings pending outcome reexamination plavix patent us patent trademark office pto described april district court denied apotexs motion stay proceedings october district court granted companies summary judgment motion awarded million damages plus costs interest apotex appealing amount damages award however validity patent claiming clopidogrel bisulfate finally judicially determined favor companies possible time determine whether amount damages award upheld appeal previously disclosed companys us territory partnership alliance sanofi also plaintiff five additional patent infringement lawsuits dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt watson pharmaceuticals inc watson laboratories inc watson sun pharmaceuticals sun lawsuits dr reddys teva cobalt relate patent may dr reddys signed consent judgment favor sanofi bms conceding validity infringement patent previously reported patent infringement actions teva cobalt stayed pending resolution apotex litigation parties actions agreed bound outcome litigation apotex consequently july district court entered judgments cobalt teva permanently enjoined cobalt teva engaging activity infringes patent patent expires cobalt teva filed appeal july circuit court issued mandate teva appeal binding teva decision apotex litigation august cobalt consented entry judgment appeal agreeing bound circuit courts decision apotex litigation lawsuit watson filed october based us patent patent discloses claims particular crystalline polymorph form hydrogen sulfate salt clopidogrel marketed plavix december court permitted watson pursue declaratory judgment counterclaim respect us patent january court approved parties stipulation stay case pending outcome trial apotex matter may bms watson entered stipulation dismiss case april pharmastar filed request inter partes reexamination patent pto pto granted request july july pto vacated reexamination proceeding lawsuit sun filed july based infringement patent patent respect patent sun agreed bound outcome apotex litigation dr reddys teva cobalt watson sun filed anda fda respect dr reddys teva cobalt watson exclusivity periods statutory stay periods hatchwaxman act expired accordingly final approval fda would provide company authorization distribute generic clopidogrel bisulfate product us subject various legal remedies companies may apply including injunctive relief damages june apotex filed request ex parte reexamination patent pto august pto agreed reexamine patent december pto issued nonfinal office action rejecting several claims covering plavix including claim previously upheld litigation apotex referred pto issued ex parte reexamination certificate withdrawing rejections nonfinal office action confirming patentability claims patent apotex filed second request ex parte reexamination patent june pto denied apotexs request reexamine patent additionally november apotex filed lawsuit new jersey superior court entitled apotex inc et al v sanofiaventis et al seeking payment million plus interest related breakup march proposed settlement agreement parties filed crossmotions summary judgment pending january apotex filed lawsuit florida state court broward county alleging breach contract relating parties may proposed settlement agreement table contents plavix litigation international plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex since changed name apotex august apotex filed application federal court australia seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september australian court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid view decision possible generic company could develop seek registration australia alternate salt form clopidogrel bisulfate hydrochloride hydrobromide taurocholate company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full federal court australia held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages expected amount damages material company plavix eu previously disclosed yes pharmaceutical development services gmbh yes pharmaceutical filed application marketing authorization germany alternate salt form clopidogrel application relied data studies originally conducted sanofi bms plavix still subject data protection eu sanofi bms filed action yes pharmaceutical partners administrative court cologne objecting marketing authorization matter currently pending although specific marketing authorizations withdrawn market plavix canada apotex inc april apotex filed impeachment action sanofi federal court canada alleging sanofis canadian patent patent invalid patent covers clopidogrel bisulfate patent issue prohibition action canada previously disclosed canadian federal court ottawa rejected apotexs challenge patent held asserted claims novel obvious infringed granted sanofis application order prohibition minister health apotex precluding approval apotexs abbreviated new drug submission patent expires decision affirmed appeal federal court appeal supreme court canada june sanofi filed defense impeachment action filed suit apotex infringement patent trial expected occur intellectual property litigation abilify previously disclosed otsuka filed patent infringement actions teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals sun zydus pharmaceuticals usa inc zydus apotex relating us patent patent covers aripiprazole expires april including additional sixmonth pediatric exclusivity period aripiprazole comarketed company otsuka us abilify nonjury trial us district court district new jersey nj district court tevabarr apotex completed august november nj district court upheld validity enforceability patent maintaining main patent protection abilify us april nj district court also ruled defendants generic aripiprazole product infringed patent permanently enjoined engaging activity infringes patent including marketing generic product us patent including sixmonth pediatric extension expires sandoz synthon sun zydus also bound nj district courts decision december tevabarr apotex appealed decision us court appeals federal circuit table contents possible time determine outcome appeal nj district courts decision otsuka prevail appeal generic competition would likely result substantial decreases sales abilify us would material adverse effect results operations cash flows could material financial condition atripla april teva filed anda manufacture market generic version atripla atripla single tablet threedrug regimen combining companys sustiva gileads truvada time companys us patent rights covering sustivas composition matter method use challenged teva sent gilead paragraph iv certification letter challenging two fifteen orange book listed patents atripla atripla product joint venture company gilead may gilead filed patent infringement action teva us district court southern district new york sdny january company received notice teva amended anda challenging eight additional orange book listed patents atripla march company merck sharp dohme corp filed patent infringement action teva also sdny relating two us patents claim crystalline polymorph forms efavirenz march gilead filed two patent infringement actions teva sdny relating six orange book listed patents atripla discovery matters ongoing possible time reasonably assess outcome lawsuits impact company reyataz teva filed anda manufacture market generic versions four reyataz dosage forms mg company received paragraph iv certification letter teva challenging two orange book listed patents reyataz december company novartis pharmaceutical corporation novartis filed patent infringement lawsuit us district court district delaware delaware district court teva infringement two listed patents covering reyataz triggered automatic month stay approval tevas anda subsequent patent infringement lawsuits filed discovery matters ongoing possible time reasonably assess outcome lawsuits impact company baraclude august teva filed anda manufacture market generic versions baraclude company received paragraph iv certification letter teva challenging one orange book listed patent baraclude september company filed patent infringement lawsuit delaware district court teva infringement listed patent covering baraclude triggered automatic month stay approval tevas anda possible time reasonably assess outcome lawsuit impact company sprycel september apotex filed anda manufacture market generic versions sprycel company received paragraph iv certification letter apotex challenging four orange book listed patents sprycel including composition matter patent november company filed patent infringement lawsuit us district court district new jersey apotex infringement four orange book listed patents covering sprycel triggered automatic month stay approval apotexs anda possible time reasonably assess outcome lawsuit impact company general commercial litigation clayworth litigation previously disclosed company together number pharmaceutical manufacturers named defendant action filed california state superior court oakland james clayworth et al v bristolmyers squibb company et al alleging defendants conspired fix prices pharmaceuticals agreeing charge drugs us charge outside us particularly canada asserting claims californias cartwright act unfair competition law plaintiffs sought trebled monetary damages injunctive relief relief december court granted company manufacturers motion summary judgment based passon defense judgment entered favor defendants july judgment favor defendants affirmed california court appeals july california supreme court reversed court appeals judgment matter remanded superior court proceedings defendants motion summary judgment grounds remains pending motion denied trial could scheduled early summer possible time reasonably assess outcome lawsuit impact company event plaintiffs successful appeal table contents antitrust litigation previously disclosed lawsuits comprised individual suits purported class actions filed company us district court southern district ohio western division various plaintiffs including pharmacy chains individually assignees whole part certain wholesalers various health welfare benefit plansfunds individual residents various states lawsuits allege among things purported settlement apotex patent infringement litigation violated sherman act related laws plaintiffs seeking among things permanent injunctive relief barring apotex settlement andor monetary damages putative class actions filed behalf direct purchasers consolidated caption plavix direct purchaser antitrust litigation putative class actions filed behalf indirect purchasers consolidated caption plavix indirect purchaser antitrust litigation amended complaints filed october defendants filed consolidated motion dismiss december district court granted defendants motion dismiss direct purchaser claims appeal taken dismissal january district court granted defendants motion dismiss respect indirect purchaser claims possible time reasonably assess outcome lawsuits impact company pricing sales promotional practices litigation investigations abilify state attorneys general investigation march company received letter delaware attorney generals office advising multistate coalition investigating whether certain abilify marketing practices violated respective states consumer protection statutes possible time reasonably assess outcome investigation potential impact company awp litigation previously disclosed company together number pharmaceutical manufacturers defendant number private class actions well suits brought attorneys general various states actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps company defendant five state attorneys general suits pending state courts around country beginning august company defendant trial commonwealth court pennsylvania commonwealth court brought commonwealth pennsylvania september jury issued verdict company finding company liable fraudulent negligent misrepresentation however commonwealth court judge issued decision pennsylvania consumer protection claim go jury finding company liable million enjoining company contributing provision inflated awps company moved vacate decision commonwealth moved judgment notwithstanding verdict alternative new trial motions currently pending commonwealth court previously reported one set class actions consolidated us district court district massachusetts awp mdl august district court granted preliminary approval proposed settlement awp mdl plaintiffs claims company million plus half costs class notice maximum payment million final approval hearing scheduled occur march california b litigation previously disclosed august county santa clara filed purported class action company numerous pharmaceutical manufacturers behalf putative class cities counties california well covered entities purchased drugs pursuant b drug discount program b entities alleging manufacturers provide proper discounts b entities may us district court northern district california district court denied plaintiffs motion without prejudice certify class september us supreme court granted certiorari issue whether b entities standing sue district court previously dismissed case finding b entities standing us court appeals ninth circuit reversed district court district court stayed case pending decision us supreme court possible time reasonably assess outcome lawsuit potential impact company table contents product liability litigation company party various product liability lawsuits previously disclosed addition lawsuits company also faces unfiled claims involving products plavix previously disclosed company certain affiliates sanofi defendants number individual lawsuits claiming personal injury allegedly sustained using plavix appear united states district court district new jersey nj district court december companies defendants actions nj district court executed tolling agreements respect unfiled claims potential additional plaintiffs possible time reasonably assess outcome lawsuits potential impact company hormone replacement therapy company one number defendants masstort litigation plaintiffs allege among things various hormone therapy products including hormone therapy products formerly manufactured company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clots cardiac injuries women defendants aware risks failed warn consumers december company defendant lawsuits filed behalf plaintiffs federal state courts throughout us company entered two separate settlements principle resolve claims approximately plaintiffs companys hormone therapy products sold companies january august environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated thirdparties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties new brunswick facility environmental personal injury lawsuits previously disclosed may lawsuits filed company superior court middlesex county nj behalf current former residents new brunswick nj live lived adjacent companys new brunswick facility complaints allege various personal injuries property damage resulting alleged soil groundwater contamination property stemming historical operations new brunswick facility october new jersey supreme court granted mass tort status cases transferred new jersey superior court atlantic county centralized case management purposes company intends defend vigorously litigation possible time reasonably assess outcome lawsuits potential impact company north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january new jersey department environmental protection njdep sent company table contents others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost company actively monitoring cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter informal means avoid litigation central component agreement provision company interim funding help defray cleanup costs assure work interrupted company transmitted interim funding payments december november parties commenced mediation late however efforts successful parties moved binding allocation process addition september township boe filed suits several parties alleged contributed waste materials site proceedings sec germany investigation previously disclosed october sec notified company conducting informal inquiry activities certain companys german pharmaceutical subsidiaries employees andor agents october sec informed company inquiry become formal secs inquiry encompasses matters formerly investigation german prosecutor munich germany since resolved company understands inquiry concerns potential violations foreign corrupt practices act company cooperating sec medarex shareholder litigation july company medarex announced signing merger agreement providing acquisition medarex company tender offer per share cash following announcement certain medarex shareholders filed similar lawsuits state federal court relating transaction medarex members medarexs board directors company following consolidation state court actions august parties entered memorandum understanding mou pursuant parties reached agreement principle settle state federal actions pursuant agreements mou among things medarex made certain supplemental disclosures tender offer period parties also agreed present superior court new jersey mercer county nj superior court stipulation settlement documentation may required order obtain approval court settlement dismissal actions upon terms set forth mou july proposed settlement approved nj superior court several objectors settlement filed motions reconsideration asking court reconsider approval settlement denied december january objectors filed notices appeal king pharmaceuticals inc november king pharmaceuticals inc king affiliated entities filed suit zymogenetics inc zymogenetics wholly owned subsidiary company see note acquisitions united states district court eastern district tennessee king alleges zymogenetics engaged unfair competition false advertising trademark infringement related claims federal law tennessee state law king seeks various forms relief including damages injunctive relief precluding company making certain representations regarding kings products companys recothrom product king also filed motions district court seeking temporary restraining orders preliminary injunctive relief december judge denied kings motions preliminary injunction lawsuit continues trial case currently scheduled fourth quarter possible time reasonably assess outcome lawsuit potential impact company table contents note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earnings continuing operations less net earnings continuing operations attributable noncontrolling interest net earnings continuing operations attributable bms net earnings discontinued operations attributable bms net earnings attributable bms eps attributable bms basic net earnings continuing operations net earnings discontinued operations net earnings per common share diluted net earnings continuing operations net earnings discontinued operations net earnings per common share dividends declared per common share cash cash equivalents marketable securities dollars millions except per share data first quarter second quarter third quarter fourth quarter year net sales gross margin net earnings continuing operations less net earnings continuing operations attributable noncontrolling interest net earnings continuing operations attributable bms net earningsloss discontinued operations attributable bms net earnings attributable bms eps attributable bms basic net earnings continuing operations net earningsloss discontinued operations net earnings per common share diluted net earnings continuing operations net earningsloss discontinued operations net earnings per common share dividends declared per common share cash cash equivalents marketable securities earnings per share quarters may add amounts year period computed discrete basis marketable securities includes current noncurrent assets table contents following specified items affected comparability results dollars millions first quarter second quarter third quarter fourth quarter year restructuring activity downsizing streamlining worldwide operations impairment loss sale manufacturing operations accelerated depreciation asset impairment shutdown costs pension curtailment settlement charges process standardization implementation costs total restructuring litigation charges net upfront licensing milestone payments iprd impairment acquisition related items product liability charges total income taxes items outofperiod tax adjustment specified tax charge decrease net earnings continuing operations dollars millions first quarter second quarter third quarter fourth quarter year restructuring activity downsizing streamlining worldwide operations accelerated depreciation asset impairment shutdown costs pension curtailment settlement charges process standardization implementation costs gain sale product lines businesses assets total restructuring litigation charges bms foundation funding initiative loss sale investments upfront licensing milestone payments acquisition related items debt repurchase swap terminations product liability chargesinsurance recoveries total income taxes items decrease net earnings continuing operations table contents report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income retained earnings cash flows three years period ended december financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america discussed note consolidated financial statements company adopted accounting standard related business combinations effective business combinations entered january also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february table contents item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes companys internal control financial reporting quarter ended december materially affected reasonably likely materially affect companys internal control financial reporting item b information none table contents report independent registered public accounting firm board directors stockholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements company year ended december report dated february expressed unqualified opinion financial statements deloitte touche llp parsippany new jersey february table contents part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item table contents part iv item